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XAbstract
Five classes of melanocortin receptors (MCI, MC2, MC3, MC4, and MC5) have been 
cloned to date. The MC1-R was found in melanocytes and melanoma cells, and 
macrophages, and shows high affinity and activity for a-MSH, while MC2-R is an 
ACTH receptor expressed in the adrenal gland. The MC3-R, MC4-R, and MC5-R 
have been found in brain and peripheral tissue, however, the function of the MC3-R 
and MC5-R remain unknown. It has been reported that mouse agouti peptide displays 
antagonist activity at MC4-R, and there are indications that the MC4-R is involved in 
the control of feeding behaviour.
The significance of the structure-activity relationship are discussed in the context of 
current knowledge.
The work presented in this thesis focus on the relationship between structure and 
activity of a-MSH and y-MSH analogues at the mouse MC1-R, rat MC3-R and rat 
MC4-R. In this study the native MC1-R was expressed by B16 murine melanoma 
cells, and cDNAs encoding the rat MC3-R and human MC4-R were stably expressed 
by transformed human embryo kidney cells (HEK 293). Initially substitution was 
carried out at position 12 of a-MSH to test the importance of this position in 
interaction of a-MSH and y-MSH with the MC1-R and MC3-R. In later studies 
modification of [Phe7] was investigated at the MC1-R, MC3-R, and MC4-R in an 
effect to find a selective and potent ligand for each receptor. Cyclic peptides of 
[Nle4,Asp5,D-Phe7,Lys10]a-MSH4.j3 were studied at the MC1-R to investigate the 
properties of these bioactive conformers which have less flexibility and may be 
constrained in a ’receptor-specific’ conformation. Throughout the study a-MSH 
analogues were synthesised by solid-phase techniques and assayed for both receptor 
binding (by competitive inhibition) and stimulation (as determined by cAMP 
production).
1Chapter 1: INTRODUCTION
1.1. Melanocytes and Melanoma
The skin protects the body against heat, light, infection, and injury. It also stores 
water, fat, and vitamin D. The skin consists of two main parts, the epidermis and 
dermis, and several kinds of cells. The outer layer of skin is called the epidermis
cell layer (stratum basale) comprised mostly of keratinocytes, and melanocytes, 
which are able to synthesise melanin. 2) The prickle cell layer (stratum spinosum), 
which consists of basal cells that migrate upwards to form a layer of polyhedral 
cells. 3) The granular layer (stratum granulosum), contains cells which become 
flattened and lose their nuclei. 4) The homy layer (stratum comeum) is the end 
result of keratinocyte maturation, and is comprised of sheets of overlapping 
polyhedral cells with no nuclei (comeocytes).








Figure 1.1: Layers of the epidermis and other structures1.
The fashionable demand for tanned skin, and loss of the protective ozone layer 
because of environmental pollution (choroflurocarbon, methane, etc.) have led to a 
dramatic increase in the number of people suffering from skin cancer. There are 
several types of cancer that start in the skin. The most common are basal cell and 
squamous cell cancers, which arise from the basal keratinocytes of the epidermis. 
The main difference between basal cell and squamous cell cancers is that basal cell 
cancer does, in general, not metastasise, whereas squamous cell cancer may 
metastasise. Malignant melanoma is a malignant tumour of melanocytes, usually 
arising in the epidermis and is the most lethal of the main skin tumours.
According to recent reports2’3, the incidence of malignant melanoma has increased 
by 4 percent each year since 1973. About 38,000 cases of melanoma were 
diagnosed in the US in 1996 and approximately 7,000 deaths are expected . Basal 
cell and squamous cell skin cancers, which are not as serious as melanomas 
account for more than 800,000 skin cancer cases in the US annually but cause only 
2 ,1 0 0  deaths because they are highly curable.
1.2. Treatment of Skin Cancer
There are several approaches to treatment of skin cancer, depending upon the 
particular type, but the preferred treatment remains surgery4. Surgery, however, 
may not only scar the skin, depending on the size of the cancer, but complete 
removed of the tumour is not always successful for malignant melanoma, which 
has a tendency to metastasise at an early stage. Radiation therapy uses x-rays to 
eradicate cancer cells and shrink tumours for basal cell and squamous cell cancers 
and chemotherapy drugs are administered to kill cancer cells.
At present there are a number of both physical methods and new chemotherapeutic 
agents undergoing assessment for the management of advanced cutaneous 
malignancy. In general, it is unlikely that these approaches will result in the 
complete cure of advanced disease4. Recently, interferon and interleukin-2 are 
under clinical trial in melanoma. Interferon showed a 15 percent response rate in 
approximately 309 melanoma patients5. However, there were a number of 
detrimental side-effects such as fever; low blood count; and liver toxicity4. 
Interleukin-2 stimulates growth of T-cells in vitro, and in vivo also appears to 
activate killer cells. The report proposed a 50 percent response rate in malignant 
melanoma raised great hope6for it application as a clinical tool. But the significant 
toxicity includes dramatic fluid shift problems4.
Any preferred treatment would be more specific with fewer side effects. One such 
approach is the use of MSH peptides. a-MSH is active in skin pigmentation, and 
melanocortin receptor MC1-R is specific for a-MSH, so, study of the relationship 
between a-MSH and MC1-R may have potential as a new approach to therapy or 
as an aid in the diagnosis of skin cancer.
Peptide hormones such as a-MSH are key regulators many of cellular, 
intercellular, organ, and other physiological processes, so they may not be as toxic 
as current drugs7. a-MSH has a number of attractive features as a model peptide. 
As well as being a natural hormone, a-MSH is 13 amino acids which is large 
enough to provide technically the opportunity for significant structural alteration in 
the preparation of analogues and is small enough to facilitate synthetic procedures.
There are many reports in the literature about the physiological roles of a-MSH in
8-vivo and a number of melanoma cell lines are known to express a-MSH receptors
M. This will be discussed in more detail later in this chapter. Recently, molecular 
biology techniques have provided a combination of specific and comprehensive in 
vitro and in vivo bioassays and binding assays to provide detailed descriptions of 
the biochemical and biophysical events related to biological activity. The 
characterisation of partial agonists or antagonists may lead to the development of 
receptor antagonists as potential therapeutic agents. It is important to recognise 
that most peptide hormones interact with complex multiple receptor subtypes, and 
it is necessary to use multiple assays to obtain insights into the differential 
structural, conformational and dynamic requirements for each individual receptor 
subtype. Thus, studying the different receptors in order to define different 
physiological roles of MSH is another approach to the design of potential 
therapeutic agents. Several attempts have already been unable to exploit a-MSH in 
specific during targeting to melanoma.
a-MSH and J3-MSH12’15 have been conjugated to FAB fragments of antibodies for 
drug targeting. Their uptake into cells is receptor-mediated, and specific for certain 
cell types. However, most of them have demonstrated poor results when carried 
out in vivo for most receptors are widely distributed in different tissues, making 
selective delivery impossible by MSH-antibody conjugates. a-MSH analogues 
have also been tested clinically for other purposes.
Two compounds are in clinical studies as potential tanning agents without the need 
for sunlight exposure. [Nle4,D-Phe7]a-MSH called Melanotan-I (MT-I) has shown 
to be non-toxic in mice16. A preliminary clinical trial of MT-I in normal males 
showed that tanning could be achieved in the absence of sunlight exposure, and
there were only minor side effects, consisting of transient facial flushing and 
rarely, gastrointestinal upset17.
Ac-[Nle4,Asp5,D-Phe7,Lys10] a-MSHno, called Melanotan-II (MT-II), is able to 
increase human skin pigmentation at much lower dose than MT-I. MT-II, however, 
has more potent dose-related side effects such as mild nausea. At lower dose, MT- 
II interacts with MC1-R in melanocytes to produce tanning, and at high doses, with 
MC3-R in the brain to produce fatigue and nausea18.
13. POMC Peptides
Hormones are chemical messengers manufactured by the endocrine glands. They 
regulate the function of many vital organs. Hormones fall into four categories19: 1) 
Peptide, secreted by the anterior pituitary. 2) Steroids, from the adrenal cortex and 
gonads. 3) Iodothyronines, from the thyroid gland. 4) Catecholamines, from 
adrenal medulla. There are differences in the synthesis, physical state in the 
circulation, half life, metabolism, and mechanism of action of these four hormonal 
groups.
Peptide hormones are synthesised from large precursors and stored in the gland of 
origin. They are soluble in aqueous solvents, circulate in unbound form and have a 
half-life of minutes. Peptide hormones may act at the plasma membrane by binding 
to specific receptors and stimulating the synthesis of cyclic adenosine 
monophosphate (c-AMP) and other second messengers (as described in section
1.3.1.).
Steroid hormones are synthesised by a series of enzymatic reactions from a 
common precursor, cholesterol. Glandular storage of steroids is minimal. They are
soluble in nonaqueous solvents, circulate predominantly bound to plasma proteins, 
and have a half-life of hours. Steroids cross the plasma membrane of target cells, 
bind to cytoplasmic receptors, and act at the nucleus by initiating transcription. 
Iodothyronines are similar to steroid hormones in many respects. They are 
synthesised in the thyroid gland from iodine and tyrosine. The half-life of 
iodothyronines in circulation is longer than that of steroids (a span of days). 
Catecholamines share many of the properties of peptide hormones, but their 
synthesis, like that of steroids and iodothyronines, involves a series of enzymatic 
modifications of a precursor, in this case phenylalanine.
1.3.1. Biosynthesis of Peptide Hormones
Peptide hormones are synthesised in the rough endoplamic reticulum, translocated 
to the Golgi, where they are modified (glycosylated, phosphorylated, acetylated, 
amidated, sulphated or methylated) in order to be secreted20,21. Secretion of peptide 
hormones occurs by exocytosis, where the storage granule is translocated to the 
cell surface and its membrane joins with the plasma membrane. Peptide hormones 
are delivered to specific target cells where they are recognised by specific 
receptors. Peptide hormones interact reversibly with receptors on the surface o f the 
target cell. Intermediate molecules called second messengers deliver the signal to 
the intracellular organelles responsible for carrying out the hormonal command, c- 
AMP is the second messenger for many peptide hormones including a-MSH 
(Fig. 1.2).
c-AMP is formed from ATP within the cell by the action of adenylate cyclase, 
which is located on the inner face of the plasma membrane. Adenylate cyclase is
ll. This will be discussed in more detail later in this chapter. Recently, molecular 
biology techniques have provided a combination of specific and comprehensive in 
vitro and in vivo bioassays and binding assays to provide detailed descriptions of 
the biochemical and biophysical events related to biological activity. The 
characterisation of partial agonists or antagonists may lead to the development of 
receptor antagonists as potential therapeutic agents. It is important to recognise 
that most peptide hormones interact with complex multiple receptor subtypes, and 
it is necessary to use multiple assays to obtain insights into the differential 
structural, conformational and dynamic requirements for each individual receptor 
subtype. Thus, studying the different receptors in order to define different 
physiological roles of MSH is another approach to the design of potential 
therapeutic agents. Several attempts have already been unable to exploit a-MSH in 
specific during targeting to melanoma.
a-MSH and p-MSH12' 15 have been conjugated to FAB fragments of antibodies for 
drug targeting. Their uptake into cells is receptor-mediated, and specific for certain 
cell types. However, most of them have demonstrated poor results when carried 
out in vivo for most receptors are widely distributed in different tissues, making 
selective delivery impossible by MSH-antibody conjugates. a-MSH analogues 
have also been tested clinically for other purposes.
Two compounds are in clinical studies as potential tanning agents without the need 
for sunlight exposure. [Nle4,D-Phe7]a-MSH called Melanotan-I (MT-I) has shown 
to be non-toxic in mice16. A preliminary clinical trial of MT-I in normal males 
showed that tanning could be achieved in the absence of sunlight exposure, and
there were only minor side effects, consisting of transient facial flushing and 
rarely, gastrointestinal upset17.
Ac-[NIe4,Asp5,D-Phe7,Lys10] cc-MSFLmo, called Melanotan-II (MT-II), is able to 
increase human skin pigmentation at much lower dose than MT-I. MT-II, however, 
has more potent dose-related side effects such as mild nausea. At lower dose, MT- 
II interacts with MC1-R in melanocytes to produce tanning, and at high doses, with 
MC3-R in the brain to produce fatigue and nausea18.
1.3. POMC Peptides
Hormones are chemical messengers manufactured by the endocrine glands. They 
regulate the function of many vital organs. Hormones fall into four categories19: 1) 
Peptide, secreted by the anterior pituitary. 2) Steroids, from the adrenal cortex and 
gonads. 3) Iodothyronines, from the thyroid gland. 4) Catecholamines, from 
adrenal medulla. There are differences in the synthesis, physical state in the 
circulation, half life, metabolism, and mechanism of action of these four hormonal 
groups.
Peptide hormones are synthesised from large precursors and stored in the gland of 
origin. They are soluble in aqueous solvents, circulate in unbound form and have a 
half-life of minutes. Peptide hormones may act at the plasma membrane by binding 
to specific receptors and stimulating the synthesis of cyclic adenosine 
monophosphate (c-AMP) and other second messengers (as described in section
1.3.1.).
Steroid hormones are synthesised by a series of enzymatic reactions from a 
common precursor, cholesterol. Glandular storage of steroids is minimal. They are
soluble in nonaqueous solvents, circulate predominantly bound to plasma proteins, 
and have a half-life of hours. Steroids cross the plasma membrane of target cells, 
bind to cytoplasmic receptors, and act at the nucleus by initiating transcription. 
Iodothyronines are similar to steroid hormones in many respects. They are 
synthesised in the thyroid gland from iodine and tyrosine. The half-life of 
iodothyronines in circulation is longer than that of steroids (a span of days). 
Catecholamines share many of the properties of peptide hormones, but their 
synthesis, like that of steroids and iodothyronines, involves a series of enzymatic 
modifications of a precursor, in this case phenylalanine.
13.1. Biosynthesis of Peptide Hormones
Peptide hormones are synthesised in the rough endoplamic reticulum, translocated 
to the Golgi, where they are modified (glycosylated, phosphorylated, acetylated, 
amidated, sulphated or methylated) in order to be secreted20,21. Secretion of peptide 
hormones occurs by exocytosis, where the storage granule is translocated to the 
cell surface and its membrane joins with the plasma membrane. Peptide hormones 
are delivered to specific target cells where they are recognised by specific 
receptors. Peptide hormones interact reversibly with receptors on the surface of the 
target cell. Intermediate molecules called second messengers deliver the signal to 
the intracellular organelles responsible for carrying out the hormonal command, c- 
AMP is the second messenger for many peptide hormones including a-MSH 
(Fig. 1.2).
c-AMP is formed from ATP within the cell by the action of adenylate cyclase, 
which is located on the inner face of the plasma membrane. Adenylate cyclase is
the catalytic part of the hormone-receptor complex, which consists of at least two 
other components: the recognition component, which binds to the hormone, and a 
regulatory protein, which couples the recognition component to the catalytic 
portion. The regulatory protein, which binds guanine nucleotides, is called the G 
protein or N protein. Binding of hormone by the recognition component prompts 
the regulatory subunit to replace its guanosine diphosphate (GDP) with guanosine 
triphosphate (GTP), activating the catalytic portion. While the catalytic unit is 
resting, the inactive state is achieved by hydrolysis of GTP to GDP via the 
regulatory protein. The presence of GTP on the regulatory protein lowers the 
affinity of the recognition component for the hormone, and the bound hormone is 
released. The inhibitory actions involve a guanine nucleotide binding regulatory 
protein, which inhibits the adenylate cyclase component. Because the guanine 
nucleotide regulatory proteins may be either stimulatory or inhibitory they are 
called Gs and Gi.
c-AMP produces its physiological effect by activating protein kinase A (PKA). 
PKA has regulatory and catalytic subunits; c-AMP binds reversibly to the 
regulatory subunit, causing it to dissociate from the catalytic subunit, which is then 
free to exert its physiological activity (Fig. 1.3). c-AMP is destroyed by cyclic 
AMP phosphodiesterase (PDE), which converts it to 5'-AMP. The decrease of 
cAMP allows the re-association of regulatory and catalytic subunits of PKA, thus 
it inactivates.
Calcium has been recognised as a major regulator of cellular processes. It plays an 
important role in activation of various enzymes. The concentration of free calcium 
in the cytoplasm of resting cells is low, about 1 micromolar or less. Upon 
activation of the cell by neural or hormonal signals, the free calcium concentration
rises promptly, increasing perhaps 1 0 0 0 -fold and may reach the millimolar range. 











Figure.1.2.: Adenylate cyclase system. Hs= stimulatory hormone. Hi= inhibitory 
hormone Rs and Ri= recognition components of the receptor complex. Gs and Gi= 
guanosine nucleotide binding proteins. PDE= cyclic nucleotide phosphodiesterase, 
which inactivates cAMP. The plot is base on20.
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Figure.13: Activation of protein kinase A by cAMP. Inactive protein kinase 
consists of catalytic units (C), which binds with regulatory unit (R). When cAMP 
binds to the regulatory unit, the catalytic unit is released and activated. A decrease 
in cAMP allows the regulatory unit to rebind to the catalytic unit. The plot is 
adapted from20.
storage sites mainly within the endoplasmic reticulum and by influx of calcium 
from the extracellular fluid. Virtually all cells are endowed with a protein called 
calmodulin, which is the intracellular receptor for calcium. When bound to
calcium, calmodulin is able to bind to a variety of cellular proteins and activate 
them. When some hormones or neurotransmitters bind to their receptors on the 
surface of cells, they activate an enzyme, phospholipase C, which splits the 
membrane phospholipids, phosphatidylinositol 4,5-bisphosphate, into 
diacylglyceride (DAG) and inositol 1,4,5-triphosphate (IP3). Both of these 
compounds behave as second messengers. The role of IP3 is to mobilise 
intracellular calcium from storage sites in the endoplasmic reticulum, and DAG 
activates protein kinase C (PKC), which catalyses the phosphorylation of various 
cellular proteins to activate or inhibit them20.
The mechanism of action of a-MSH and related peptides have been reported. In a 
cAMP assay, melanoma cells showed a dose-dependent cAMP increase on 
treatment with a-MSH, [Nle4,D-Phe7]a-MSH, and p-MSH22-23. Freshly isolated 
intact E l5 rat Dorsal Root Ganglia (DRG) showed a dose-response curve with a 
maximal increase in cAMP production of 70-85%, when treated with 1-10 nM a- 
MSH or 10 nM ORG276624. With regard to intracellular calcium/inositol 
phosphate responses, there are indications that phosphoinositides play a role in the 
mechanism of action of melanocortins in CNS tissue. Lysed synaptosomes treated 
with 100 jiM ACTH1.24, ACTHm6, or a-MSH show an increase in IP325. In the 
absence of the melanotropin, frog (Rana pipiens) skins previously darkened with 
[Nle4,D-Phe7]a-MSH, a potent synthetic analogue of a-MSH, could be lightened 
by removal of calcium from the incubation medium but could be redarkened by 
adding calcium26. Thus, MSH darkening actions increase in the presence of 
calcium27.
10
a-MSH enhances PKC in B16 mouse melanoma cells28. Some reports have shown 
that PKC is involved in human29 and murine melanogenesis30 by activating 
tyrosinase. Depletion of PKC results in a complete inhibition of a-MSH induced 
melanogenesis30.
It is possible that some receptors are linked to the formation of more than one 
second messenger or that different classes of receptor for a single hormone exist 
on a single cell, each with its own second messenger19. For example, Konda et 
al?1 demonstrated that at the MC3-R both a-MSH and ACTH at human were able 
to stimulate both cAMP/PKA and inositol phospholipid/Ca+2 at concentrations as 
low as 10' 11 M.
1.3.2. Peptides Encoded by the Pro-opiomelanocortin Gene
Studies of adrenocorticotropic hormone (ACTH) led to the discovery of pro­
opiomelanocortin (POMC). When Mains et al?2 and Roberts and Herat33,34 
demonstrated that a larger protein contained both ACTH and p-endorphin, the 
precursor, POMC, was soon identified35. Nakanishi et al?5 determined the amino 
acid structure of bovine POMC, providing for the first time the complete sequence 
of the molecule. They used the nucleotide sequence of cloned DNA 
complementary to POMC mRNA to predict the entire amino acid sequence of the 
protein. POMC was found to be released from pituitary gland, and cleaved into 
three parts: The N-Terminal peptide (103 amino acids), ACTH (39 amino acids), 
and P-lipotropin (P-LPH, 93 amino acids). The N-terminal peptide is processed to 
yield y-MSH, while ACTH is processed in some tissues to a-MSH and
corticotropin-like intermediate lobe peptide (CLIP), and p-LPH gives rise to y- 
LPH, p-MSH, and p-endorphin (Fig.1.4)21.
Studies of the mechanisms involved in the production of bioactive peptides from 
POMC show that different peptides are produced from POMC in different tissues. 
This introduced the concept of tissue specificity to the processing of peptide 
hormone21.
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Figure 1.4: Tissue-specific processing in the two lobes of the rat pituitary. In the 
anterior lobe POMC is only processed to yield the N-terminal peptide, ACTH, p- 
LPH, whereas in the neurointermediate lobe POMC is further processed to yield y- 
MSH, the joining peptide, a-MSH, CLIP, y-MSH, and p-endorphin21.
133 . Tissue-specific Processing of POMC
The anterior and neurointermediate lobes of the rat pituitary provide means of 
studying tissue-specific expression of POMC-derived peptides. The anterior lobe 
contains predominantly ACTH1-39, as where in the neurointermediate lobe ACTHj. 
39 is processed to yield a-MSH (ACTH1-13 with an acetylated N-terminal and 
amidated C-terminal) and CLIP (ACTHi8-39)36- The two lobes also differ in the 
amounts of P-LPH and p-endorphin produced37.
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1.33.1. a-MSH
Mammalian a-MSH (Ac-Serl-Tyr2-Ser3-Met4-Glu5-His6-Phe7-Arg8-Trp, -Gly10-
11 12 12
Lys -Pro -Val -NH2) is a basic tridecapeptide. It also exists in des-acetyl- or di­
acetyl forms. Its amino acid sequence was first published in 1957 by Harris and 
Lemer38. a-MSH is not only found in the brain but also in peripheral tissues, e.g. 
skin, gastrointestinal tract, placenta39. a-MSH release from the CNS is controlled 
by MSH releasing factors (MRF) and inhibiting factors (MIF). Some mammalian 
MIFs are dopamine, y-aminobutyric acid (GABA), enkephalin, melatonin, 
serotonin, somatostatin, and adenosine40. Some MRFs are (nor)adrenaline, 
vasopressin, corticotrophin releasing factor (CRF) and opiates41,42.
133.1.1. Distribution
In most vertebrates, a-MSH is formed mainly in the pars intermediate of the 
pituitary gland. Adult humans lack a pars intermedia, but it is present in the human 
foetus. Thus, the human foetus contains a high a-MSH bioactivity which decreases 
after birth43,44. Rudman et a l45,46 studied the occurrence and localisation of MSH 
peptides in various regions of bovine, simian, human and rat brain. The highest 
concentration of MSH in the brain is found in the hypothalamus47. 
a-MSH bioactivity or immunoreactivity has been found in various peripheral 
tissues, such as skin48, testes49, placenta50, and gastrointestinal tract51. Plasma a -  
MSH levels have been reported as being elevated in some melanoma patients with
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an increase of about one third above levels found in controls52. A more detailed 
review of the biological actions of a-MSH is given in section 1.4.
1.3.3.2. p-MSH
The C-terminal of POMC cleavage fragment p-lipotropin (P-LPH), which is 
processed further to y-lipotropin (y-LPH), p-endorphin and p-MSH. p-MSH is an 
octadecapeptide and corresponds with the sequence Y-LPH41-58. The structure of p- 
MSH in different vertebrates is more variable than that of a-MSH. Certain species 
produce two forms of p-MSH, indicating either the expression of two different 
genes or a posttranslational modification. In common with a-MSH, p-MSH 
contains the heptapeptide sequence: Met-Glu-His-Phe-Arg-Trp-Gly.
1 3 3 3 . y-MSH
y-MSH is this ACTFLno-like sequence displaying structural homology to be a-and 
p-MSH peptides potentially derived from it. Although Nakanishi et al. only 
hypothesised the natural occurrence of a 12 amino acid residue “y-MSH”, Ling et 
a / . 53 predicted the existence of a family of y-MSH peptides, using the presence of 
basic amino acid pairs and established putative posttranslational processing 
reactions; e.g., NH2-terminal acetylation or COOH-terminal glycine deletion and 
amidation. Three classes of y-MSH peptides were synthesised accordingly: y r  
MSH, containing 11 amino acid residues with an amidated COOH-terminal Phe; 
Y2-MSH, a COOH-terminal Gly extension of yi-MSH; and Y3-MSH, a 15-amino
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acid residue extension of Y2-MSH52. The majority of the naturally occurring y- 
MSH peptides contains a lysine residue in the N-terminal region39. The structures 
of y-MSH are as follows:
y 1 -MSH H-Tyr-Val-Met-Gly-His-Phe-Arg-T rp- Asp- Arg-Phe-NH2
Y2-MSH H-T yr-V al-Met-Giy-His-Phe-Arg-T rp-Asp-Arg-Phe-Giy-OH
Y3-MSH H-Tyr-Val-Met-Gly-His-Phe-Arg-Trp-Asp-Arg-Phe-Gly-Arg-Arg-
Asn-Gly-Ser-Ser-Ser-Ser-Gly-Val-Gly-Gly-Ala-Ala-Gln-OH 
[Lysjy 1 -MSH H-Lys-Tyr-Val-Met-Gly-His-Phe-Arg-Trp-Asp-Arg-Phe-NH2 
[Lys]y2-MSH H-Lys-Tyr-Val-Met-Gly-His-Phe-Arg-Trp-Asp-Arg-Phe-Gly-OH 
Shibasaki et a / . 54 have demonstrated that only yi-MSH immunoreactivity could be 
found in bovine neurointermediate lobe, while Y3-MSH was the product of NH2- 
terminal POMC posttranslational processing in bovine anterior lobe, yi-and y2- 
MSH are the predominant molecular species present in human pituitary55. Fodor et 
al.56 demonstrated that [Lys]y2-MSH and y2-MSH are widespread in rat brain, 
where they are found in intermediate and anterior lobes of the pituitary gland, the 
hypothalamic arcuate nucleus and the commissural part of the nucleus o f the 
solitary tract (NTS). The occurrence of [Lys]y2-MSH immunoreactivity in many of 
the brain regions which are involved in cardiovascular regulation suggests a role of 
y-MSH in the regulation of cardiac function; The iv. administration of y2-MSH and 
[Lys]y2-MSH in rats produced dose-dependent increases in arterial pressure and 
significant cardioacceleration57,58. Similar effects were noted for yi-MSH59, but yi- 
MSH had no presser activity58.
Recently, Bergen et al.57 showed that C-terminal shortening of Y2-MSH resulted in 
y-MSH peptides which had no effect on mean arterial pressure and heart rate.
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These results suggest that the intrinsic activity of Y2-MSH is carried by the C- 
terminal y-MSH fragment Asp9-Arg10-PheM. It has been postulated that the 
cardiovascular effects of y-MSH are dependent on the Arg-hydrophobic amino 
acid sequence located at or near its C-terminus58. a-MSH, Y3-MSH and ORG2766, 
which do not contain this sequence in the C-terminus, show no cardiovascular 
activity in conscious rats58,60,61.
Within the anterior pituitary, y-MSH peptides were unable to evoke the release of 
luteinising hormone, follicle stimulating hormone, prolactin, growth hormone or 
thyrotropin53. Unlike y-MSH, a-MSH was able to affect the release of other 
pituitary hormones via feedback loops. For example: a-MSH stimulated growth 
hormone and thyrotropin, inhibited prolactin release and modulated luteinising 
hormone39. y-MSH peptides may not act as releasing factors for anterior pituitary 
hormones, thus they may exert other physiological effects. 
yi-MSH, Ac-yi-MSH, Y2-MSH and ys-MSH were tested in the Rana pipiens 
melanophore assay53. All peptides were able to stimulate melanocytes, but only at 
very high concentrations compared to a-MSH. The most active peptide in this 
assay was Ac-yi-MSH, a peptide synthesised in analogy to the N-terminus o f a -  
MSH. Y3-MSH was the least active peptide in the study.
So far, the specific receptors for y-MSH in involved in mediating its cardiovascular 
action are unidentified, though, it has been postulated that some of the actions o f y- 
MSH are mediated by the MC3-R62,63.
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1.3.4. Biological Activity of Peptides Derived from POMC
Peptides derived from POMC have diverse activities in both the nervous system 
and peripheral tissues64. POMC derived peptides are thought to be involved in 
enhancing attention, behaviour, learning and memory65,66, control of 
cardiovascular function60, thermoregulation67, analgesia68, and effects on the
Mimmune system .
While the most important peripheral effect of a-MSH is stimulation of 
melanogenesis by pigment cells39, ACTH is best known for regulating adrenal 
cortical cells and aldosterone production, and p-endorphin is for its analgesic 
effects70,71. Recently, y2-melanocyte stimulating hormone (Y2-MSH) has been 
suggested to enhance effects on cerebral blood flow in the rat61,72 . The 
melanogenic effects of ACTH/a-MSH related peptides were a suitable focus for 
this study, as it provided a means of investigating melanoma.
1.4. Biological Effects of a-MSH
1.4.1. Effect on Pigmentation
The most clearly defined physiological role of a-MSH is to control melanin 
pigmentation of the skin in most vertebrate species. In mammals and many other 
vertebrates melanocytes, melanin-producing pigment cells, are found in the basal 
layers of the epidermis. Melanocytes are derived from the neural crest from where 
they migrate as undifferentiated melanoblasts into the dermis and later invade the
epidermis and there differentiate into melanocytes39. These melanocytes in 
mammals (melanophores in lower vertebrates) utilise tyrosine to produce, through 
a number of biochemical events controlled by one or more enzymes, coloured 
polymers called melanins. Brown and black melanins are referred to as 
eumelanins, whereas red or yellow melanins are known as phaeomelanin (Fig. 1.5). 
The biosyntheses of these compounds initially have a common metabolic 
pathway73,74. Tyrosine is hydroxylated to dihydroxyphenylalanine (DOPA) in 
eumelanin formation which is further oxidised to dopaquinone. Both steps are 
catalysed by tyrosinase, the enzyme in melanin biosynthesis. In eumelanin 
formation, Dopaquinone undergoes a spontaneous irreversible and rapid 
intramolecular cyclization reaction to form leucodopachrome which is further 
oxidised to dopachrome, then rearranges to 5,6-dihydroxyindole, is oxidised to 
indole-5,6 -quinone and converted into melanochrome. For phaeomelanin 
biosynthesis, Dopaquinone proceeds through glutathionedopas, cysteinyldopas, 
cysteinyldopaquinones and 1,4-dihydrobenzothiazines, then phaeomelanin. At low 
tyrosinase activity, levels of dopa are low and the predominating pathway is the 
synthesis of cysteinyl-dopa which is incorporated into melanin to give 
phaeomelanin. On excess production of DOPA, as results after maximal 
stimulation by MSH, DOPA is converted to dopachrome which gives black 
eumelanin.
Mammals with varied coloured pelage pattern produce one or another of these 
melanins in different anatomical area of the skin39. a-MSH enhances melanin 
production within melanocytes, and the melanosomes produced migrate into the 
dendrite processes of the cells where they are released into the surrounding cells of
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the epidermis. Repeated injections of a-MSH or a synthetic analogue of a-MSH 
into individuals increases epidermal pigmentation, which is readily visible after a 
few days, demonstrating the capability of the human melanocyte system to respond 
to a-MSH75,76. Recently it has been also shown that [Nle4,D-Phe7]a-MSH
•  •  •  Rincreased skin darkening in human by after injection .
Hunt et al?1 showed that ACTH stimulated melanogenesis in cultured human 
melanocytes. Later, they also demonstrated that a-MSH increased tyrosinase 
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Figure.1.5: The melanin pathway39
I.4.I.I. Extension and Agouti
Melanogenesis in mammalian melanocytes leads to the formation of either 
eumelanin or phaeomelanin, resulting in a brownish and black or yellowish and
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red coat colour, respectively. The pathways are controlled by the products of two 
classical coat-colour controlling gene loci, extension and agouti.
1.4.1 .2 . Extension
Extension encodes the melanocortin receptor MC1-R, which is G coupled protein. 
MC1-R binds a-MSH and is expressed on pigment cells. The extension locus 
extends the range of brown/black pigment when dominant, and blocks eumelanin 
synthesis when recessive, thereby extending the range of red/yellow pigment. Coat 
colours in wild and domesticated animals are often determined by extension alleles 
at what is thought to be a homologous gene locus80.
1.4.13. Agouti
The murine agouti gene encodes for a novel 131 amino acid agouti protein. The 
sequence includes a secretion signal, a lysine-rich basic region, and a C-terminal
o 1
domain containing 10 cysteines with the potential to form 5 disulfide bonds . The 
importance of the signal peptide and the C-terminal cysteine residues for full 
biological activity have been established in vitro. But the lysine-rich basic region
51*5appears not to be essential for normal function .
The function of the agouti protein is to regulate the differential production of 
melanin pigments by melanocytes83, by acting in a paracrine manner to shift 
melanogenesis towards phaeomelanin84,85. It competes with a-MSH in binding to 
MC1-R and inhibiting MSH-induced cAMP formation81,86'88. Siegrist et al,87 
proposed that the antiproliferative action of the agouti protein in B16 melanoma
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cells in vitro could be caused by a down-regulation of MCI-R, resulting in lower 
levels of intracellular second messengers, such as cAMP, which are required for 
normal cell growth and function.
Agouti is also found to be an antagonist of MC4-R86,89, but not MC3-R or MC5-R. 
When agouti is overexpressed in yellow mutant mice, it induces obesity, insulin 
resistance and increased susceptibility to neoplastic lesions90,91. 
Intracerebroventricular administration of the agouti-mimetic peptide SHU9119, a
* 89potent MC4-R antagonist, induced a significant increase in food intake .
•  •  •  2"bRecent evidence has suggested that agouti might also increase intracellular Ca 
concentrations via a mechanism that may not involve antagonism of the 
melanocortin receptor92. The agouti protein antagonises the effect of verapamil, a 
Ca2+ antagonist; on melanogenesis, suggesting that Ca2+-dependent mechanisms 
may be involved in mediating the action of agouti protein93.
1.4.1.4.UV Radiation
Melanin production in melanocytes can also be enhanced by factors other than a- 
MSH, such as UV radiation, especially UVB, which has been speculated to be a 
risk factor for the development and progression of human cutaneous 
melanoma71,94. Interactions between MSH, IL-1 and UV light were examined in 
Cloudman mouse melanoma and human squamous carcinoma cell lines95. The data 
suggested that both cell lines produced IL-1 and that production was stimulated by 
exposure of the cells to UV; both cell lines possessed high affinity binding sites for 
MSH, and their ability to bind MSH was modulated by IL-1; the stimulatory effect 
of IL-1 on MSH binding to melanoma cells was reflected in enhanced cellular
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responsiveness to MSH regarding tyrosinase activity and melanin content. 
Recently, it has demonstrated that UVB radiation stimulates increased expression 
of the POMC gene, accompanied by production and release of MSH and ACTH by 
both normal and malignant human melanocytes and keratinocytes96'98, where MSH 
receptors were found to be expressed94. Thus, UVB, and a-MSH, enhance MSH 
receptor activity in mouse melanoma cells95,99 or human melanocytes97,98.
I.4.I.5. Variants of the MCI Receptor
Eumelanin is photoprotective whereas phaeomelanin may contribute to UV- 
induced skin damage. Individuals with red hair have a predominance of 
phaeomelanin in hair and skin or a reduced ability to produce eumelanin, which 
may explain why they fail to tan and are at risk from ultraviolet radiation(UVR)100. 
It has been reported that red hair and pale skin show strong association with 
variants of MCI-R100, suggesting that the majority of changes found were at codon 
92 and 294. Hunt et al.101 extended the study and reported that unresponsiveness to 
MSH is particularly prevalent in epidermal melanocytes from individuals with red 
hair. It indicated that the lack of functional MSH receptors on these melanocytes 
among these groups was a factor in their failure to response to MSH101. Recently, 
it has also been reported that the Asp84Glu ,replacing Aspartate with Glutamate, 
variant was only present in melanoma cases and appears to be of particular 
significance102.
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1.4.2. Effect of a-MSH on the CNS
1) Effect on grooming and stretch-yawn behaviour
Intraventricular administration of many a-MSH and ACTH-like peptides in the 
nanogram to microgram range produces a series of vigorous stretching and 
yawning in rats103'106. a-MSH was the most potent in this assay, then P-MSH and 
ACTHi-24, whereas Y2-MSH, ACTH4-10, and [Leu9]a-MSH were inactive. The 
synthetic, “superpotent” peptide, [Nle4,D-Phe7]a-MSH had more activity than a- 
MSH107.
2) Effect on sexual behaviour
a-MSH, ACTH, and related peptides have been reported to influence sexual 
behaviour in male and female rats. Both a-MSH and ACTH4.10 are effective in 
inducing sexual behaviour in ovariectomized rats receiving both estrogen and 
progesterone108,109.
3) Effects on arousal, attention, learning, and memory
The effects of ACTH4-10 peptides have been investigated in human volunteers and 
patients, and results are consistent with an improvement in subject attention caused 
by these peptides. a-MSH and ACTH4.10 have been reported to cause subjects to 
maintain high vigilance levels, prevent the decay of performance due to decreased
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motivation and mental fatigue and improve visual attention and visual motor 
learning. Verbal memory, however, was not enhanced110'112.
4) Effect on neural regeneration in the peripheral nervous system
Several authors have shown that a-MSH, ACTH, and ORG2766, ([Met(C>2)4,D- 
Lys8,Phe9]ACTH4_9), have effects on nerve regeneration113'116. Specifically the 
ACTH4-9 analogue ORG2766 is known to accelerate and enhance recovery of 
damaged peripheral nervous tissue113. Electrophysiological studies revealed that 
ORG2766 increased the speed of muscle contraction and decreased muscle fatigue 
during periods of prolonged stimulation117. The amino acid sequence of the 
ACTH4-9 core contains the essential information for acceleration of functional 
recovery after nerve damage. ORG2766 did not compete with [Nle4 ,D-Phe7]a- 
MSH for binding in the CNS, implying the existence of further melanocortin 
receptors to mediate the effects of this peptide118.
5) Effect on temperature control
a-MSH and ACTH1.24 have been reported to lower core temperature of febrile 
rabbits when given peripherally or centrally119. Centrally administered a-MSH was 
25000 times more potent than acetaminophen (paracetamol) in reducing fever in 
febrile rabbits67. a-MSHn-13 was reported to not only to reduce fever, but also 
possess anti-inflammatory actions. However, it was much less potent than the full- 
length peptide a-MSH120. The conformation of the C-terminal tripeptide of a-
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MSH affects its activity. D-substitutions in position Ac-[D-Val13]a-MSHn.i3 and 
11 1Ac-[D-Lys ,D-Val ]a-MSHi, -13 increase the antipyretic actions and anti­
inflammatory, but Ac-[D-Pro12]a-MSHn-i3 leads to loss of its anti-inflammatory
121 •  effects . Recently, a study demonstrated a-MSH was released in normal human
subjects with high fever induced by endotoxin122. Endotoxins are components of
the bacterial cell wall which reach the circulation during bacterial infection. The
injection of endotoxin causes a number of physiological changes such as
increasing fever.
6) Anti-inflammatory activity
a-MSH is a potent suppresser of inflammation, acting by down-regulating the 
activity or production of many cytokines. Administration a-MSH into mouse 
inhibited the peripheral inflammatory actions of the mediators, IL-lp , IL-6 , and 
tumour necrosis factor (TNF)123'125.
a-MSH inhibited the inflammatory mediator nitric oxide (NO) in cultured 
murine126 and human macrophages125 via inhibition of NO synthase II mRNA. 
MC1-R were found on cultured murine and human macrophages126,127. a-MSH is 
released by macrophages in response to cytokine treatment. a-MSH binds with 
MC1-R on macrophages, where it stimulates intracellular cAMP and inhibits NO 
production in monocytes126,127. a-MSH exerts its protective action against liver 
damage by binding MC1-R on mouse hepatic macrophages. MC1-R have been 
found in human neutrophils, and a-MSH has been reported to induce inhibition of 
neurophil migration to inflammatory sites128. Stimulation of Melanocortin receptor 
(MC receptors) inhibits cytokine and mRNA accumulation (including TNF, IL-8 ,
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MCP-1) resulting in a reduction in the release of cytokines. This results in a 
decrease of neutrophil and macrophage host cell infiltration into the liver and 
inhibition of liver injury129. a-MSH and a-MSHn.13 are able to promote IL-10 
production130. IL-10 inhibits the production of proinflammatory and 
immunomodulating cytokines, caused by binding of a-MSH with MC1-R to 
human monocytes. [Nle4,D-Phe7]a-MSH does not effectively block IL-1 action on 
thymocytes , suggesting that the immunomodulatory effects of a-MSH may not 
be mediated by the classic melanocyte a-MSH receptor (MC1-R).
7) Effect on cardiac contractability
In conscious rats, iv. administered ACTH4-10 and Y2-MSH induced a dose- 
dependent increase in blood pressure (BP), heart rate (HR) and pulse pressure 
(PP). a-MSH only caused an increase in HR, whereas the stable ACTH4-9 
analogue,ORG2766, was without effect on BP and HR61.
1.5. Structure-Activity Relationships
The principal aim of this study is the design of hormone analogues with features of 
practical utility for medical application, such as increase potency, greater 
metabolic stability, increased selectivity, prolonged time course of action or 
ability to inhibit the natural hormone (antagonistic properties). Structure activity 
studies have proved to be very useful for the elucidation of the mechanism of 
hormone-receptor interactions. Since a peptide hormone usually has more than one
physiological role, the investigation within the peptide should precede any further 
study on the transmission of hormonal information from the peptide to the cell.
To date, most studies have been carried out with a-MSH and a-MSH analogues on 
the MC1-R, and were reviewed by Eberle up to 198839.
1.5.1. Core sequence: Glu-His-Phe-Arg-Trp
His-Phe-Arg-Trp (a-MSH^) is found in all naturally occurring melanocortin 
peptides and because of its importance for biological activity, therefore, it is 
considered to be the core sequence of melanocortin peptides. In general, 
replacement of naturally occurring L-amino acids within this “core sequence” with
* 131D-amino acids led to a significant decrease in potency with the exception o f [D- 
Phe7]a-MSH or [D-Phe7JD-Trp9]a-MSH, where the potency is increased by a 
factor of about 10. Recently, Ac-D-Phe-Arg-D-Trp-NH2 has been reported as the
•  132most potent tripeptide in sustained melanotropic activity in frog skin . 
Replacement of Arg8 by D-Arg reduced the melanotropic potency133. Thus, both 
Phe7 and Arg8 are considered to be particularly sensitive to alterations and 
probably play a key role in eliciting the MSH response.
Glu5 residue is the least important for melanotropic activity in the (5-9) core o f a - 
MSH39. Replacement of Glu5 with alanine did not significantly alter the activity of 
a-MSH at neither MC1-R nor MC3-R134’135.
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1.5.2. N-Terminal Ser-Tyr-Ser-Met:
Structure-activity studies show that receptors on different melanophores exhibit 
slightly different recognition patterns for linear a-MSH peptides, i.e. certain 
residues are more crucial for biological activity in some bioassays than in others. 
For example, the Ser-Tyr-Ser segment is important for stimulation of Rana MSH
IQ
receptors but dispensable for eliciting the response in Xenopus .
Acetylation at the N-terminal protects the molecule from enzymatic degradation, 
and increased activity is due to the prolonged half life136.
Ser-Tyr-Ser is a hydrophilic part of the peptide. If these residues were substituted 
with lipophilic residues, a decrease in activity is seen39. Iodination at the [Tyr2] 
will increase the lipophilicity, so the potency of [125I-Tyr2]a-MSH is slightly lower 
than that of a-MSH by about 2-fold137. H-Ser-Tyr-Ser-Met is inactive but on 
addition of H-Ser-Tyr-Ser-Met to a-MSHs.i3 the potency increases 50-100 fold44. 
The Met4 residue is important since oxidation of methionine to methionine 
sulphoxide led to a large decrease in potency (1 0 -1 0 0  times) for the hormone. 
Substitution of Met4 by the isosteric norleucine Nle4 results in analogues that are 
resistant to oxidation and led to an increase in potency23,138. Replacement of Met 
with cysteine, which is structurally related, is possible, but replacement with 
alanine is not possible134. Some reports demonstrate that Ser-Tyr-Ser- is relatively 
unimportant to the overall biological activity and binding affinity of the native 
hormone139,140, while a-MSH4.i3 is as active as a-MSH.
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1.5.3. C-Terminal Gly-Lys-Pro-Val
Gly10 has an important spacer function between the central and C-terminal 
hormonal active sites141. Alteration of Lys11 in the tripeptide a-M SHn-13 
inactivates the fragment if the replacing residue is lipophilic or does not contain a 
basic side-chain. A change to [D-Pro12] abolishes activity. Lys11 can be replaced by 
alanine without effect134, attachment of a photoaffinity label in this position135,162 
has no effect as long as position 1 2  is not changed at the same time134. 
Modification at Val13 does not influence the potency of the peptides as long as the 
side-chain remains lipophilic39.
Addition of Lys-Pro-Val-NH2 to the C-terminus of the core heptapeptide resulted 
in a 1000 times increase in activity39, suggesting that the tetramer 10-13, Gly-Lys- 
Pro-Val, is an important second hormonal ‘active site’ of a-MSH . Some 
reports139,140,142,143 found that addition of Lys11, and Pro12 residues to cyclic
(-711#
melanotropin greatly enhanced biological activity. For example: [Cys ,Cys ]a-
MSH exhibits potency >10000 a-MSH activity in the frog skin bioassay, while 
I 1
[Cys4,Cys10]a-MSH4.io was found to be less active than a-MSH in frog skin assay,
r 1 I------1
though [Cys4,Cys10]a-MSH4-i3 was equipotent to [Cys4, Cys10]a-MSH139. This 
also demonstrated that N-terminal, Ser-Tyr-Ser-, is not important to whole 
sequence.
Incorporation of the Val13 residue results in no increase of potency. It is clear that 
the 4-12  sequence is the minimal sequence required for maximum potency140,142.
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1.5.4. [Nle4,D-Phe7] a-MSH
Melanotropic activities of synthetic stereoisomers of His-Phe-Arg-Trp-Gly showed 
that analogues replaced with D-Phe, D-Trp, or both, appear to have higher activity 
than the all-L-pentapeptides131,133 in skin bioassays. [Nle4,D-Phe7]a-MSH is a 
’’superpotent” agonist of a-MSH and is 26 times as potent as a-MSH in the mouse 
melanoma adenylate cyclase assay23. A single injection of [Nle4,D-Phe7]a-MSH 
into frogs caused near maximum darkening of the skins of the frogs for at least 6 
weeks . Injections of the natural hormone a-MSH or [Nle ]a-MSH also caused 
darkening, but this effect lasted only a few days26. Catt et al.144 have suggested that 
initial hormone interaction with receptor can effect a conformational change at the 
receptor resulting in tighter binding of the hormone to the receptor. [Nle4,D- 
Phe7]a-MSH may also induce tighter (apparently irreversible) binding to its 
receptor, leading to a sustained, biological activation of adenylate cyclase and 
cAMP production26,145.
[D-Phe7]a-MSH has been shown to protect the peptide from chemical degradation 
during in vitro and in vivo conditions. This would explain the higher prolongation 
as well as potency observed with [D-Phe7]a-MSH analogues to the [L-Phe?]a- 
M s h 26’138’146; [Nle4,D-Phe7]a-MSH4.n has similar properties to [Nle4,D-Phe7]a- 
MSH in that it has high affinity, and in the tyrosinase assay the compound was 
100-fold more active than a-MSH147. [125I-Tyr2,Nle4,D-Phe7]a-MSH is more 
stable to enzymatic degradation and is more resistant to oxidative conditions found 
during radioiodination. Therefore it is routinely used as a standard in biological 
assays and facilitates radioiodination for use in binding assays.
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1.5.5. Cyclic Peptides
Since linear peptides can adopt a multitude of conformational states, restriction of
conformational flexibility is a prerequisite for studying the “receptor-specific”
conformation of the peptide. The only practical way to obtain semi-rigid analogues
of peptides is by cyclization of suitable linear derivatives. It has been suggested
that a p-tum or other peptide chain-reversal region within the central active site
His-Phe-Arg-Trp of a-MSH might be functionally related to its biologically active
conformation39. To evaluate the effect of covalently locking a-MSH into a reverse-
tum conformation, Sawyer et a / . 148 substituted cysteine residues for Met4 and
Gly10, and oxidised the intermediate free disulfhydryl analogue to its
intramolecularly disulfide-bridged derivative, the cyclic analogue Ac- 
I 1
[Cys4,Cys10]a-MSH. They reported that it had superpotent bioactivity in the frog
I 1
skin bioassay but lacked significant prolonged activity139,148. Ac-[Cys4,Cys10]a- 
MSH has shown similar affinity as a-MSH in B16 murine melanoma cells 
expressing the MC1-R. Ac-[Cys4,Cys10]a-MSH had significantly higher affinity 
than its linear counterpart although the activities of the linear and cyclic analogues 
were similar149.
Al-Obeidi et al.150,151 designed cyclic lactam analogues of a-MSH resulting in
superpotency and prolongation in lizard skin. The most active compounds were
I----------------1 I I
Ac-[Nle4,Asp5,D-Phe7,Lys'°]a-MSH4.io and Ac-[Nle4,Asp5,D-Phe7, Lys10, Gly11]
a-MSH4.i3. Recently, Ac-NIe-hsp-His-D-Phe-Arg-Trp-iys-NPL has been shown
•  4 7to have higher affinity and more prolonged activity compared to [Nle ,D-Phe ]a- 
MSH, indicating that the available conformations of the peptide can increase
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receptor-ligand binding affinity and induce a receptor conformational change that 
effects the generation of cAMP by the same relative orders152,153.
1.5.6. Antagonists
A specific, competitive and potent antagonist would be a useful guide to 
understanding interactions of a-MSH with its receptors, but how a-MSH 
specifically interacts with its receptor to trigger activation or which regions of the 
molecule should be modified to produce antagonist action is as yet unclear. The 
mechanism of a-MSH antagonist action can be studied by evaluating large 
numbers of structural variants of the molecule. Structure modification of a-MSH 
by substitution or deletion of certain amino acids has been used as an approach to 
identify a-MSH antagonists in various melanocyte bioassays. However, in 
previous studies, a-MSH antagonists have either not been highly potent or were 
agonists at high concentrations. Thus, much less has been achieved on the design 
of competitive antagonists of a-MSH.
Al-Obeidi et al. have synthesised a selective antagonist for the frog skin receptor, 
Ac-Nle-Asp-Trp-D-Phe-Nle-Trp-Lys-NH2. Castrucci et a/.154 demonstrated that H- 
His-D-Arg-Ala-Trp-D-Phe-Lys-NH2 was an antagonist in vivo in the lizard skin 
assay although in both cases the concentration of antagonist was very high in the 
1 O'5 M range.
Recently, a series of potent antagonists of a-MSH has been published by 
Jayawickreme et al.155: Met5-Pro6-D-Phe7-Arg8-D-Trp9-PheI0-Lysn -Pro12-Val13- 
NH2 (153N-6) and Ala5-Leu6-D-Phe7-Arg8-D-Trp9-Phe10-Lysn -Pro12-Val13-NH2,
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both inhibited the activity of a-MSH as measured in the c-AMP assay. Most 
antagonists contained the [D-Phe-Arg-D-Trp]a-MSH7_9, and L-Phe (corresponding 
10 position of a-MSH) may be important for antagonist activity. The peptide,
153N-6, could competitively inhibit the binding of [125I-Tyr2,Nle4,D-Phe7]a-MSH 
binding at every melanocortin receptor albeit with different potency156. The shorter 
tripeptide, D-Trp-Arg-Leu-NH2, was reported157 to antagonise the human 
melanoma MC1-R with an IC50 of 0.6pM. Some antagonists were found by Adan
1 ^ 9et a l and tested on rat MC3, human MC4 and ovine MC5 receptors with
alteration in the ACTH4-10 positions. The structures used were [Phe-I7]-ACTH4_io,
which antagonised all three receptors although activity was very low in vitro', and
[D-Arg8]-ACTH4-io, [Pro8,1 °,Gly9]-ACTH4 .10 antagonised the MC4-R and MC5-R.
Hruby et al, 159 suggested that modifications of the phenyl ring of the D-Phe7
residue of a cyclic lactam derivative, while retaining the aromatic character, can
result in melanocortin receptor antagonists with high potency and specificity and
the activity was found to be very low in vitro. In this study, naphthylalanine was
4 1 5introduced in position 7 to give the cyclic lactam peptide Ac-Nle -[Asp ,(D- 
Nal(2)7,Lys10]a-MSH4_io-NH2(SHU9119). This was a potent antagonist of MC4-R 
and less potent antagonist of MC3-R but a full agonist of the MC1-R and MC5-R. 
Likewise, substitution with [D-p-iodophenylalanine7] to Ac-Nle4-[Asp5,D-Phe 
(pi)7, LysIO]a-MSH4-io was found to be a potent agonist at the cloned human MC1- 




There are numerous targets for drugs, the most common being enzymes, receptors, 
ion channels, and active transport complexes. Melanocortins exert their effects by 
binding to G-protein-coupled cell surface receptors and couple with the adenylate 
cyclase second messenger, cAMP (see section 1.3.1.). Since 1992, molecular 
cloning identified a family of G-protein coupled receptors that bind and are 
stimulated by melanocortic peptides. Up until now, five melanocortin receptors 
have been identified; the melanocyte MSH receptor MCI, and the adrenal ACTH 
receptor MC2 are located in the periphery, while MC3, MC4 and MC5 are 
localised mainly in the brain. MC3 is situated in the hypothalamus. MC4 is 
widespread in the brain and MC5 has not yet been mapped sufficiently.
1.6.1. MCI Receptor
The first melanocortin receptors cloned were the mouse and human melanoma 
MSH receptors15,16. The mouse receptor is 315 amino acids long and human 
receptor is 317 amino acids. The Human MC1-R is 76% homologous with the 
mouse MC1-R. Transfection of human embryo kidney 293 cells with mouse MCI 
cDNA results in the expression of a functional MC1-R. The measurement of 
cAMP production following stimulation with MSH peptides revealed the activity 
profile: [Nle4,D-Phe7]a-MSH> a-MSH= p-MSH>ACTH. Moutjoy et al showed 
that y-MSH was not able to cause cAMP production15,53. L cells, which are derived 
from murine fibroblasts, transfected with human MC1-R gave a slightly different 
result: [Nle4,D-Phe7]a-MSH> a-MSH = ACTH> P-M SH» y-MSH17. Similar
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results apply to human melanocytes naturally expressing MC1-R as shown by c- 
AMP assays and competitive binding160. In human melanocytes, y-MSH increased 
cAMP production, although it was not a full agonist17. Competitive binding 
(displacement of [125I]NLDP-MSH by other melanocortins) in COS-7 cells 
transfected with the human MC1-R cDNA showed that [Nle4,D-Phe7]a-MSH> a- 
MSH> ACTH> p-MSH>y-MSH» ACTH4-1016 and human MC1-R expressed in 
COS cell display [Nle4,D-Phe7]a-MSH> a-MSH> desacetyl-aMSH> ACTHmo> 
p-MSH> y3-MSH>ACTH > yr MSH> y2-MSH> ACTH4-1018.
Northern blot analysis showed that the MC1-R is naturally expressed in most 
melanoma cell lines15,16 and in cultured murine and human macrophages126,127. 
Moreover, an MCI-type receptor isolated from primary rat Schwann cells has been 
reported161 detected by photoaffinity labelling with [^I-Tyr2,Nle4,D-Phe7, ATB- 
Lysn ]a-MSH. In this study it was shown that the molecular weight of the 
Schwann cell receptor was 42-45 kDa, similar to that found in the B16 melanoma 
cell line, 43-46 kDa, and was thought to be an MC1-R162. The functions of the 
MC1-R are considered to be pigment dispersion in melanocytes and modulation of 
anti-inflammatory activity in monocytes126,127.
1.6.2. MC2-Receptor
The MC2-R, specific for ACTH, is expressed only in the adrenal gland15. The gene 
encoding the mouse MC2-R was recently cloned and shown to possess 89% amino 
acid sequence homology with the human MC2-R, the mouse ACTH receptor is 
296 amino acids long163, and shows, 38,42,46,44% amino acid homology with the
35
MC1-R, MC3-R, MC4-R, and MC5-R, respectively164. ACTH was reported to 
induce up-regulation of both ACTH receptor transcripts and ACTH receptor 
numbers in cultured human adrenocortical cells165. Some studies164,166 
demonstrated that ACTH receptor specifically binds ACTH but not other 
melanocortin peptides, explaining why the MSH peptides are not known to induce 
steroidogenesis.
1.6.3. MC3-Receptor
The MC3-R is found in brain and placenta but not in melanoma cells or adrenal
•  17 17tissue . The cloned human receptor is 361 amino acids long , and the rat and 
mouse receptor 323 amino acids62,63. It has been confirmed by Desamaud et al the 
difference between human and mouse receptor is 37 amino acids63. Despite the 37 
amino acid difference, mouse and human receptors are 88% homologous. The 
amino acid sequence of MC3-R is 43-46% homologous with that of MC1-R or 
MC2-R. The activity profile of melanocortin peptides at the MC3-R on cAMP 
accumulation is as following: a-MSH= p-MSH= y- MSH= ACTH17, [Nle4,D- 
Phe7]a-MSH> yi-MSH= y2-MSH= a-MSH= ACTH(i-39)> y3-MSH> desacetyl a -  
M S H »  ACTH4-1062, and [Nle4,D-Phe7]a-MSH= y2-MSH> p-MSH= 
aMSH>ACTHi-39 >> ACTH4.1063. The competitive binding assay shows that 
[Nle4,D-PHe7]a-MSH> desacetyl-aMSH> yr MSH> y3-MSH> p-MSH> y2-MSH> 
a-MSH> ACTH> ACTHi-io> ACTH4.1018. The order of activity differs for a-MSH 
but all authors agree that the MC3-R responds relatively strongly to y-MSH, and 
all reports show that certain brain areas express this receptor17,62,63. The MC3-R
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does not bind ORG2766. The inactivity of ORG2766 means that the MC3-R is not 
likely to be involved in neural regeneration62. It has been suggested that MC3-R 
might be specific for y-MSH62 and may be involved in cardiovascular function. 
However, several reports have shown that neither MC3-R nor MC4-R is involved 
in the centrally mediated presser activity of y-MSH57,167,168 so the main function of 
the MC3 receptor is still unknown.
1.6.4. MC4-Receptor
Human MC4-R are located mainly in the brain169,170. The human MC4-R is 333 
amino acids long170 and the rat MC4-R is 332 amino acids long169. They have 
approximately 95% homology. The MC4-R is most closely related to the other two 
newly described melanocortin receptors, MC3-R17,62 and MC5-R171'174, with 55- 
61% homology, demonstrates slightly less homology (46-47%) with MC1-R and 
MC2-R. The activity established by cAMP accumulation caused by different 
peptides at MC4-R are the following: [Nle4,D-Phe7]a-MSH> desacetyl-a- 
MSH>/ACTH>/a-MSH» y2-MSH> ACTUmo169. a-MSH= ACTH= P-M SH » y- 
MSH >ACTHi.io>ACTH4-io170. The potency in the binding assay shows the 
following profile: [Nle4,D-Phe7]cc-MSH> [Nle4]oc-MSH > P-MSH> desacetyl-a- 
MSH>a-.MSH> ACTH> ACTH4.io>yi-MSH> y2-MSH175. Among the endogenous 
MSH peptides, p-MSH shows the highest affinity for MC4-R175. It has therefore 
been suggested that p-MSH might be the natural ligand for this receptor175.
Ligands binding to MC4-R induce excessive grooming behaviour in rats, and the 
potency for excessive grooming behaviour via MC4-R is: [Nle4,D-Phe7]a-MSH>
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a-MSH> ACTH(4-i3)158’167. The MC4-R is more widely distributed in the central 
nervous system than the MC3-R and is represented at multiple sites in almost 
every brain region. Like the MC3-R, MC4-R does not respond well to ACTH4-10 
and does not respond at all to ORG2766. These compounds are more active than 
native melanocortins in behavioural assays involving the retention of acquired 
behaviour113 and they enhance nerve regeneration114. Thus, neither MC3-R nor 
MC4-R appear to be involved in nerve regeneration and acquired behaviour. 
Recently, some reports have shown that mouse agouti peptide displayed antagonist 
activity at MC4-R86,89. Intracerebroventricular administration of agouti-mimetic 
peptide, Ac-Nle4-c[Asp5,(D-Nal(2)7,Lys10]a-MSH4.io-NH2 (SHU9119), was 
shown to be a potent antagonist of MC4-R159, and ,like the agouti peptides, was 
able to enhance food intake significantly. This indicates that the MC4-R might be 
involved in the control of feeding behaviour.
1.6.5. MC5-Receptor
The MC5-R has been cloned from genomic libraries of different species, 
human174,176, ovine177, mouse171,172, rat173. In all species the predicted receptor is 
325 amino acids in length and the amino acid sequence shows 42%-50% 
homology with MC1-R, 45% with MC2-R, 53-69% with MC3-R, and 62% with 
MC4-R. MC5-R has been detected in skeletal muscle, adrenal gland, brain, and 
wide variety of peripheral tissues172'174,177. The potency with which the MC5-R 
responds to melanocortin peptides with c-AMP accumulation is the following: 
[Nle4, D-Phe7]a-MSH> a-MSH> ACTHd.39) = P~MSH= yr MSH > y2-MSH= y3-
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MSH171, [NIe4,D-Phe7]a-MSH= a-MSH= ACTHi.24> ACTH= p-MSH> y- 
M S H »  ACTHU-io173, [Nle4,D-Phe7] a-MSH> ACTH|.24> a-MSH> p-MSH> y- 
MSH174, a-MSH> P-MSH> ACTH> y-MSH172, [Nle4,D-Phe7] a-MSH= a-MSH= 
P-MSH . Competitive binding assays show the following activities: [Nle4,D- 
Phe7]a-MSH> a-MSH= ACTH> p-MSH> y-MSH176, [Nle4,D-Phe7] a-MSH> a- 
MSH> P-MSH> ACTH> y3-MSH> y,-MSH> y2-MSHm , [Nle4,D-Phe7] a-MSH> 
a-MSH= ACTH> P-MSH177. [Nle4,D-Phe7]a-MSH > desacetyl-a-MSH> a- 
MSH>p-MSH> A CTH ^-M SH 18. MC5-R differs from MC1-R, MC2-R, MC3-R 
, and MC4-R by its presence in skeletal muscle, in addition to brain and adrenal 
gland.
1.6.6. Differences Between MCI and MC3 Receptor
MCI receptors appear to occur primarily in peripheral cells. For example, MC1-R 
were found in mouse and human melanocytes and melanoma cells, and in murine 
and human macrophages126,127. MC1-R shows high and selective affinity and 
activity for a-MSH, but y-MSH peptides, which are predominant in human 
pituitary55, have very low affinity and activity at MC1-R15,17. This indicates that y- 
MSH has no function in pigmentation. Ling et al.55 demonstrated that yi-MSH, Y2- 
MSH, or Y3-MSH were unable to stimulate the melanocytes in the Rana Pipiens 
melanophore assay except at very high concentrations compared to a-MSH. Due to 
the localisation of MC1-R, this receptor may mediate skin pigmentation effects 
and anti-inflammatory activities of a-MSH.
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MC3-R are found in brain and placenta but not in melanoma cells or adrenal
17 _
tissue . The distribution of y-MSH immunoreactivity corresponds well with that 
of MC3-R mRNA expression in brain, and y-MSH possess a higher affinity and 
activity for MC3-R than for the MC1-R, MC3-R has thus been implicated in the 
control of cardiovascular function17,62. The pharmacological profile of the MC3-R 
in vitro is not consistent with the in vivo cardiovascular actions of y2- 
MSH57,61,167,168. ACTH4-10 showed no affinity or activity at MC3-R, suggesting 
that MC3-R might not have an effect on nerve regeneration in the peripheral 
nervous system or induction excessive grooming behaviour167.
1.6.7. Summary
The main characteristics of the five MC receptors are: MC1-R is a specific a-MSH 
receptor expressed only in melanoma cells and melanocytes and macrophage, 
while MC2-R is an ACTH receptor expressed in the adrenal gland. MC3-R, MC4- 
R, and MC5-R are detected in brain tissue. MC3-R differs from MC4-R and MC5- 
R as it specifically recognises peptides with the ACTH4.10 core sequence. MC5-R 
differs from MC3-R and MC4-R in its pattern of expression. Besides the brain, 
MC5-R is also found in the adrenal gland and skeletal muscle. Which MC receptor 
is involved in the neurotrophic and neuroprotective actions of melanocortins is not 
yet clear. The most promising candidates are the MC3-R, MC4-R, and MC5-R, as 
they are expressed in brain and peripheral tissues. The MC5-R may be responsible 
for the effects of melanocortins on regeneration and development in muscle, as this
171 172 174is the only member of the MC receptor family present in skeletal muscle ’ ’ .
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A problem is that ACTH4-10, which is fully active in peripheral nerve regeneration, 
is much less potent than a-MSH or has no effect on the cAMP production in cells 
transfected with the MC3-R62, MC4-R168, and MC5-R171. Thus, it is possible that 
fewer melanocortin receptors exist. An overview of the pharmacological data 
published for melanocortin receptors is given in Table. 1.1.
R species Cell Efficacy Order of Melanocortin No Effect Ref
1 mouse human 293 A:NLDP>a-MSH=3-MSH=ACTH y-MSH 15
1 human COS7 B:NLDP>a-MSH>ACTH>3 -MSH>y-MSH>ACTH4-,o 3 -endorphin 16
1 human murine L A:NLDP>a-MSH=ACTH>3-MSH»y-MSH 17
1 human COS B:NLDP>a-MSH>desacetyl a-MSH>ACTH, .10 >3-MSH 
>y3-MSH >ACTH>YrMSH>Y2-MSH>ACTH4-io
18
3 human murine L A:NLDP=a-MS=3-MSH=y-MSH=ACTH>ACTH , .,0 > 
ACTH4.10
17






3 mouse CHOK A:NLDP^2-MSH>3 -MSH=a-MSH>ACTH»ACTH4-10 3-Endoephin 63
3 human COS B :NLDP>desacety 1 a-MSH>yr MSH>r3-MSH>P-MSH 
>Y2-MSH>a-MSH>ACTH>ACTHMO>ACTH4.io
18
4 rat human 293 A:NLDP>desacetyl a-MSH>/ACTH>/a-MSH»y2-MSH 
=ACTH4.io
ORG2766 169
4 human murine L A:a-MSH=3 -MSH=ACTH»Y-MSH=ACTHMo=ACTH4-
10
170
4 human COS B:NLDP>[Nle4] a-MSH>3-MSH>desacetyl a-MSH>oc- 
MSH>ACTH>ACmno >yr MSH>Y2-MSH
175







5 rat CHO A:NLDP=a-MSH=ACTH1.24>ACTH=3-MSH>Y
M SH »A C TH 4.io
173
5 human COS1 A:NLDP>ACTH,.24>a-MSH>3 -MSH>Y-MSH 174
5 mouse mouse L A: a-MSH>3-MSH>ACTH>y-MSH 
A: a-MSH>ACTHM0>ACTH4.i3
172





5 human COS7 B:NLDP>a-MSH=ACTH>3-MSH>y-MSH 176
5 human COS B :NLDP>desacety 1 a-MSH>a-MSH>3-MSH>ACTH>yr 
MSH
„
Table l.l.:Functional Coupling of Melanocortin Rs to Adenylate Cyclic AMP and 
Binding. A: c-AMP assay, B: competitive binding assay, NLDP: [Nle4,D 
Phe7] a-MSH. The activities and affinities observed were measured after 
transfecting cells with the receptors.
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1.7. Aims and Objectives
The long-term aim of this study is to characterise promising approach to the 
selective drug treatment for malignant melanoma. Melanoma is notorious for its 
difficulty of detection and its tendency to metastasise at an early stage. So far, the 
treatment for melanoma is still limited to surgery, which is only possible at early 
stage. In this study, we focus on the study of a-MSH and related peptides as 
putative candidates for a more selective treatment of malignant melanoma. 
a-MSH and its analogues are found in the brain as well as in peripheral tissues. 
Therefore, the functions of a-MSH not only have great impact in pigmentation but 
the peptides possess many CNS effects such as influence on learning, attention, 
and memory, anti-inflammatory, cardioacceleration, nerve regeneration, and 
antipyretic. Since so many physiological actions are displayed by a-MSH and its 
analogues, there must be multiple and specific receptors to mediate these various 
effects. The existence of several different melanocortin receptors could be 
exploited when trying to target specific type receptors at present only in the cell 
type of interest.
Up to date, five melanocortin receptors have been cloned. The specific functions of 
MC1-R and MC2-R are known to be pigmentation and anti-inflammatory activity, 
and steroidogenesis respectively. The functions of the other receptors are still 
uncertain.
In this study, I focus on the relation of the a-MSH and its analogues with different 
receptors, in particular the MC1-R from B16 murine melanoma cells and the MC3- 
R from rat hypothalamus as tested by binding assay and cAMP accumulation.
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Several approaches have been attempted to achieve the discovery of selective 
ligands for melanocortin receptor subtypes:
Position 12 of a-MSH (Proline) has been suggested to be an important position for 
its activity. We have attempted to modify this position to test how it affects the 
activity at MC1-R and MC3-R as well as corresponding modifying position in yi- 
MSH peptides.
•j
[D-Phe ]a-MSH is very important to enhance its prolongation and potency. A
recent paper has suggested that substitute [D-Phe?]a-MSH residues with bulky
aromatic amino acids may act as potent and receptor selective antagonist. Thus,
alterations of [D/L-Tyr7]a-MSH and [D/L-Trp7]a-MSH have been made to
investigate antagonist activity at MC1-R, MC3-R and MC4-R.
Cyclic peptides have been proposed to be more stable and have higher activity than
I--------------------- 1
linear ones. Several Ac-[Nle4,Asp5,D-Phe7,Lys]a-M SH 4-i0 analogues have been 
synthesised and tested their affinity and activity at MC1-R.
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Chapter 2: Materials and Methods
2.1. Peptide Synthesis
2.1.1. Materials for Peptides Synthesis
a-MSH and yi-MSH were obtained from Bachem, Switzerland. Alanine-substituted 
peptides and analogues modified in position 7 were synthesised by Dr. U.G.Sahm in 
our laboratory and cyclic peptides by Dr. S.Bansal at Pharmacy, King’s college, 
London. All amino acids, Polydimethylacrylamide-Kieselguhr resin (Pepsyn K) and 
p-(R,S-L-1 (^H-fluoren-9-yl)methoxy-formamide-2,4-dimethoxybenzyl) 
phenoxyacetic acid (AM-linker) were obtained from MilliGen, Watford. 
Hydroxybenzotriazole (HOBT), trifluoroacetic acid (TFA), diisopropylcarbodiimide 
(DIC), 1,2-ethanedithiol (EDT), anisole and thioanisole were from Aldrich, 
Gillingham, Dorset. Activated esters used were pentafluorophenyl esters (PFP), except 
for serine which was used as 3,4-dihydro-4-oxyobenzotriazin-3-ylester (ODhbt), all 
amino-protecting group were Fluorenylmethoxycarbonyl (Fmoc). Purified peptides 
were stored at -20°C, and peptides on resin were kept at 4°C.
All peptides were synthesised using a MilliGen 9050 pepsynthesizer. The column for 
analytical HPLC was 250mm X 4.9mm, and for preparative HPLC 250mm X 25mm; 
they were obtained from LKB and Waters, respectively. The Packing material for both 




After peptide synthesis using the automatic synthesizer, resin was washed with 
dichloromethane to remove impurities and dimethylformamide (DMF), followed by 
methanol and diethylether washes. The washed resin was under dried N2.
2.1.2.2. Deprotection and Cleavage from Resin:
The peptide was deprotected and cleaved from the resin using 90% TFA, 5% 
ethanedithiol, 2% anisole and 3% thioanisole, over a period of 8  hours as determined 
by preliminary experiments. The peptide was then washed with petroleum ether to 
remove TFA and scavengers, and precipitated with diethyl ether. The crude peptide 
was redissolved in distilled water and freeze dried.
The crude peptide was analysed by analytical grade HPLC using a gradient elution 
with 0.1% TFA in water/ 90% acetylnitro (CAN), 0.1% TFA in water at 1% per min. 
The eluent was monitored at 217nm.
2.1.2.3. Purification by Preparative HPLC
The crude peptide was redissolved in 3.5% ACN, 0.1% TFA and purified by 
preparative HPLC using the above gradient. Fractions were collected at appropriate 
elution times. Fractions were analysed by analytical HPLC; fractions containing the 
target peptide were pooled and freeze dried. Peptides were identified by mass 
spectrometry and their purity confirmed using capillary electrophoresis which is from 
BioRad.
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2.1.3. Results for Peptide Synthesis:
All the peptides were tested by the mass spectrometiy. FAB-MS was carried out at 
Swansea University SERC, and electrospray mass spectrometry were provided at 
University of Bath. Results are shown the Table.2.1.
The capillary electrophoresis showed oniy a single peak for each peptides.
Peptides Molecular Weight 
Calculated Found
|Nle4 ,D-Phe7 la-MSH 1646.8 1647.0
[Nle4,D-Phe7 ,Phe1 2 la-MSH 1696.9 1695.3
fNle4 ,D-Phe7, Serl2 la-MSH 1636.7 1635.4
[Nle4 ,D-Phe7 ,Leu1 2 la-MSH 1663.9 1663.2
rAsp1 0 la-MSH 1722.8 1721.1
|Phel2 l<x-MSH 1715.9 1715.4
[Asp1 0 ,Phe1 2 la-MSH 1772.9 1772.2
[Nle3 ]Y!-MSH 1494.0 1495.0
Na -Lys-[Nle%i-MSH 1622.0 1623.0
[Nle3 ,Pron ]yi-MSH 1444.0 1444.0
[Nle3 ,Ser1 1 ]yi-MSH 1434.0 1434.0
[Nle3 ,Leu1 1 ]Yi-MSH 1460.0 1461.0
[Ala“ ,AlaI2la-MSH 1582.7 1580.7
[Alall,Alal3la-MSH 1580.7 1579
rAla12^ \la l3la-MSH 1611.7 1610.1





[Nle4,cyc-Asp5,D-Phe7,cyc-Lys10la-MSH (4-i3) 1348.8 nd
[cyc-Asp5,D-Phe7,cyc-Lysl0]a-MSH (5-i3) 1235.7 1234.8
[Nle4,cyc-Asp5,D-Phe7,cyc-Lysl0]a-MSH(i-i3) 1685.8 1685.0






Water for the preparation of all cell culture media and solutions was freshly double 
glass distilled using a bi-distillation Fistreem still fitted with a Fistreem predeioniser. 
(Fisons Ltd.)
2.2.1.2. Balanced Salt Solutions
Phosphate buffered saline (PBS) without divalent cations was obtained from Oxoid 
Ltd in tablet form. One tablet was dissolved in 100 ml of freshly double distilled water 
and autoclaved. Solutions were stored at 4 °C for up to four weeks.
2.2.1.3. Base and Acid Solutions
Solutions of 7.5% w/v sodium bicarbonate and 1 M sodium hydroxide were prepared 
using double distilled water and were steam sterilised. 0.1 mM HC1 was prepared by 
diluting 1M HC1 (BDH Laboratory Reagent Ltd.) in double distilled water followed by 
filter sterilisation. Solutions were kept at room temperature.
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2.2.1.4. Ethylenediaminetetraacetic Acid (EDTA)
A 0.02% w/v solution of the disodium salt (BDH Laboratory Reagents Ltd.) was 
prepared in PBS, sterilised and stored at 4°C , and made up monthly.
2.2.1.5. Trypan Blue
The stain was obtained from BDH Laboratory Reagents Ltd. and dissolved at 0.1 % 
w/v in PBS and filter-sterilised.
2.2.1.6. Growth Medium and Additives
RPMI 1640 (without L-glutamine and sodium bicarbonate) 10X, MEM non-essential 
amino acids 100X, L-glutamine 200mM, Penicillin (10,000 IU/ml) and streptomycin 
(10,000 mg/ml) were obtained from Gibco, Paisley, UK.
Batches of foetal calf serum were tested prior to routine use to ensure support of cell 
growth. Batches used were obtained from ICN and Gibco. All cells lines were cultured 
in RPMI 1640 medium supplemented with 10 % FBS, 200mM L-glutamine, 100 
IU/ml penicillin and 100 IU/ml streptomycin, MEM non-essential amino acids and 




Double distilled water 450
RPMI 1640 50
Foetal Calf Serum 55
7.5%NaHC03 13.5
MEM Nonessential amino acids 5
Penicillin + Streptomycin 5
L-Glutamine 5
INNaOH adjust to pH: 12-1A
The pH was adjusted to 12-1A  by the addition of an appropriate volume of IN 
sodium hydroxide or 1M HC1. The medium was stored at 4°C and used within two 
weeks. Culture of HEK cells transfected with the MC3 and MC4 receptors required 
addition of 0.5 mg/ml amphotericin B.
2.2.2. Laboratory Apparatus
All aseptic techniques were performed in a laminar flow cabinet (MDH Ltd.) with 
vertical recirculation. Cells were maintained at 37°C in a LEEC PF2 anhydric 
incubator (Laboratory and Engineering Company). An inverted microscope, WILD 
M40 (Wild Heerbrugg Ltd.) was used for monitoring cell growth and determining cell 
numbers together with a standard double grid haemocytometer (Fisons Ltd.).
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2.2.2.1. Disposable Items
Sterile tissue culture flasks were obtained from Falcon (Fahrenheit Labs, Bristol) and 
polypropylene ampoules for cell freezing from Coming, (Fahrenheit Labs.) 96- and 
24- well culture plates were supplied by Nunc. 96-well filtration plates and filters 
were from Millipore.
2 .2 .2 .2 . Glassware
Used glassware was soaked in a 2 % v/v solution of RPS (Fisons) for 30 minutes with 
rinsing in three changes of single distilled water. Items were subsequently soaked in 
double distilled water for about 2 hours, dried in a hot air oven (Gallenkamp) capped 
with aluminium foil and oven sterilised (Gallenkamp) by dry heat at 160 °C for 1 hour.
2.2.3. Cell Culture
2.2.3.I. Cell Lines
A B16 murine melanoma cell line was donated by L.R.Kelland, Institute of Cancer 
Research, Sutton. Human 293 cells transfected with the genes for the expression of the 
MC3 and MC4 receptors, respectively were obtained from R.D.Cone, Vollum 
Institute, Portland, Oregon, USA.
2.2 3 .2. Cell Storage and Recovery
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Cells were stored in 2 ml ampoules in the vapour phase of a Union Carbide LR-40 
liquid nitrogen refrigerator at approximately -148°C. Cells were prepared for storage 
by detaching confluent cells from the flasks using the method described for cell 
subculture. Cells were resuspended in culture medium, centrifuged for 10 minutes at 
1 0 0 0  rpm and resuspended in culture medium containing 1 0 % dimethyl sulphoxide 
(Aldrich, spectrophotometric grade) as a cryprotectant. Ampoules were then placed in 
a Union Carbide BF6  biological freezer unit plug and put in a Union Carbide LR-33 
liquid nitrogen refrigerator to allow them to cool below -70 °C at a rate of about 1 °C/ 
min'1. They were then transferred to the liquid nitrogen refrigerator for long term 
storage.
To recover cells from storage, the cryotubes were placed in a 37 °C water bath and 
defrosted. Cells were suspended in 10ml of culture medium, centrifuged for 10 min at 
1000 rpm, the cell pellet was resuspended and transferred to a 175 cm2 tissue culture 
flask containing prewarmed medium.
2.2.3.3. Cell line Maintenance and Subculture
Cells were grown as monolayers in 175 cm2 tissue culture flasks and examined daily 
for possible microbial contamination. The time to reach monolayer coverage varied 
between cell lines. In order to maintain a pH 7.2-7A, the medium was routinely 
changed the day before the cells reached confluence. When cells reached confluence
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(roughly 2xl07 cells/175cm2), they were subculture by the monolayer twice with 5 ml 
PBS to remove traces of serum which would inhibit the action of EDTA. This was 
followed by a 10 minute incubation at 37°C with 2 ml 0.02% w/v EDTA/PBS. 
Detached cells were diluted with culture medium to 10 ml, a sample was taken and 
counted and flask were inoculated with 2 x 106 cells per 175 cm2 in new flask 
containing 50-75 ml of fresh medium. All cell lines were maintained in a LEEC 
anhydric incubator at 37°C under standard conditions of 95 % air 5% CO2 in a 
humidified atmosphere.
2.2.3.4. Determination of Cell Density
After detached the cells from the flasks, a 0.4 ml sample of the cell suspension was 
mixed with 0.1ml trypan blue solution. Viable cells exclude the dye, and nonviable 
cells are stained dark blue. A sample of the stained suspension was loaded into a grid 
haemocytometer under the coverslip. A count of the four comers and the central 
square was viewed with an inverted microscope, then the number of cells was 
calculated using the following equation.: 
cells/ml = (Total cells in 5 chambers x 104)/4
2.3. Radioiodination at [Nle4,D-Phe7]<x-MSH
Iodination was carried out at the [Tyr2] position of [Nle4,D-Phe7]a-MSH by the 
oxidative chloramine-T method described by Eberle .
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2.3.1. Solutions
• 1% Polypep: 0.05 g of polypep (Sigma) was dissolved in 1ml phosphate buffer, 
PH 7.4 and 4ml of Double distilled water (DDH) directly before use.
• 0.25%BSA: 0.0025g BSA (Sigma) was weighted and dissolved into 1ml 
phosphate buffer, PH 7.4 and 4ml of DDH directly before use.
• 0.1% Chloramine T: 0.0lg  of chloramine T (Fisons) was weighted and dissolved 
in 10ml of DDH directly before use.
• 0.25M Phosphate Buffer, PH 7.4: mixture of 0.25M Na2HP0 4  and 0.25M 
NaH2P 0 4
Na2HP04 (BDH): 4.45g dissolved in 100ml DDH.
NaH2P 0 4 (BDH): 3.90g dissolved in 100ml of DDH.
• The pH 7.4 of Na2HP04 is adjusted by NaH2P 04. The stock solutions are stored at 
4°C and prepared monthly, and the phosphate buffer is prepared on the day o f the 
iodination.
• 1%TFA: 1ml of pure TFA is diluted to 100ml DDH and stored at 4°C.
• 80% MeOH + 1%  TFA: 80ml methanol and 1ml TFA are diluted to 100ml DDH 
and placed at 4°C. TFA was obtained from Alsrich.
• 60% MeOH + 1 % TFA: 60ml methanol and 1ml of TFA are diluted to 100ml 
DDH and stored at 4°C.
• 50% MeOH + 1 % TFA: 50ml methanol and 1ml of TFA are diluted to 100ml 
DDH and placed at 4°C. The MeOH is from Fisons.
•
2.3.2. Preconditioning of Purification Columns
A C l8  reverse phase bond-elute column packed with Spherisorb ODS (Anachem) was
preconditioned by washing according to the following protocol:
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Step 1: 3 X lml 1%TFA
Step 2: 3 X lml 80% MeOH /1%  TFA
Step 3 : 1 X 1 %  polypep
Step 4: 3 X 1 ml 80% MeOH/1% TFA
Step 5: 3 X 1 ml 1%TFA
The last wash of 1% TFA on the top of the column to avoid "dry out"
2.3.3. Iodination
1.5 pi of lmg/ml solution of [Nle^, D-Phe^J-aMSH is added to 20pl of 0.25M
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phosphate buffer, P H  7.4. Then,10pl of Na I and lOpl of chloramine-T are added 
and allowed to react for 30 seconds before addition of 0.6ml BSA solution. The 
reaction mixture is transferred to the Bond Elut column to separate free iodine from 
mono-iodinated and di-iodinated [ N l e ^ ,  D - P h e ^ j - a - M S H .  The column is washed as 
following:
Step 1: 2 X lml 0.25 M Phosphate buffer 
Step 2: 4 X lml 50%MeOH/l%TFA 
Step 3: 2 x lml 60% MeOH/l%TFA.
The first 2ml of wash, are discarded. The remainder is purified by HPLC.
2.3.4. Purification of [Tyr2,Nlc4,D-Phe7]a-MSH
The methanol wash is purified by HPLC with an exponential gradient of 0.1 %TFA in 
water and 0.1%TFA in 70% Acetonitrile/ 30% water, lml/min fractions are collected
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between 25 and 45 minutes after injection. The monoiodinated peptide elutes before
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the diiodinated derivative. The I activity of each lml fraction is determined by 
transferring tubes to a LKB Wallac 1277 Gammamaster automatic gamma-counter 
and those with radioactivity associated with the peak of monoiodinated peptide are 
pooled and their is activity counted again. The radiolabelled peptide could be stored at 
-20°C for up to 20 days.
2.3.5. Calculation of Radiotracer Concentration
According to the definition, 1 atom of 125I associates with 1 mole [Nle4,D-Phe7] a- 
MSH to give 1 mole [125I-Tyr2,Nle4,D-Phe7]a-MSH.
Carrier-free Na125I has a specific activity of 80.5 x 1015 Bq/atom (Amersham), so the 
activity of 1 mole [125I-Tyr2,Nle4,D-Phe7]a-MSH.= 80.5 x 1015 Bq.
lBq= 1 decay per second, or 60 decays per minute and the efficiency of the gamma 
counter =70%
1 mole [125I-Tyr2,Nle4,D-Phe7]a-MSH would register 80.5 x 1015 x 60 x 70% = 3.38 x 
1018 cpm on the LKB 1277 Gammamaster.
2.4. Binding Assays
179Binding assays were carried out following a method adapted from Siegrist et al. and 
as described by Erskine-Grout180.
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2.4.1. Binding Medium
The binding medium consisted of RPMI 1640 medium without additives, 25mM N- 
(2-hydroxyethyl)piperazine-N’-2-ethane sulphonic acid (HEPES) and 2% BSA were 
prepared as 1 0  times concentrates in serum-free medium.
• 2%BSA: 2g of BSA is weighed and dissolved in 100ml serum free medium, 
aliquoted into 5ml bottles and stored at -20°C.
• HEPES: 5.96g of HEPES is dissolved in 100ml serum free medium and buffered 
to PH 7.4 with 1M NaOH, distributed into 5ml bottles, and stored at -20°C.
Serum free RPMI 1640:
Reagent Volume(ml) Supplier
DDH 450 .
RPMI1640 lOx 50 Gibco
NaHC0 3 ; 7 .5 % 13.5 Sigma
NaOH, 1M adjust to PH7.2-7.4 Alrich
Binding Buffer:
Reagents Volume(ml) Supplier
2% BSA 5 Sigma
5.96% HEPES 5 Sigma
Serum free 1640 40 _
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2.4.2. Binding Assays with [125I-Tyr2,Nle4,D-Phe7]a-MSH at Different Receptors
2.4.2.1. MCI Receptor (B16 cells)
Cells were detached from the flasks, counted and seeded at a density of 5 X 1 0  ^ cells 
per well in 24-well plates. They were then incubated for 12-16 hours before being 
washed twice with ice-cold RPMI 1640 serum free medium and allowed to cool to 4°C 
while the binding buffer was prepared. A fixed concentration of [125I-Tyr2,Nle4,D- 
Phe ]a-MSH (normally 0.1 nM) was added to the medium and different concentrations
4 7
of [Nle , D-Phe ]a-MSH or other non-labelled peptide were added to medium; the 
range was from 10^ to 10'12M according to peptide’s affinity. 0.5ml binding medium 
containing [I25I-Tyr2,Nle4,D-Phe7]a-MSH and the peptides were added to the wells 
and cells were incubated for 8hr. at 4°C. After the incubation, the binding medium 
was washed off with ice-cold serum free medium, cells were lysed with 1M NaOH, 
and their radioactivity determined. The dissociation constant (Kd) was obtained using 
a non-linear least square regression (MINSQ) see section 2.4.5.
2.4.2.2. MC3 and MC4 Receptor (293 Cells)
Since HEK 293 cells could not be maintained in 24-well plates at 4°C for a long 
period, experiments were used in 96-well filtration plates. The plates were made of a 
solvent resistant plastic with polyvinylidene difluoride filters welded to the bottom of 
each plate which was removed after the incubation before counting the cell-associated 
radioactivity. The filter plates permitted the washing the cells to utilise a vacuum- 
manifold and detached cells which were not lost during the washing procedure. The 
plates were incubated with 10$ cells per well and incubated for 4 hr. at 37°C, then
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washed three times with cold serum free medium. 0 .1ml binding buffer was added and 
incubated for 24hr at 4°C. After the incubation, cells was washed three times and 
filters with cells transferred to LP4 tubes using the Multiscreen assay system. The 
radioactivity was measured on the LKB 1277 Gammasmaster gamma counter.
2.4.3. Binding Assays with [125I-Tyr2,Nle4,D-Phe7] a-MSH at Different 
Temperature and Time Intervals
The signalling of hormone and receptor is terminated by dissociation of the hormone 
from the receptor and/or by internalisation/inactivation of the hormone. It is not yet 
clear which pathway predominates in switching off a stimulated MSH and receptor 
complex. According to Eberle39, association at 37°C and 25°C at B16 melanoma cells 
is rapid but does not reach a steady state, i.e. the specific binding decreases 
immediately after reaching its maximal value because of decomposition of the trace. 
At 25°C, 50% dissociation was occurred after 90 min.
In Dr. R. Cone’s laboratory, the binding assay was performed at 25°C for 45 min. 
However, our binding experiment was demonstrated at 4°C for 24 hours to reach the 
equilibrium binding. Hence it was attempted to compare the differences at temperature 
in various time in MC3 receptor at [Nle4,D-Phe7]a-MSH. We found that there was not 
much difference in the dissociation constant at 25, 45, and 90 min. compared to our 
result, approximately Kd=10'8, but it was shown that the reaction did not reach to 
equilibrium at 25 and 45 minutes (or 90 min as well). This result might suggest that it 







—o— 45 min 
— a —  90 min
200 -
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[Nle4 ,Phe7]a-MSH at 25 °C at MC3 receptors at different time
NLDP at 25 #C Mean Standard
Derivations
25 min 2.86x10° 2.52x1 O'8 2.69x1 O'8 2.4077x10'a
45 min 6.24x1 O'8 1.79x10° 2.48x1 O'8 3.50x10'“ 2.393x10'“
90 min 3.49x1 O'8 1.81x10'° 2.65x10'“ 1.18249x10'“
2.4.4. Binding Isotherm of | l25I-Tyr2,Nle4,D-Phe7]a-MSH
An isotherm was generated using a range of radioligand concentrations. Non-specific 
binding was determined using a 1000-fold excess of cold ligand. Specific binding was 
calculated by subtraction of total and non-specific binding.
2.4.4.1. Binding Isotherm Analysis
Receptor numbers and dissociation constants were determined using MINSQ non­
linear least squares regression analysis employing the Langmuir Isotherm equation:
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n Ka [H] n [H]
[HR] = -------------------=  - I —
1 + Ka [H] Kd+ [H]
Where:
[H]= Concentration of free hormone.
[HR]= Concentration of hormone-receptor complex 
n= Total receptor number.
Ka= Association constant of ligand-receptor complex.
Kd= 1/Ka= dissociation constant of ligand-receptor complex.
Binding isotherms have previously been carried out in our laboratory; the affinity of 
[I25I-Tyr2,Nle4,D-Phe7]a-MSH was determined to be 0.48 nM, 1.66 nM and 7.68 nM 
for MCI, MC3 and MC4 respectively.
2.4.5. Analysis of Competition Binding Data
MINSQ non-linear least squares regression analysis was used to calculate dissociation 
constants from the competition binding data employing the following equation.
( CPM(max) -  CPM(rnin) ) X [R]
CPM (test) = CPM(min)
[R] + KdrX-tP-
Where:
CPM (test)= CPM Associated with a given competitor concentration
CPM (max)= CPM Associated with maximum radioligand binding without competitor.
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CPM  (min)= C PM  Associated with minimum radioligand binding with excess 
competitor.
[R]= Concentration of radiotracer
[I]= Concentration of competitor 
K<ir= Dissociation constant of radiotracer 
K j= Dissociation constant of competitor
2.5. cAMP Accumulation
Biological activity of the test peptides was analysed by measurement of cAMP 
concentration after stimulation of the receptor. The method was based on the 
procedure described by Salomon et al.181,182.
2.5.1. Solutions
• 2% Bovine serum albumin (BSA) (Sigma): 2g of BSA were weighted and 
dissolved in 100ml serum free medium as stock solution and stored at -20°C.
• lOmM 3-isobutyl-1 -methylxanthine; IBMX (Sigma): 22.23 mg were dissolved in 
10 ml DD water in a boiling water bath as a stock solution and stored at -20°C for 
a maximum of three months.
• 25% v/v Perchlorate; PCA (BDH Chemicals) was prepared as a stock solution and 
kept in the dark at room temperature.
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• 0.1 M cAMP (Sigma): 351.2 mg were weighed in 10 ml DD water as stock
solution and stored at -20°C.
• 4.2 N KOH (BDH Chemicals) 117.56g were dissolved to 500 ml DD water as a 
stock solution and kept at room temperature.
• Preincubation medium: contained [8-H]Adenine (Amersham) 0.025pCi/ well 
(0.05pCi/ml) in RPM I1640 culture medium.
• Incubation medium: contained 0.1 mg/ml BSA and 0.1 mM IBMX in serum-free 
medium as well as various concentrations of peptide.
• Stop solution: PCA 2.5%, cAMP 0.1 mM were prepared freshly from stock 
solution and used ice cold.
2.5.2. Assay Procedure
Cells were seeded into 24-well plates at a density of 5 x 105 cells /well and incubated 
overnight at 37°C. in a humidified atmosphere of 5 % CO2 and 95% air. Different cell 
lines required different incubation times for attachment, as B16 needed around 16 
hours however, MC3 took up to 22 hours. Cells were incubated with prewarmed 
preincubation medium for 2 hours at 37°C. The radioactive medium was removed and 
the cells washed with 0.5ml prewarmed PBS. Serial dilutions of peptides were made 
in the incubation medium. Cells were stimulated with 0.5 ml samples of this medium 
for 45 minutes at 37°C. Each concentration was assayed in triplicate. The medium was 
removed and stop solution added to each well for 30 minutes at 4°C. The culture 
dishes were occasionally agitated for efficient [3H]-cAMP extraction. 0.8 ml PCA
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extracts were transferred to clean tubes and neutralised with 80 pi 4.2N KOH. A 
sediment of potassium perchlorate could be observed. Samples could be store at 4°C 
overnight or at -20°C for longer periods181.
Distilled water was added to each tube to a final volume of 1.3 ml and mixed to allow 
crystals to resettle. A 0.9 ml sample was submitted to double-column chromatography 
in order to separate the /*HJcAMP from [J//]cATP and other radioactive 
contaminants .
2.5.3. Column Apparatus and Reagents
2.5.3.1. Columns
Two sets of 17 ml polypropylene separation columns (Mitchell Plastics Inc.) with 
plastic filter discs were mounted over each other in a tiered rack set which in turn was 
suspended over 4 ml collection tubes.
2.5.3.2. Reagents
• Dowex 50 AG50W-X8 resin 100-200 mesh (Bio-Rad): before use the Dowex 50 
was washed with 6  volumes each of 0.1N NaOH, water, IN HC1 and water, and 
poured into the first set of columns in an approximately 2:1 slurry. After each use, 
Dowex 50 columns were regenerated by washing with 5  ml of IN HC1, and stored
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until reused. Before use the columns were washed 3 times with 10 ml of water. 
The columns could be reuse several times.
• Neutral aluminated 100-200 mesh (Sigma WN-3): amunima 0.6 g was poured dry 
into the lower column set. Before initial use alumina columns must be washed 
once with 10 ml of 100 mM Tris-Cl at pH 7.5. After each use the columns are 
washed with 10 ml of 100 mM Tris-Cl at pH 7.5. The columns could be reused 
several times.
• Elution buffers was lOOmM Tris-Cl( Sigma), pH 7.5. The purpose of the buffer 
was to elute cyclic nucleotides. Since eluate from the Dowex 50 columns was 
acidic, which enhanced adsorption of cyclic nucleotides to alumina, elution of 
cyclic nucleotides was achieved through an increase in the pH of the buffer.
• IN HC1 was prepared for final washed of Dowex 50.
2.5.4. Column Chromatography Procedure
The Dowex 50 columns were washed with 30ml distilled water and the alumina 
columns with 8  ml 100 mM Tris-Cl, which the PH is 7.5., before samples were added. 
The neutralised PCA extract solutions 0.9 ml were pipetted into Dowex 50 columns, 
leaving the perchlorate crystals undisturbed. Each column was washed with 3 ml 
water and the eluate discarded. The Dowex 50 columns were mounted above an equal 
number of the alumina columns and washed with 8  ml water. The eluate from the 
Dowex 50 columns was slightly acidic and caused retention of [3HJcAMP was on the 
alumina. Then columns were placed over collection tubes and [3HJcAM? was eluted
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with 4 ml lOOmM Tris-Cl. A 0.5 ml sample of each eluate was added to 4 ml 
Optiphase scintillation cocktail (Wallac) and vigorously mixed. Radioactivity of the 
scintillation vial contents was quantified on a LKB Wallac 1215 RackBeta liquid 
scintillation counter. The Dowex 50 columns were regenerated after each use with 5 
ml IN HC1 and alumina columns with 8  ml Tris-Cl.
2.5.5. Calculation of EC50 values
MENSQ non-linear least squares regression analysis was used to calculate EC50 values 
for the tested peptides employing the following equation:
DPM (test, = DPM(max) + ( DPM(min) ~ DPM(max) )
1 +  E C jo
Where:
DPM (test)= DPM Associated with a given peptide concentration 
DPM (maxp DPM Associated with maximum stimulation 
DPM (min)= Background dpm without stimulation 
[C]= Peptide concentration
EC50= Concentration required to produce half maximal stimulation
2.5.6. Determination of Antagonist Activity
Cells of 5 x 105 cells/well were plated in 24-well tissue culture dishes and grown in 
RPMI1640 medium at 37 °C for overnight. Cells were incubated for 2 hours with
I
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prewarmed preincubation medium at 37°C. Medium was aspirated and the cells were 
washed once with prewarmed PBS. The cells were then exposed for 45 min at 37°C to 
varying concentrations of peptides in the presence of serum-free medium containing 
0.1% BSA, 0.5 mM IBMX and 10'8 M a-MSH. The medium with peptides was 
aspirated off and the cells solubilized with stop solution, which was 1 ml 2.5 % 
perchloric acid, 0.1 mM cAMP for 30 min at 4°C. Lysate 0.8 ml was removed, 
neutralised with 80pl 4.2 NKOH, and 0.42 ml H2O. The samples were mixed and the 
sediment was allowed to settle. [SH\-cAMP was separated from the lysate after 
sequential chromatography over Dowex and alumina columns as described in section
2.5.4.
2.5.7. Calculation of IC50 Values
( DPM(maX) -  DPM(mjn) ) X [CaMSH ]
DPM = DPM(min) + ----------------------------------------------
[C]
[C a MSH 1 +  E C 50aMSH *  ------
IC50
Where DPM(min) = Background DPM 
DPM(max) = Maximum counts 
Ca-MSH =Fixed concentration of a-MSH 
ECsoa-MSH = EC50 of a-MSH in control experiment 
C = Concentration of antagonist 
IC50 = IC50 of antagonist
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IC50 values were calculated with the above equation using MINSQ non-linear least 
square regression
2.6. Statistical Analysis
Data analysis was performed using MINITAB 9.1. Significant differences were 
determined using a one-way analysis of variance following Fisher’s multiple 
comparison procedure at the 95% confidence interval.
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Chapter 3: Activity of C-terminally Modified 
Melanocortin Analogues at MCI and MC3 
Receptors
3.1. Introduction
The results presented in this chapter are concerned with the putative differences in 
activation between the MC1-R and the MC3-R. The design of selective ligands for 
either subtype of the receptor would greatly enhance the possibilities for studying 
receptor subtype function and might also have clinical prospects.
Structure-activity studies with natural and synthetic analogues have been carried 
out for all the receptors known to date, but the analogues tested show only a small 
degree of selectivity towards one or the other o f the receptor subtypes. A common 
feature of all melanocortin receptors is that the synthetic analogue [Nle4,D-Phe7]a- 
MSH appears to be more potent than the endogenous ligand, a-MSH. However, 
on the MC3-R isolated from rat hypothalamus, most known naturally occurring 
MSH peptides act with the same potency134, implying that the rat MC3-R is more 
sensitive to y-MSH than are other melanocortin receptors.
a-MSH and y-MSH show structural differences mainly within the C-terminus and 
it has already been suggested that the presence of proline 12 (number with 
reference to a-MSH) is an important feature for the binding of a-MSH to the 
MC1-R134, but not the MC3-R135,184. Eberle, however, suggested that position 11 is 
very important for the activity of the C-terminus of a-MSH at MC1-R, for since 
Trp-Gly-OH and H-Pro-Val-NH2 are inactive, it appears that Lys 1 is the crucial 
position within the C-terminus39. However, when Sahm et at/.134 replaced every
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position of a-MSH by alanine, there were some degrees of difference observed at
12
position Pro between the MC1-R and MC3-R rather than at position 11. Cody et
al.H2 demonstrated that Ac-rCys4,Cys1 °]a-MSPLt-1?-NH? is more potent than Ac- 
I I I I
[Cys4,Cys10] a-MSH4_n-NH2 and is equipotent as [Cys4,Cys10] a-MSH at the frog, 
lizard and mouse melanoma. Sawyer et a l m  also pointed out that Lys11 in Ac-a- 
MSH6-11-NH2, was not essential to the potency of this a-MSH fragment derivative 
for it only showed a relative potency of 5.0 in both the frog and lizard skin 
compared to Ac-a-MSH6-9-NH2. However, addition of P r o  to Ac-a-MSH6-i2- 
NH2 exhibited markedly improved potency relative to Ac-a-MSH6-9-NH2 in both 
bioassays (500-fold in frog skin and 100-fold in lizard skin). Therefore, Pro12 
significantly contributed to melanotropic potency143.
To test this hypothesis C-terminally modified analogues of both a-MSH and y- 
MSH were synthesised to investigate whether the C-terminus plays a role in 
promoting selectivity of melanocortin peptides. These analogues were tested for 
receptor binding and stimulation of adenylyl cyclase in B16 murine melanoma 
cells expressing the MC1-R and HEK-293 cells stably transformed to express the 
gene encoding the rat hypothalamus MC3-R.
3.2. Results
125All peptides tested were able to inhibit completely the binding of [ I- 
Tyr2,Nle4,D-Phe7] a-MSH to both receptors and exhibit full biological activity at 
appropriate concentrations (Table.3.1, Table.3.2 and Table.3.4). To facilitate the 
comparison of affinity and activity at both receptors, the data is presented relative 
to a-MSH in Table. 3.3 and Table 3.5.
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3.2.1. C-Terminal Modified a-MSH and y-MSH Analogues
3.2.1.1. MCI Receptor
Data from representative experiments are shown in Fig. 3.1 and 3.2. At the MC1- 
R, all compounds derived from [Nle4,D-Phe7]a-MSH, a potent synthetic analogue 
of a-MSH181, showed approximately 10 times higher affinity and activity than a- 
MSH itself (compounds 2-5) (Table.3.1and 3.3A). Among the substitutions, 
[Nle4,D-Phe7,Phe12]a-MSH had slightly higher affinity than the other compounds
2-5 (Fig.3.1.A). [Nle4,D-Phe7]a-MSH and [Nle4,D-Phe7,Leu12]a-MSH had similar 
affinity to each other. [Nle4,D-Phe7]a-MSH had slightly higher activity than other 
compounds although compounds 3-5 were not significantly different (Fig 3.IB and 
Table 3.1). Neither affinity nor activity were affected by substitutions in position 
12 (Fig.3.1A and 3.IB). However, when a-MSH itself was substituted with 
phenylalanine in position 12, the potency of the resulting peptide (compound 7) 
(Table.3.1) was reduced to 1-2 % of that of the natural ligands potency (Fig.3.2). 
Substitution in position 10 with aspartate showed a similar effect. When both 
substitutions were made (compound 8) the peptide was rendered virtually inactive 
(Table 3.3 A) with 0.06% of the affinity and 0.009% of the activity of a-MSH.
yi-MSH (compound 9) showed very low affinity and activity at the MC1-R (0.4% 
and 0.06% that of a-MSH, respectively). Its synthetic analogue [Nle3]yi-MSH 
(compound 10), was synthesised in analogy to [Nle4, D-Phe7]a-MSH, and on the 
basis that this peptide would be more resistant to oxidation. It was decided not to
introduce the D-Phe residue in position 7 as this had proven to encourage high 
affinity binding to the receptor regardless of amino acid replacements within the 
C-terminal region when substituting a-MSH analogues in this study. Several 
substitutions were made in position 11 (corresponding to position 12 in a-MSH). 
Most of these analogues (compound 9-14) (Table.3.1) exhibited approximately the 
same activity as yi-MSH itself. For [Nle3]yi-MSH the biological activity could not 
be determined; it appeared to be very low (EC50 > 10"6M), but results were 
inconclusive. However, an analogue that was substituted with proline in position
o 1 1 # 9
11, [Nle ,Pro Jyi-MSH (compound 12), showed significantly increased binding 
and biological activity at the MC1-R when compared to yi-MSH (Table 3.1). In 
terms of binding affinity, [Nle3, Pron]yi-MSH shows the similar to [Phe12]a-MSH 
and in biological activity, [Nle3, Pro1 ^ yi-MSH demonstrated similar activity to 
[Asp10]a-MSH. Nevertheless, even this peptide did not show more than 2-3% of 
the affinity and activity of a-MSH (Table 3.3 A).
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Figure.3.1A: Displacement of [125I-Tyi*, Nle4, D-Phe7]a-MSH from the MC1-R 
by [Nle4, D-Phe7,Phe‘2]a-MSH and [Nle4,D-Phe7]cc-MSH.
72
2 5 0 0 -




1 5 0 0 -
1000 -
5 0 0 -
.io-10 io-« io -8 Log concentraton
Figure.3.1B: Stimulation of cAMP production at MC1R by [Nle4, D-Phe7, 
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Figure.3.2A: Displacement of [‘^ I-Tyr2, Nle4, D-Phe7]ct-MSH from the MC1-R
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Figure3.2B: Stimulation of cAMP production at MC1R by [Phe12]oc-MSH and a-
MSH.
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Figure 3.2.C. Displacement of [^I-Tyr2, Nle4, D-Phe7]a-MSH from the MC1-R
by a-MSH and yiMSH.
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Figure 3.2.D. Stimulation of cAMP production at MC1R by [Nle3,Pron]a-MSH
and [Nle4,D-Phe7]a-MSH.
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Table.3.1. Molar dissociation constants, EC50 values, and their standard deviations 
for a-MSH analogues in B16 melanoma cells. Each value is the mean of three or 
more experiments (Statistics data, appendix 1.1 & 1.2)._______________________
No Binding (Kd) c-AMP (EC50)
a-MSH 1 1.68 x 10'*
± 3.88 x 10"9 
n=5
2.74x 10‘9 
± 9.56 x Iff10 
n=6
[Nle4,D-Phe7]a-MSH 2 3.27x10 •*
± 1.78 x Iff9
n=5
1.67 x Iff10 
± 1.30 x Iff10
n=6
[Nle4,D-Phe7,Phe12]a-M SH 3 9.80 x 1 O'10 
± 9.97 x Iff11
n=3
5.93 X Iff19 
± 2.58 x 10‘10 
n=5
[Nle4,D-Phe7,Ser12]a-MSH 4 1.88 x Iff9 
± 8.33 x Iff10
n=3
3.08 x 1 O'10 
±1.23 x"10 
n=3
[Nle4,D-Phe7,Leul 2]a-MSH 5 2.70x10‘9 
± 7.42 x Iff10
n=5
2.38 x lff10 
±1.33 x Iff10 
n=4
[Asp10]a-MSH 6 1.39x 10-6 
± 6.13 x Iff7
n=3
2.25 x 10'7 
± 2.06 x Iff7 
n=3
[Phe12]a-MSH 7 5.25 xlO -1 
± 3.78 x Iff7
n=3
4.50 x Iff7 
± 1.61x 10'7 
n=3
[Asp *0,Phe 12]a-MSH 8 2.74 x 10'5 
± 3.2 x 10'5 
n=3
3.06 x Iff5 
± 2.35 x Iff5 
n=3
yr MSH 9 3.86 x Iff6
± 2.31 x 10^ 
n=3
4.47x 10'6 
± 1.53 x 10‘7 
n=3
[Nle3]y,-MSH 10 1.35 x Iff5 
± 7.62 x l o '6 
n=3
» 1 .0 x  Iff6 
n=3






[Nle3,Pro 1 IJYj-MSH 12 5.82 x Iff7 
±4.61 x Iff7
n=3
1.36 x lO '7 
±1.11 x Iff7 
n=4
[Nle3,Ser11]y1-MSH 13 7.28 x Iff6 
±3.11 xlO ’6
n=3
2.97 x 1 O'6 
±1.16 xlO"6 
n=3
[Nle^Leu^fy-M SH 14 1.53 x Iff5 
± 3.80 x Iff6 
n=3






Figure.3.7A : Relative affinity and activity of a-MSH and yi-MSH analogues to 
a-MSH at MC1-R (log scale). Individual bars represent single experiments. Black 
= Affinity, Grey = Activity.
No Binding(Kd) c-AMP(EC5o)
a-MSH 1 1.0 1.0
[Nle^,D-Phe7]a-MSH 2 5.14 16.4
[Nle4,D-Phe7,Phe12la-MSH 3 17.14 4.62
pSlle4 D-Phe7, Ser12la-MSH 4 8.94 8.9
[Nle4 ,D-Phe7,Leu12la-MSH 5 6.2 11.5
[Asp10la-MSH 6 0.012 0.012
[Phe12la-MSH 7 0.032 0.006
[Asp10,Phe12la-MSH 8 0.0006 0.00009
y,-MSH 9 0.004 0.0006
[Nle3]Yr MSH 10 0.0012 n.d.
Na -Lys-[Nle3]Y,-MSH 11 0.0009 0.0005
[Nle3,Pron ]Yr MSH 12 0.029 0.02
[Nle^SerHfy-MSH 13 0.002 0.0009
[Nle3,Leu11]Y,-MSH 14 0.001 0.0007




At the MC3-R, the binding affinities of [Nle4,D-Phe7]a-MSH and its analogues 2- 
5 (Table 3.2 and Table 3.3B) were 30-80-fold stronger than that of a-MSH; their 
biological activities were higher by a factor of 5-20 (Fig. 3.3B). Among the 
compounds 2-5, they were not significantly different in affinity and activity7 
whereas [Nle4,D-Phe7,Ser12]a-MSH showed higher affinity and [Nle4,D-Phe7]a- 
MSH had slightly higher activity than other analogues. Substitution in position 12 
in compounds 2-5 did not appear to make a significant contribution to affinity or 
activity. However, when substituting phenylalanine for proline in position 12 of a- 
MSH itself (compound 7), the affinity of the peptide was reduced to 10%, whereas 
the activity remained unchanged compared to a-MSH (Fig.3.4). The same effect 
was observed when position 10 was changed from glycine to aspartate (6); the 
affinity was affected more markedly (reduction to 0.8%) than the biological 
activity of the peptide (reduction to 20% that of a-MSH). The [Asp10,Phe12]a- 
MSH analogue showed the same properties as [Asp10]a-MSH (Fig.3.4A).
None of the yi-MSH peptides compounds 9-14 (Table.3.2) exhibited a very high 
affinity for the rat MC3-R. Their dissociation constants were all in the micromolar 
range and their affinities did not exceed 5% of that of a-MSH. Among compounds 
9-14, the [Nle3,Pron]yi-MSH and [Nle3]yi-MSH had slightly higher affinity than 
other yi-MSH analogues. However, when compared to the MC1-R, their biological 
activity appeared to be significantly less reduced (Table.3.1 and Table.3.2) than 
that of a-MSH. [Nle3,Pro1 ^ yi-MSH had similar activity to yi-MSH and still higher 
than other compounds (9-14). [Nle3]yi-MSH, Na-Lys-[Nle3]yi-MSH, and
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[Nle3,Leun]yi-MSH had lower activity among yj-MSH analogues although their 
affinities were similar to yr MSH analogues.
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Figure.3.3A: Displacement of [^^-Tyr2, Nle4, D-Phe7]a-MSH from the MC3-R 
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Figure.33B : Stimulation of cAMP production at MC3-R by [Nle4, D-Phe7]a-
MSH and [Nle4, D-Phe7, Phe12]a-MSH.
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Figure.3.4A : Displacement of [125I-Tyi*, Nle4, D-Phe7]a-MSH from the MC3-R
by a-MSH and a-MSH analogues.
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Figure 3.4.C. Displacement of [^I-Tyr2, Nle4, D-Phe7]a-MSH from the MC3-R
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Figure 3.4.D. Stimulation of cAMP production at MC3-R by yi-MSH and a-
MSH.
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Table.3.2. Molar dissociation constants, EC50 values, and their standard deviation 
for a-MSH analogues at MC3-R cell. n= The number of the experiments 
(Statistics data, appendix 1.3 & 1.4). ___________________ _______________
No Binding(Kd) c-AMP(ECso)
a-MSH 1 6.59 x 10"7±
6.60 3.14 x 10'7
n=3
2.36 x 10-8 
± 2.55 x 10‘8 
n=4
[Nle4,D-Phe7]a-MSH 2 2.16 x 10'8 
± 1.18 x 10'8
n=5
1.25x1 O’9 
±8.20 x 10'10 
n=3
[Nle4,D-Phe7,Phe12]a-MSH 3 1.22 X 1 O'8 
± 4 .85x1  O'9
n=5
3.58 x 1 O’9 
± 1.96 x 10'9 
n=3
[Nle4,D-Phe7,Ser12]a-MSH 4 8.21 x 10’9 
± 2.49 x 10'9
n=5
2.73 x 10'9 
+1.58 x 10‘9 
n=3
[Nle4,D-Phe7,Leu12]a-MSH 5 1.62 x 10‘8 
±6.91 x 10-9 
n=6
2.89 xlO'9 
± 1.59 x 10'9 
n=3
[Asp10]a-MSH 6 8.56 xlO"5 
± 5.14 x 10'5 
n=3
9.98 x 1 O'8 
± 1 x 10'7
n=3
[Phe12]a-MSH 7 6.19 x lO-9 
± 1.25 x 10-6 
n=3
9.35 x 10'9 
± 3.73 x 10'9 
n=3
[AsplO,phel 2]a-MSH 8 7.59 xlO 5 
± 5.53 x 10'5 
n=3
2.09 x 10‘7 
± 3.08 x 10‘7
n=3
yr MSH 9 2.69 x 10‘5 





[Nle3]y!-MSH 10 1.69x 10‘5 
± 1.99 x 10-6 
n=3
4.42 x 10'7
± 2 .5 4 x l0 ‘7
n=4
Na -Lys-[Nle3]yi-MSH 11 3.30 x 10"5 
± 7.21 x 10-*
n=3
1.12 xlO '9 
±4.11 x 10'7
n=3
[Nle3,Pro11]yi-MSH 12 1.95 X 10‘5 
± 1.24 x 10'5
n=3
4.43 x 10"8 
± 3.8 x 10'8 
n=3
[Nle3,Ser^ ^]yj-MSH 13 4.71 x 10’5 
± 2.47 x 10 s
n=3
1.55 x 10‘7 
± 8.96 x 10'8
n=3
[Nle3JLeu1l]yi-MSH 14 3.41 x 10'5 
± 1.14 x 10'5 
n=3
6.28 x 10'7 





Figure.3.7B : Relative affinity or activity of a-MSH and yj-MSH analogues to a- 
MSH at MC3-R (log scale). Individual bars represent single experiments. Black = 
Affinity, Grey = Activity.
No Binding(Kd) c-AMP(EC50)
a-MSH 1 1.0 1.
[Nle4 ,D-Phe7la-MSH 2 30.5 19
rNle4,D-Phe7,Phe12 la-MSH 3 54.0 6.6
fNle4 ,D-Phe7,Ser12la-MSH 4 80.3 8.6
[Nle4 ,D-Phe7,Leu12la-MSH 5 40.7 8.17
[AspiOfa-MSH 6 0.008 0.24
[Phe12la-MSH 7 0.106 2.5
rAsplO,Phe12la-MSH 8 0.009 0.11
yr MSH 9 0.025 0.54
[Nle3]Y!-MSH 10 0.039 0.05
Na -Lys-[Nle3 ] y 1 -MSH 11 0.02 0.02
[Nle3,Prou ]Yi-MSH 12 0.034 0.53
[Nle3,Serll]Yi-MSH 13 0.014 0.152
[Nle3,Leun ]Yi-MSH 14 0.019 0.038
Table.3.3B. Relative affinity constants and EC50 values for a-MSH analogues at 
MC3-R.
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3.2.2. Analogues with Multiple Alanine Substitutions
3.2.2.I. M CI Receptor
Analogues with multiple alanine substitutions within the C-terminus (compounds 
3-6) (Table.3.4A and Table 3.4B.) showed that both affinity and activity of the 
peptides were decreased significantly from 5% to 50% for affinity and from 0.7% 
to 9% for activity when compared to a-MSH. In particular, substitutions in 
position 11 and 12 reduced the affinity to 5% and activity to 0.7% for the MC1-R 
compared to a-MSH. Compound 6  had less lost affinity while reducing the activity 
significantly to 0.7% of the a-MSH value. Among the compounds 3-6,
[Alan ,AlaI3]a-MSH showed the least reduced affinity and activity (Fig. 3.5).
No Bindmg(Kd) c-AMP (EC50)
a-MSH 1 1.68x1 O'8 
± 3.88 x 10'9 
n=5
2.74 x 10'v 
±9 .56x  10' 10 
n= 6
[Nle4 ,D-Phe7 ]a-MSH 2 3.27 x 10‘v 
+1.78 x 10'9
n=5
1.67 x 10‘10 
± 1.30x 10' 10 
n= 6
[Alan ,Ala12]a-MSH 3 3.53 X 10'7 
± 8 .0 2  x 1 0 '8
n=3
3.79 x 10'7 
+ 2 .6 8  x 1 0 '7 
n=3
[Alan ,AlaI3]a-MSH 4 3.44 x 10‘8 
± 1.62 x 1 0 ‘8
n=3
2.99 x lC 8 
± 1.51 x 10-8 
n=3
[Ala12,Ala13]a-MSH 5 4.33 X 10'8 
± 2 .2 2  x 1 0 '8 
n=3
7.26 x 10‘8 
± 1.24 x 10'8
n=3
[Alall,Ala12,Ala13]a-MSH 6 1.24 x 10‘7 
±3.46x  10"8
n=3
3.73 x 10‘7 
± 1.91 x 10'7
n=3
Table.3.4A : Molar dissociation constants, EC50 values, and their standard 
















Figure.3.5A : Displacement of [125I-Tyr2, Nle4, D-Phe7]a-MSH from the MC1-R





















Figure.3.8A : Relative affinity or activity alanine analogues of a-MSH at MC1-R 
(log scale). Individual bars represent single experiments. Black = Affinity, Grey = 
Activity.
B16 No. Binding (Kd) c-AMP (EC50)
a-MSH 1 1.0 1.0
JNle4,D-Phe7] a-MSH 2 5.14 16.4
[Alan,Ala12la-MSH 3 0.048 0.007
[Alan ,Ala13la-MSH 4 0.49 0.09
[Ala12,Ala13la-MSH 5 0.39 0.04
[Alan ,Ala12,Ala13la-MSH 6 0.14 0.007




With multiple alanine substitutions (compounds 3-6) (Table.3.5A,and Talbe.3.5B), 
there was to a significant drop in the binding to the receptor with relative affinities 
of 4-10% except [Ala12,Ala13]a-MSH, which had similar properties to a-MSH. 
However, the biological activity of peptides with multiple alanine substitution at 
MC3-R was not significantly different from a-MSH. [Ala11, Ala12]a-MSH 
demonstrated that the lowest affinity to 4% and activity to 74% among compounds
3-6. [Ala11, Ala12, Ala13]a-MSH showed the lower affinity to 5% but the similar 
activity to a-MSH. [Alau ,Ala13]a-MSH had affinity reduced to 10% but the 
activity was similar to a-MSH. In general, with multiple alanine substitutions, 
decreased binding affinity could be observed but activity at MC3-R was
maintained (Fig 3.6).
MC3-293 No Binding(Kd) cAMP(EC50)
a-MSH 1 7.56 x 10'7 
±7.87 x 10"8
n=3
2.36 x 1 O'8 
± 2.55 x 10'8 
n=4
[Nle4,D-Phe7]a-MSH 2 3.27x10'*
± 1.78 x 10'9 
n=5
1.67 x 1 O'10 
± 1 .30x1  O'10 
n=6
[Alan ,Ala12]a-MSH 3 1.95 x 10'5 
±3 .26x 10"4 
n=5
3.21 x 10-8 
±7.65 x 1 O'9 
n=4
[Alau ,Ala13]a-MSH 4 7.27 x 1C6 
+ 2.59 x 1C6
n=5
2.82 x 10"8 
± l .lx  10'8 
n=5
[Ala12,Ala13]a-MSH 5 1.06 x lO* 
±2.01 x 10'7 
n=3
5.62x10'9 
± 3 .52x1  O'9 
n=3
[Ala11,Ala12,Ala13]a-MSH 6 1.42 x 10'5 
±4.85 x 10*6 
n=3
1.57x1 O'8 
± 3.99 x 10'9 
n=3
Table.3.5A. Molar dissociation constants, EC5o values, and their standard deviation for Alanine 
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Figure.3.6A : Displacement of [^I-Tyr2, Nle4, D-Phe7]a-MSH from the MC3-R
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Figure.3.8B : Relative affinity or activity alanine analogues of a-MSH at MC3-R 
(log scale). Individual bars represent single experiments. Black = Affinity, Grey = 
Activity.
MC3-293 No. Binding (Kd) c-AMP(EC50)
a-MSH 1 1.0 1.0
JN le4,D-Phe7] a-MSH 2 35 19
JA la“ ,Alal2]a-MSH 3 0.039 0.74
JA la",A la13]a-MSH 4 0.104 0.84
[Ala12,Alal3]a-MSH 5 0.713 4.2
[Ala",Ala12,Ala13]a-MSH 6 0.053 1.5




The "core" sequence of a-MSH, 6-9, has been identified as a basic sequence for 
melanotropic activity. Indeed, the tetrapeptide alone still retains some activity39. 
Any substitution within the 6-9 region, except with D-Phe7 and/or D-Trp9, leads to 
a loss of activity and affinity. Therefore it could not provide selectivity for one 
subclass of MSH receptors..
The N-terminus, Ser-Tyr-Ser, does not appear to have activity on its own. 
Therefore it is not likely to confer any selectivity.
The C-terminus of a-MSH, Lys-Pro-Val, provides distinct activity alone although 
it is not competitive as core sequence. Thus, the C-terminus could be a place to 
confer some selectivity of agonist or antagonist activity for a-MSH and y-MSH.
In a previous study, Sahm et a / . 135 substituted every position of a-MSH with 
alanine, and it appeared that position 1 2  conferred some degree of selectivity 
between MC1-R and MC3-R. As the MC1-R has strong binding with a-MSH and 
yi-MSH has by comparison better binding affinity with the MC3-R, we included 
yi-MSH in the study.
4 7
Substitutions made were in position 12 by Phe, Ser, and Leu on [Nle ,D-Phe ]a-
3
MSH and position 11 with Pro, Ser, and Leu on [Nle fy-MSH. Substitution of 
Pro by Phe in a-MSH and Phe by Pro in Yj-MSH were made because they
correspond to each other in the different peptides, and it was proposed that they are 
important for selectivity. The reason for substitution with Ser12 was that Ser has 
the closest hydrophobicity to proline but does not have a cyclic structure, and the 
reason for substitution with Leu is that Leu has stronger hydrophobicity than Pro, 
but likewise no cyclic structure.
When analysing the data it was observed that modification of the melanocortin 
peptide often led to analogues where either affinity or activity, but not both, were 
significantly changed. This is of interest in establishing the requirements for
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stimulation of each receptor. It was therefore useful to find a comparative measure 
for the peptides’ efficacy at each receptor by calculating the ratio between their 
activity and their affinity for each ligand (Fig 3.9A + 3.9B and 3.11A + 3.1 IB). 
Another purpose of the study was to establish the requirements for ligand binding 
selectivity which implies a relative difference in affinity of ligands for different 
subclasses of receptor. Therefore, to enable the comparative analysis between the 
receptors, selectivity of the analogues was determined by calculating a ratio 
between their respective affinities for each receptor (Fig. 3.10 and 3.12). Both of 
these ratios are expressed relative to a-MSH to facilitate comparison.
At the murine MC1-R, all analogues of [Nle4,D-Phe7]a-MSH bound with equal 
affinity and exhibited the same biological activities irrespective of their 
substitution at position 12; this effect was not be observed for a-MSH itself. It has 
been postulated that analogues of [Nle4,D-Phe7] a-MSH might interact with the 
MC1-R in a different way to a-MSH145 and the results presented in this study 
support this hypothesis. However, it has to be noted that [Nle4,D-Phe7,Phe12]a- 
MSH was the only one of the series that showed decreased efficacy compared to 
both a-MSH and the other [Nle4,D-Phe7]a-MSH analogues (Fig3.9A).
a-MSH, when substituted with phenylalanine in position 12, showed a significant 
reduction of both affinity and activity; it was therefore concluded that position 1 2  
might play an important role in the interaction of a-MSH with murine MC1-R.
* 135This is further supported by reports that substitution of proline with alamne , D- 
proline, norvaline and glycine39 all significantly decreased affinity and/ or activity 
of the peptide at the MC1-R. It has been suggested previously that position 10 of 
a-MSH, glycine, might function as a “spacer” between the core sequence and that 
the C-terminus of the molecule could be of importance in the interaction with the 
receptor141. In the studies, glycine could be replaced cysteine185 and lysine 146,150 
,both introduced to enable cyclisation, and alanine135, without affecting the
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peptides’ properties; however, introduction of the acidic amino acid aspartate 
significantly reduced both receptor binding and biological activity. A peptide 
containing both substitutions, synthesised in analogy to y-MSH, [Asp10,Phe12]a- 
MSH (8 ) (Table 3.1), was virtually inactive with both its affinity and activity being 
lower than that of y-MSH. All three peptides showed a reduced efficacy on the 
MC1-R compared to a-MSH.
Peptides with multiple alanine substitutions within the C-terminus all were less 
active than a-MSH; in the case of one, [Alan ,Ala13]a-MSH (4) (Table.3.3), the 
biological activity was reduced by the replacement, but not its affinity for the 
receptor. Generally, the biological activity was more affected than the receptor 
binding, leading to peptides with decreased efficacy (Fig.3.11A). Substitution at 
either position 11 and 12 (Table 3.4A), or 11,12, and 13 had the greatest effect; in 
contrast, very little change was observed following substitutions at position 11  or 
13. Therefore it was concluded that the residue with the most influence on receptor 
binding and biological activity is proline 12, followed by lysine 11. This is in 
agreement with previous studies using single substitutions with alanine in this 
region; in this study [Ala12]a-MSH bound with significantly lower affinity than a- 
MSH, [Alan ]a-MSH was nearly as active as the native peptide and no difference 
could be found between [Ala13]a-MSH and a-MSH135. The reduced efficacy 
caused by multiple amino acid replacements in the C-terminus might also support 
the hypothesis that this region may contain a second message sequence. This is 
further supported by the significantly lower affinity and activity of a-MSHi.io 
reported in previous studies39,134.
All y-MSH peptides tested showed very low affinity to and activity at the MC1-R. 
This was expected from the literature53,186. The synthetic analogues, [Nle3]yi-MSH 
and Na-Lys-[Nle3]yi-MSH bound with even lower affinity than yi-MSH, and for 
[Nle3]yi-MSH, it was not possible to determine accurately the biological activity of
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this peptide. Of all y-MSH peptides, only [Nle3,Pro11] yi-MSH was more potent 
than yi-MSH and its activity was comparable to that of [Asp10]a-MSH, which it 
resembles structurally. It was also the only yi-MSH peptide tested that showed an 
increased selectivity for the MC1-R (Fig.3.10A). All C-terminally modified yi- 
MSH peptides showed an increased efficacy at the MC1-R compared to y-MSH; 
but in all cases it was lower than that of a-MSH itself (Fig.3.9A).
The data obtained for the MC1-R support the hypothesis that proline 12 
(numbering with respect to a-MSH) is an important residue for recognition at the 
mouse MC1-R. Replacement of this position with any residue will influence the 
properties of a-MSH and y-MSH analogues as long as they contain L- 
phenylalanine in position 7. However, it appears that introduction of phenylalanine 
in position 1 2  will affect the peptide in a particularly adverse manner.
At the MC3-R, as at the MC1-R, all analogues of [Nle4,D-Phe7]a-MSH showed 
higher affinity and increased biological activity (Table 3.2 and 3.3B). C-terminal 
substitutions exerted no visible effects on the potency at the MC3-R. [Nle4,D- 
Phe7] a-MSH and all its analogues showed reduced efficacy compared to a-MSH 
(Fig.3.9B), however, their selectivity for the MC3-R was slightly increased 
(Fig.3.10B).
Substitution of position 1 2  with phenylalanine (compound 7) (Table 3.2) decreased 
the affinity of a-MSH, but left its activity virtually unchanged. The replacement of 
glycine 1 0  with aspartate had a more pronounced effect on both affinity and 
activity. The peptide with both substitutions, [Asp10,Phe12]a-MSH, compound 8 , 
behaved in a similar way to the peptide with only position 10 changed. It has to be 
noted that the latter two peptides showed an increased selectivity for the rat MC3- 
R in comparison with a-MSH (Fig 3.1 OB).
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Multiple substitutions with alanine in the C-terminal region (compounds 3-6) 
(Table 3.5.B) failed to result in peptides with significantly different activity from 
a-MSH, although for most of them a slight reduction in binding affinity could be 
observed. In a previous study, single amino acid replacements with alanine failed 
to yield peptides with significantly different binding activities from a-MSH135,181. 
However, in another study, it was shown that ACTHmo showed an approximately 
50 times lower biological activity than ACTHm3 (which is equivalent to a- 
MSH)184; therefore the C-terminal end of the peptide must have a role in 
interacting with the MC3-R. Also, it was observed that all C-terminally modified 
L-Phe analogues of a-MSH showed a greater efficacy than a-MSH at the MC3-R 
(Fig. 3.9B). As this could not be seen with analogues of [Nle4,D-Phe7]a-MSH, it 
opens the question whether [Nle4,D-Phe7]a-MSH and its analogues might interact 
in a different manner from a-MSH with this MC3-R as has been postulated for the 
MC1-R145.
y-MSH peptides bound to the rat MC3-R with reduced affinity compared to a- 
MSH, but their biological activity was in the same range as that of a-MSH (Table 
3.3). From that if follows that y-MSH peptides have an increased efficacy at the 
MC3-R versus a-MSH; of all y-MSH peptides tested, [Nle3,Leun ]yi-MSH 
(compound 14) was the analogue with the lowest potency and efficacy. 
Substitution of phenylalanine 11 with proline (in analogy to a-MSH) did not affect 
the activity of the peptide; this was in agreement with a study in which Miwa et 
allM. concluded that the position 11 of y-MSH might not significantly contribute to 
the biological activity at the MC3-R, however in this study we observed that all y- 
MSH except [Nle3,Pro1 ^ yi-MSH showed increased selectivity for MC3-R. 
[Nle3,Pro1 ^ yi-MSH was not more selective for the MC3-R than a-MSH. This 
together with the reduced activity observed for A C T H m o at the MC3-R184 might
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well indicate a role for the C-terminal end of melanocortin peptides in the 
interaction with MC3-R. Also, the observation of increased efficacy and selectivity 
of y-MSH peptides at the MC3-R supports the suggestion originally made by 
Roselli-Rehfiiss et al.62 that y-MSH might be the natural ligand for the MC3-R.
The results reported here support the suggestion of a different manner of 
interaction for [Nle4,D-Phe7]a-MSH and its analogues with melanocortin receptors 
as has already been postulated for the human MC1-R145. These authors present 
further evidence for the crucial role of proline 12 in the interaction of a-MSH with 
the MC1-R. However, these results are in contradiction to the hypothesis that the 
C-terminus of melanocortin peptides might play a limited role in the recognition of 
and activity at the MC3-R184. The role of the C-terminal amino acids will need to 
be re-examined in relation to both a-MSH and y-MSH. Overall, it can be 
concluded that the C-terminal amino acids play a pivotal role in differentiating 
between MC1-R and MC3-R subtypes and it is likely that this will also be the case 
at the MC4-R and MC5-R subtypes. In fact, this has already been suggested for the 
MC4 -R184.
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Figure.3.9A : Relative efficacy function (REF) at a-MSH analogues for MC1-R 
referring to Table3.1.
REF= K d/E C so test 
Kd/ECso a-MSH
103
Figure.3.9B : Relative efficacy function (REF) at a-MSH analogues for MC3-R 
referring to Table3.2.
d e c -  KCI/EC5 0  test
l » t l  ™  . .  . ^
K d /E C 50 a-MSH
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Figure.3.10A : Relative binding selectivity function (RBSF) at a-MSH analogues 
for MC1-R.
Ka (test) MC1/Ka (test)MC3 
RBSF= -----------------------------------------
K a (a-MSH) MC1/Ka (a-MSH)
Figure.3.10B : Relative binding selectivity function (RBSF) at a-MSH analogues 
for MC3-R.
Ka (test) MC3/Ka (test)MC1 
R B S F =  ------------------------------------------------









Figure.3.11A : Relative efficacy function (REF) at alanine analogues for MC1-R 
referring to Table 3.4A.
p e p =  KCI/EC50 test
Kd/EC50 a-MSH
1 2 3 4 5 6
Figure.3.11B : Relative efficacy function (REF) at alanine analogues for MC3-R 
referring to Table 3.5A.
REF= K d/E C 50 test 
Kd/ECso a-MSH
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Figure.3.12A : Relative binding selectivity function (RBSF) at alanine analogues 
for MC1-R.
Ks (test) MC1/Ka (test)MC3 
RBSF= -----------------------------------------
Ka (a-MSH) MC1/Ka (a-MSH)
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Figure.3.12B : Relative binding selectivity function (RBSF) at alanine analogues 
for MC3-R.
^3 (test) MC3/Ka (test)MC1 
RBSF= --------------------------------------
K a (a-MSH) MC3/Ka (a-MSH)
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Chapter 4: Activity of Melanocortins Modified at 
position 7 at the MCI, MC3, and MC4 Receptors
4.1. Introduction
The studies in this chapter focus on the importance of position 7 of a-MSH at the 
receptors MC1-R, MC3-R and MC4-R, and in particular, the effects of altering the 
sequence at position 7 and subsequent effects on ligand binding and cAMP 
production.
Hofmann et al.m  first demonstrated that the entire 13 amino acid sequence of a- 
MSH is not required for melanotropic activity by synthesis of a bioactive peptide, 
Met-Glu-His-Phe-Arg-Trp-Gly. Furthermore, Yajima et a i m  found that the His- 
D-Phe-Arg-Trp-Gly fragment showed a greater activity than an analogue 
containing only L-amino acids in vitro frog skin assay. Introduction of a second D- 
residue is only possible in position 9133. Replacement of D-His or D-Arg rendered 
the peptide inactive. Substituting more than two amino acids with their D-isomers 
as in D-His-D-Phe-D-Arg-Trp-Gly and His-D-Phe-D-Arg-D-Trp-Gly gave 
peptides without activity, but were weakly inhibitory when administered at the 
same time as the L-L-L-L- pentapeptide131, while the all D-isomer showed even 
stronger inhibitory effects194.
Later the ’’superpotent” agonist of a-MSH, [Nle4,D-Phe7]a-MSH, was discovered 
and shown to be 26 times as potent as a-MSH in the mouse melanoma cAMP 
assay23. A single injection of [Nle4,D-Phe7]a-MSH into frogs caused near 
maximum darkening of the skins for at least 6  weeks26. Injections of the natural 
hormone a-MSH or [Nle4]a-MSH also caused darkening, but this effect lasted
I l l
only a few days26. [Nle4,D-Phe7]a-MSH may therefore induce tighter (apparently 
irreversible) binding to its receptor, leading to a sustained, biological activation of 
adenylate cyclase and cAMP production26,145.
Wilkes et al.195 have investigated the [Phe7] position in the Ac-[Nle4]a-MSH4-n- 
NH2 analogue. In order to investigate the influence of this particular amino acid, 
replacement of [Phe7] by tyrosine, p-nitrophenylanine, alanine or glycine as well as 
by their corresponding D-amino acids was carried out. It was concluded that the D- 
Isomers were more potent than the L-forms in both the frog and lizard skin assays 
except for the [D-Ala7] analogue. However, none of them were as potent as Ac- 
[Nle4]a-MSH4-ii-NH2 or Ac-[Nle4,D-Phe7]a-MSH4-n-NH2. Later, Hruby et a l}96 
replaced Phe7 with phenylglycine (Pgl) and 1,2,3,4-tetrahydroisoquinoline (Tic) 
and their D-isomers, but none of them were more potent than Ac-[Nle4]a-MSH4- 
h-NH2, or Ac-[Nle4,D-Phe7]a-MSH4-n-NH2, except Ac-[Nle4,Pgl7]a-MSH4-n- 
NH2 in the frog skin assay. Replacement by D-Pgl led to a major reduction in 
activity in both frog and lizard bioassays whereas introduction of Tic affected the 
results in lizard skin significantly more than those from the frog skin assay196. 
Introduction of D-Phe7 into the a-MSH molecule has been shown to make the 
molecular resistant to chemical degradation under in vitro and in vivo conditions, 
explaining the prolongation of effect and higher potency observed with [D-Phe7] a- 
MSH analogues to [L-Phe7]a-MSH26,138,146.
[Met] can be replaced with [Nle] at position 4 of a-MSH because it is 
pseudoisosteric to [Met4], but does not contain sulphur which is oxidised easily 
with loss of potency. Activity of [Nle4]a-MSH is similar to a-MSH about 6x10" 
10M in the frog skin assay39.
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Ac-[Nle4,D-Phe7]a-MSH4-n-NH2 has similar properties to [Nle4,D-Phe7]a-MSH 
in that it has high affinity, and in the tyrosinase assay the compound was 1 0 0 -fold 
more active than a-MSH147. [Nle4,D-Phe7]a-MSH is stable to enzymatic 
degradation and is resistant to oxidative conditions found during radioiodination. 
Therefore it is routinely used as a standard in biological assays and facilitates 
radioiodination for use in binding assays.
Recently, Hruby et a l 159 have reported that substitution in the 7 position of Ac- 
[Nle4,Asp5 ,D-Phe7,I*,ys10]a-MSH4-io can produce potent and selective antagonists 
for melanocortin receptors. Therefore, a series of substitution at 7 have been 
attempted. [D-p-iodophenylalanine7]a-MSH was a potent antagonist at MC1-R in 
the frog skin( Rana pipiens) assay but a potent agonist at the human MC1-R and 
mouse MC1-R. In addition, it was a potent antagonist at the human MC3-R and 
MC4-R. D-2’-naphthylalanine 7 was a potent antagonist of the MC4-R and a less 
potent antagonist of the MC3-R and a frill agonist of the MC1-R and MC5-R. 
Hruby et a l}59 indicated that modifications of the phenyl ring of the [D-Phe7] 
residue of a cyclic lactam derivative of a-MSH4-io that retain aromatic character 
can result in melanocortin receptor antagonists with high potency and specificity. 
The aim of this chapter is to find more potent and receptor selective analogues by 
substitution at position 7. Replacements were made by [D/L-Tyr7]a-MSH and 
[D/L-Trp7]a-MSH and the peptides were tested at mouse MC1-R, rat MC3-R and 
rat MC4-R through binding and c-AMP assays.
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4.2. Results
The B16 murine melanoma cells naturally expressing MC1-R and human embryo 
kidney cells expressing MC3-R and MC4-R were used to evaluate both the binding 
affinity and their ability to generate cAMP in response to the melanotropin 
peptides a-MSH, [D/L-Tyr7]a-MSH, and [D/L-Trp7]a-MSH. Results from 
binding and cAMP assays as well as values relative to a-MSH are given in Tables
4.1.4.2, and 4.3 for the MC1-R, MC3-R and MC4-R, respectively. Fig 4.1 and 4.2 
show the peptides binding activity at MC1-R; Fig 4.3, 4.4 give those at MC3-R; 
and Fig 4.5 shows their affinities and activities at MC4-R. Fig4.6A, 4.6B and 4.6C 
present the relative affinity and activity at MC1-R, MC3-R, and MC-4R, for each 
peptide examined in this study.
4.2.1. M CI Receptor
[Nle4,D-Phe7] a-MSH had 2-fold higher affinity and 16-fold higher activity than a- 
MSH. Replacement of Phe7 by [L/D-Tyr7] or [L/D-Trp7] led to loss of binding to 
the receptors and of the ability to activate cAMP production significantly (Table 
4.1). In general, D-substituted peptides were more potent and active than L 
counterparts in B16 melanoma cells (Fig 4.1 and 4.2). However, a-MSH still 
remained more potent than D-substituted peptides. The only peptide to show 
similar properties to a-MSH was [D-Tyr7]a-MSH (Fig 4.1 A). [D-Trp7]a-MSH 
had similar affinity (Fig 4.IB), but not activity to a-MSH. Biological activity was
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also reduced significantly for [L-Tyr7]a-MSH, [L-Trp7]a-MSH and [D-Trp7]a- 
MSH to 0.05%, 0.13%, and 17% respectively, but not for [D-Tyr7]a-MSH.
B16 No Binding (K<]/M) c-AMP (EC50)
a-MSH 1 6.59x 10'*
± 9.97 x 10'10
n=5
2.74 X 1 O’9 
± 9.56 x 10'10
n=6
[Nle4,D-Phe7] a-MSH 2 3.27x 10'7 
± 1.78 x 10‘9 
n=5
1.67 x 10‘19 
± 1.3 x 10'10
n=6
[L-Tyr7] a-MSH 3 1.90 x 1 O'7 
± 6.62 x 10‘8 
n=3
5.13 xlO '6 
±3.1 x 10-6 
n=4
[L-Trp7] a-MSH 4 5.68 x 1 O'6 
±2.37 x 10"6
n=3
2.1 X 10-6 
±4.45 10'7 
n=4
[D-Tyr7] a-MSH 5 4.27 x 10'7 
+ 1.1910-9
n=5
4.91 x 10'9 
±3.81 xlO '9
n=3
[D-Trp7] a-MSH 6 1.53 x lO-8 
± 6.57 x 10'9 
n=4
1.63x 10‘8 
± 5.79 x 10"9
n=3
Table 4.1A: Molar dissociation constants, EC50 values, and their standarc
deviation for [D/L-Tyr7] / [D/L-Trp7]a-MSH in B16 melanoma cells (Statistics 
data, appendix 1.9 & 1.10).
B16 No Kd/M EC50
a-MSH 1 . 1 .0 1 .0
[Nle4,D-Phe7] a-MSH 2 2.015 16.4
[L-Tyr7] a-MSH 3 0.035 0.0005
[L-Trp7] a-MSH 4 0 .0 0 1 0.0013
[D-Tyr7] a-MSH 5 1.543 0.56
[D-Trp7! a-MSH 6 0.43 0.17
Table 4.1B: Binding affinity and biological activity of [D/L-Tyr7] / [D/L-Trp7]a- 
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Figure 4.2B: Stimulation of cAMP production at MC1-R.
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Figure 4.2C: Stimulation of cAMP production at MC1-R.
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4.2.2. MC3 Receptor
Modifications of position 7 by [L/D-Tyr7] and [L/D-Trp7] gave very different 
results at the MC3-R compared to the MC1-R (Table 4.2A and 4.2B). [L-Tyr7]a- 
MSH and [D-Tyr7]a-MSH were able to stimulate cAMP production, whereas both 
[L-Trp7]a-MSH and [D-Trp7]a-MSH were inactive (Fig 4.3B + 4.3C). However, 
[D-Trp7]a-MSH had the ability to antagonise the effect of a-MSH (Fig 4.4). [L- 
Tyr7]a-MSH had affinity and activity significantly reduced to 1.4% and 1.8% 
compared to a-MSH, respectively. [L-Trp7]a-MSH had very low affinity 
compared to that of a-MSH (3.1%) but was not able to exhibit biological activity 
at the MC3-R. [D-Tyr7]a-MSH had a similar property to a-MSH (Fig 4.3A+4.3C). 
[D-Trp7]a-MSH had a similar affinity to a-MSH but possessed the ability to 
antagonise a-MSH with an IC50 of 1.95 ± 0.628 x  10'7M (Fig.4.4, Statistics data, 
appendix 1.13).
MC3-293 No Binding (K<i/M) c-AMP (EC50)
a-MSH 1 6.59 x l0 ‘7± 3.14 xlO'7 
n=3
2.36 x 10‘8± 2.55 10’8 
n=4
[Nle\D-Phe7]a-MSH 2 2.16 x 10'8± 1.18x 10'8 
n=5
1.25 x lO ^ ^ O x lO 10 
n=3
[L-Tyr7] a-MSH 3 4.83 x 10'5±5.13 x  10*6 
n=4
1.28 x lO ^  9.35xl0'7
n=3
[L-Trp7] a-MSH 4 2.09x 10‘5± 6.90 x 10-6 
n=4
No activity
[D-Tyr7] a-MSH 5 4.71 x 10‘7±L55 x 10‘7 
n=4
2.66 x 10‘8± 8.90xl0'9 
n=3
[D-Trp7] a-MSH 6 3.30 x 10’7± 8.48 x 10‘8 
n=3
No activity
Table 4.2A: Molar cissociation constants, EC50 values, and their standard
deviation for [D/L-Tyr7]/ [D/L-Trp7]a-MSH at MC3 receptor (Statistic data, 
appendix 1 .1 1  & 1 .1 2 ).
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MC3-293 No Kd ECso
a-MSH 1 1 1
[Nle4,D-Phe7] a-MSH 2 30.5 19
[L-Tyr7] a-MSH 3 0.014 0.018
[L-Trp7] a-MSH 4 0.031 No activity
JD-Tyr7] a-MSH 5 1.4 0.9
[D-Trp7! a-MSH 6 2 No activity
Table 4.2B: Binding affinity and biological activity of [D/L-Tyr7]/ [D/L-Trp7]a- 
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Figure 4.3C: Stimulation of cAMP production at MC3-R.
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Figure 4.4: Stimulation of cAMP production at MC3-R. [D-Trp7]a-MSH was an
antagonist at MC3-R. Antagonist activity of [D-Trp7] a-MSH was determined in
the presence of 10'8 M a-MSH.
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4.2.3. MC4 Receptor
Because of their interesting properties at the MC3-R, [L-Trp7] and [D-Trp7]a- 
MSH were also tested for binding and biological activity at another melanocortin 
receptor available in out laboratory, the human MC4-R stably expressed in HEK 
293 cells. On this receptors, [D-Trp7]a-MSH, which was a antagonist at MC3-R, 
showed slightly higher affinity than a-MSH, but only 15% of its activity (Table 
4.3). Nevertheless, it was a full agonist at this receptor. [L-Trp7] showed lower 
affinity (34%) and activity (5.3%) than a-MSH.
MC4-293 at agonist No Binding (Kd) c-AM P(EC50)
a-MSH 1 1.38 x 10'5 
± 4.69 x 10-6
n=3
8.05x 10'9 
± 3.25 x 10‘9 
n=3
[Nle4,D-Phe7] a-MSH 2 5.08 x 10'7 
± 1.24 x 10'7 
n=3
n.d.
[L-Trp7] a-MSH 3 4.08 x 10'5 
+ 6.92 x 10"6 
n=2
1.52 x 1 O'7 
± 2.34 x 10-8 
n=3
[D-Trp7] a-MSH 4 4.53 x 10-*
± 4.04 x 10'7 
n=3
5.23 x 10"8 
±2.34x10'*
n=3
Table 4.3.A: Molar dissociation constants, EC50 values, and their standard 
deviation for 7 position at MC4-293 cell. n.d=not determined (Statistics data, 
appendix 1.14 & 1.15).
MC4-293 No Kd EC50
a-MSH 1 1 1
[Nle4,D-Phe7] a-MSH 2 27 nd
JL-Trp7! a-MSH 3 0.34 0.053
[D-Trp7! a-MSH 4 3.05 0.154
Table 4.3B: Binding affinity and biological activity of [L/D-Trp7]a-MSH at MC4 
receptor relative to a-MSH. n.d=not determined.
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Figure 4.5B: Stimulation of cAMP production at MC4-R.
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4.3. Discussion
  7 7
[L/D-Tyr ]- and [L/D-Trp ]a-MSH were synthesised to probe for the importance 
of position 7 for interaction with MC-R subtypes. Those particular substitutions 
were chosen because they retained the aromatic structure of the residue with a 
benzene and an indole moiety, respectively. Replacement of [Phe7] with a non- 
aromatic amino acid, alanine, had been demonstrated to lead to a substantial loss 
of affinity at both MC1-R and MC3-R134,135. Introduction of a D amino acid [D- 
Phe ] had previously been shown to protect the peptide from chemical and 
enzymatic degradation152, thereby leading to a peptide with higher potency and 
prolonged activity. Thus, the both L- and D-amino acid substitutions were 
examined in this position.
4.3.1. MCI Receptor
At the MC1-R, [D-Tyr7] and [D-Trp7] peptides are more potent with regard to 
affinity and activity than are [L-Tyr7] or [L-Trp7] analogues. This agreed with 
Wilkes et a l 195 who found that the D-Isomers were more potent than the L-forms 
in both the frog and lizard skin assay. However, they showed still lower potency 
than a-MSH except for [D-Tyr7]a-MSH, which demonstrated a similar affinity 
and activity to a-MSH. In a computer modelling study by software190, it has been 
demonstrated that [D-Phe7] residue required the minimum energy among central
1 OQmessage, Glu-Hi s-Phe-Arg-Trp, and minimum energy leads to higher affinity . It 
indicated that the D-Phe isomer might have the highest affinity among other 
substitutions in this position to bind the receptor. Therefore, peptides substituted 
with D-isomers in position 7,may induce tighter binding to MC1-R, leading to a
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higher and sustained, activation of cAMP production than those substituted with 
L-isomers.
4.3.2. MC3 Receptor
At the MC3-R, as at the MC1-R, substitution with L-amino acids led to peptides 
with lower affinity than those substituted with their D-isomers. [D-Tyr7]a-MSH 
displayed properties similar to those of a-MSH itself. This was also observed at 
MC1-R. Tyrosine is structurally closer to phenylalanine than tryptophan, and this 
could be explained this phenomenon. However, despite the introduction of a D- 
residue this peptide did reach neither affinity nor activity of [Nle4,D-Phe7]a-MSH 
indicating that the phenylalanine residue is nevertheless energetically favoured. 
However, replacement of phenylalanine with D- or L-tiyptophan gave peptides 
with properties different from the others. While [L-Trp7]a-MSH displayed low 
affinity (5% of a-MSH) and was biologically inactive at the concentrations tested, 
it was found that [D-Trp7]a-MSH had an affinity similar to a-MSH but had no
•  ftbiological activity. However, it was able to inhibit the activity of a-MSH (at 10' M 
concentration) in a dose-dependent manner. This peptide was later shown to 
exhibit full agonist activity the MC4-R and it is therefore the first melanocortin 
antagonist that can distinguish not only between MC3-R and MC1-R, but also 
MC3-R and MC4-R. It might therefore prove a useful tool in the elucidation of the 
physiological role of the MC3-R which remains to be identified. In the earlier 
study by Aden et a / . 158 [Ala6]a-MSH4_io resulted in a peptide that antagonised the
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melanocortin MC3-R and MC5-R but it was less potent at MC4-R, but was still 
able to act as an antagonist of a-MSH.
4.3.3. MC4 Receptor
a-MSH had lower affinity and activity with MC4-R than that with MC1-R, but 
[Nle4,D-Phe7]a-MSH still showed higher affinity than a-MSH. Thus, the D- 
configuration remained more potent than L-configuration; this could also be 
observed for peptides substituted with [L-Trp7] and [D-Trp7].
Both [L-Trp7] and [D-Trp7] were relatively more active at the MC4-R than at 
MC1-R. The activity of [L-Trp7]a-MSH at MC4-R were 34% and 5% and at 
MC1-R were 0.1% and 0.13%, respectively. The affinity and activity of [D- 
Trp7]a-MSH relative to a-MSH at MC4 -R were 3 and 0.15, and at MC1-R were 
0.43 and 0.17, respectively. Peptides substituted with [D- or L-Tyr7] have not been 
tested at MC4-R. Other peptides substituted with bulky aromatic groups in 
position 7 have been shown to be antagonists of the MC4-R159. However, contrary 
to the MC3-R, substitution of Phe with tryptophan alone was not sufficient to 
transform this peptide into an antagonist at the MC4-R.
4.3.4. Summary
Replacement of phenylalanine in position 7 of a-MSH with its D-isomer was long 
been known to increase both stability and activity of the peptide, and has led to the 
synthesis of the highly potent analogue [Nle4,D-Phe7] a-MSH152. It has been
131
postulated that the [D-Phe7] substitution leads to minimum energy configuration 
within the central a-MSH ‘ core sequence’, His-Phe-Arg-Trp, thus causing high 
affinity binding189,190. Likewise, it has been suggested that the D-isomer might lead 










Figure 4.6A: Relative affinity or activity 7 position of a-MSH at MC1-R ( log 
scale). Individual bars represent single experiments. Black = Affinity, Grey = 














Figure 4.6B: Relative affinity or activity 7 position of a-MSH at MC3-R (log 
scale). Individual bars represent single experiments. Black =Affinity, Grey = 




Figure 4.6C: Relative affinity or activity 7 position of a-MSH at MC4-R (log 
scale). Individual bars represent single experiments. Black =Affinity, Grey = 
Activity. Refer to Table 4.3 for compound number.
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Chapter 5: Activity of Cyclic Peptides at MCI 
Receptor
5.1. Introduction
Since linear peptides can adopt a multitude of conformational, states restriction of the 
conformational flexibility is required for studying the ‘receptor-specific’ conformation 
of the peptide. The practical way to obtain semi-rigid analogues of peptides is by 
cyclisation of suitable linear derivatives39. Until recently, most structure-function 
studies were based on individual amino acid substitutions or deletions in a-MSH and 
/or shorter linear fragments. Structure-activity relationships with these linear 
analogous showed the importance of stereochemistry of the amino acid in position 7 
to biological potency and prolongation of the melanotropic effect23, and it was 
suggested that this might be related to specific conformational effects. Since linear 
peptides are flexible, interpretation of conformational data on linear D-Phe7 analogues 
is difficult192.
Sawyer et al. 148 reported that a P-tum or other peptide chain-reversal region within the 
central active site, His-Phe-Arg-Trp, of a-MSH might be important in the biologically 
active conformation of the hormone. Thus, the preparation of a series of highly potent, 
cyclic, conformationally restricted analogous, cyclized by the pseudoisosteric 
substitution of cysteine in the 4 and 10 positions for Met4 and Gly10 139,142,148 was 
based on conformational considerations. [Cys4,dys1 °]a-MSH a disulphide-bridged 
analogue, with conformational restriction compatible with a p-tum conformation, was
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the first cyclic a-MSH analogue described148. Since cyclisation leads to considerable
restriction of conformational flexibility of the peptide backbone and, to a lesser
degree, the side chains, a critical examination of these cyclic analogues can provide an
important insight into the possible three-dimensional, biologically active structure of
a-MSH. Other advantages of cyclic conformationally restricted analogues versus
linear derivatives of the native hormone can include either increased potency by
stabilisation of the bioactive conformer or decreased enzymatic degradation due to
conformational constraints148.
H ;— I
[Cys ,Cys ]a-MSH was reported to possess potency about 10000-fold higher than a-
MSH in frog skin (Rana Pipiens)l39,m. However, several studies39,142,149 with
[Cys4,Cys10]a-MSH revealed a much lower potency for this peptide. Cody et a l 142
revised their earlier reports to say that [Cys4,Cys10]a-MSH had about 10-fold higher
activity only in the frog skin assay whereas in the other systems of the activity 
I 1
[Cys4,Cys10]a-MSH was similar to a-MSH. As to the influence of C-terminal 
tripeptide142, Lys-Pro-Val-NH2, it was found that Val13 was not important, but there 
was a drastic loss of activity following the loss of Pro12, with a less dramatic loss after 
subsequent omission of Lys11.
The cyclic lactam analogues Ac-[Nle4,D-0 m5,Glu^]a-MSH4-i 1-NH2 and Ac-[Nle4,D- 
I I
Om5,D-Phe7,Glu8]a-MSH4.n-NH2 have a 17-membered ring187. The L-Phe cyclic 
analogue was slightly more potent than the linear Ac-[Nle4]a-MSH4-n-NH2 and 
exhibited prolonged melanotropic bioactivity in the frog skin bioassay but was 1 0 0 - 
fold less potent in the lizard bioassay. The D-Phe cyclic analogue was less active than 
the L-Phe in both assays.
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The cyclic lactam analogues, Ac-[Nle4 ,Asp5 ,D-Phe7,Lys10]a-MSH4-io-NH2 and Ac-
[Nle4 ,Asp5 ,D-Phe7,Lys^Gly1 were found to possess the highest
potencies among the cyclic heptapeptides in lizard skin and tyrosinase assays150,151.
The ring size is 23 atoms. The influence of N-terminal amino acids on affinity or
activity has not been tested, but it has been attempted to add fatty acids to the N-
terminal of the Ac-[Asp5 ,D-Phe7 ,Lys10]a-MSH5-io-NH2 analogue which displayed 10-
100-fold the biological activity of a-MSH in the Cloudman S91 tyrosinase 
188 ■assay .The shorter conjugates of hexanoic and decanoic acid were as potent as a-
MSH in the lizard skin bioassay, whereas the longer myristoyl and palmitoyl
I I
analogues were about 100-fold less potent188. Ac-[Nle4 ,Asp5 ,D-Phe7,Lys10]a-MSH4 . 
10-NH2 has 90 times greater potency than a-MSH in lizard skin and 100-fold in 
tyrosinase assay150,151.
The object of this study is to design of a semi-rigid synthetic analogue of a-MSH in
order to understand its physical and biological properties and their possible
relationship to the biologically active conformation of the peptide. Here, we included
the C-terminal, Lys-Pro-Val-NH2 into our study to test whether it preferably affects
I I
the conformational properties of the semi-rigid Ac-[Nle4 ,Asp5 ,D-Phe7 ,Lys1 ]a-MSH4-
I I
10-NH2, therefore, we synthesised [Nle4 ,Asp5,D-Phe7,Lys10]a-MSH4-i3-NH2 analogues 




All peptides were able to inhibit completely the binding of [125I-Tyr2,Nle4,D-Phe7]a- 
MSH to murine B16 melanoma cells and exhibit full activity at different concentration 
(Table 5.1). The relative potency of these compounds to a-MSH are given in Table
5.2. The result of competitive binding assay with [I25I-Tyr2,Nle4,D-Phe7]a-MSH for 
a-MSH, and cyclic peptides are shown in Figure 5.1. The ability to generate cAMP in 
response to melanocortin peptides is illustrated in Figure 5.2 and 5.3 and the relative 
affinity and activity are shown in Figure 5.4.
The cyclic compounds have at least 10-fold higher affinity and activity than a-MSH 
except for [Asp5,D-Phe7,Lys1 °]a-MSH5.13 (Table 5.1), which lacks Nle4 and shows the 
same affinity but slightly higher activity (4.4-fold) than a-MSH. The compound 3 has 
same affinity and about 10-fold higher activity than a-MSH. The compound 5 has 
highest affinity and activity of the peptides tested which was increased by a factor of 
17.6 and 25.6, respectively, when compared to a-MSH.
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B16 N o Binding (kd) c-AMP (E C 50)
a-MSH 1 1.68 X 10'8 
± 3.88 x 10'9
n=5
2.74 x 1 O'9 
± 9.56 x 10' 10
n= 6
[Nle4,D-Phe7]a-MSH 2 3.27 x 10'9 
± 1.78 x 10'9 
n=5
1.67 x 10‘10 
± 1.30 x 10 10 
n= 6
[Nle4,Asp5,D-Phe7,Lys10]a-MSH4-i3
3 1.80 x 1 O'9 
+ 3.57 x 10' 10 
n=3
3.00 x 10 10 
+ 2.78x1 O' 10 
n=4
r  .... ( 
[Asp5,D-Phe7,Lys10]a-MSH5_i3
4 1.72 x 10'8 
± 6.79 x 10'9 
n=4
6.24 x 10‘10 
±3.71 x 10' 10 
n=4
[Nle4,Asp5, D-Phe7, Lys10]a-MSHM3
5 9.56 x 10 ' 10
±2.99xlO ' 10
n=4
1.7 x 10' 10 
+ 5.64 x 10' 11 
n=4
Table 5.1. Binding affinity (expressed as dissociation constant) and biological affinity 
(expressed as EC50) of [Nle4,Asp::,D-Ph<i7,Lys10]a-MSH4.i3 analogues at MCI 
receptors. Errors represent the standard deviation determined from replicate 
experiments (Statistics data, Appendix 1.116).
B16 No Binding c-AMP
a-MSH 1 1.0 1.0
rNle4,D-Phe7la-MSH 2 5.14 16.4
fNle4,Asp5,D-Phe7,Lys'V-MSKU-u
3 9.3 9.13
1 .  1
[Asp ,D-Phe7,Lys10la-MSH5-i3
4 0.98 4.4
fNle4, Asp5, D-Phe7, Lys10la-MSHi_13
5 17.6 25.6
I-------------- 1
Table 5.2. Binding affinity and biological activity of [Nle4,Asp5,D-Phe7,Lys10]a-MSH 
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Figure 5.3 Stimulation of cAMP production at MCI receptors by [Nle4,Asp5,D-
















Figure 5.4. Relative affinity and activity of [Nle4,Asp5,D-Phe7,l!ys10]a-MSH 
analogues and a-MSH. Bars represent single experiments
i i i i i i
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5.3. Discussion
In general, the cyclic [Nle4 ,Asp5,D-Phe7 ,Lys10]a-MSH4 -10 analogues are reported to be
more potent than [Nle4 ,D-Phe7]a-MSH152,153 compared to a-MSH. It has been 
I I
proposed that [Nle4 ,Asp5,D-Phe7,Lys10]a-MSH4 -io has relative potency 90-fold in the
lizard skin bioassay and that 100-fold in tyrosinase assay150,151. In our study a peptide
I I
that included the C-terminal tripeptide, Lys-Pro-Val-NH2 , [Nle4 ,Asp5,D-Phe7,Lys10]a- 
MSH4 .1 3 (Table 5.1 and 5.2) is 9 times more potent in affinity and activity than a- 
MSH at murine B16 melanoma cells, giving a similar result to [Nle4 ,Asp5,D- 
Phe7 ,Lys10]a-MSH4 .io at the human MC1 -R152,153. We did not synthesise the 
[Nle4 ,Asp5,D-Phe7,Lys1 °]a-MSH4 -10 to compare result. Compared to a-MSH, our data 
suggested that the C-terminal was not as important for increasing the activity in 
[Nle4 ,Asp5,D-Phe7,Lys10]a-MSH4 .io assay. Yet, this requires to synthesis more cyclic 
peptides to be certain.
Analogue 4 (without Nle4  ) showed the same affinity as a-MSH but was slightly more 
active than a-MSH, indicating that [Nle4] is important for activity. Nle is 
pseudoisosteric to Met, but does not contain sulphur which is easily oxidised with 
subsequent loss of potency in a-MSH191. Studies with linear a-MSH fragments have 
already revealed the relative importance of this residue for affinity and activity of the 
peptide39,140.
The peptide which included N-terminal, Ser-Tyr-Ser- had the highest affinity and 
activity compared to others in this study, suggesting that the N-terminal was important 
to enhance the activity of [Nle4 ,Asp5 ,D-Phe7 ,l!ys10]a-MSH4_io analogues. Compound
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5, had 17-fold higher affinity and about 25-fold higher activity than a-MSH. That the 
cyclic peptide, 5 , has a higher affinity and activity than [Nle4,D-Phe7] a-MSH 
indicated that restricted analogues versus linear derivatives might increase potency by 
stabilisation of the bioactive conformer or reduce enzymatic degradation due to 
conformational constraints as has been suggested previously148.
Modem computer technology has made it possible to extend theoretical 
conformational studies of peptides to examine their molecular dynamics and internal 
energetics, and energy minimisation of peptide structure has been used recently190. 
High affinity ligands in general have low conformational energies, and high 
conformational energies correspond to low affinity ligands189. D-Phe7, Asp5 
substitutions have shown the lowest energy in molecular modelling190, indicating that
7 5 •D-Phe , Asp analogues might have high affinity toward melanocortin receptors. This 
could explain why the affinity of [Nle4,yisp5,D-Phe7,Lys1 °]a-MSH 1-13 is higher than 
[Nle4,D-Phe7] a-MSH.
5.4. Future Studies of Cyclic Peptides
Due to their stronger activity compared to a-MSH at MC1-R, [Nle4,D-Phe7]a-MSH 
and [Nle4,Asp5,D-Phe7,Lys10]a-MSH4-io have been tested for clinical use as tanning 
agents. A great deal more work needs to be done to evaluate the structural-activity 
relationships between cyclic analogues and melanocortin receptors. So far, the cyclic 
peptides have only been examined at MC1-R, so it would be worthwhile to study 
effects of melanocortin peptides at different receptors.
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Efforts to understand the relationships of conformational to biological activity of a- 
MSH utilising physical and molecular modelling methods are still in an elementary 
state. The studiy192 reported indicate that an aqueous solution of a-MSH and its 
analogous can assume energetically preferred conformations, but there is still much to 
be done to determine with greater certainty and clarity the precise nature of these 
conformational preferences. Also, it remains questionable whether an aqueous 
solution of the peptide reflects the physiological conditions at the moment of receptor 
binding.
Linear and cyclic analogues of a-MSH have been developed which have receptor 
selectivity, potency, and exceptionally prolonged in vitro and in vivo biological 
activities. These findings offer considerable incentive to develop conformational 
structure models which might explain these biological results, and to test these models 
with appropriate conformational constraints consistent with the biological and 
biophysical data. It can be anticipated that a combination of design and synthesis 
based on conformational and modelling molecular mechanics, and molecular 
dynamics approaches, and biophysical studies on constrained analogous, will provide 
significant new insights into a-MSH conformation-activity relationship.
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Chapter 6: Discussion
The work in this thesis is concerned with elucidating the structure-activity 
relationships of melanocortin peptides. A series of peptides were tested at the 
melanocortin MCI and MC3 receptors with the aim of designing receptor-specific 
ligands. While this was originally undertaken with a view to the therapeutic 
potential melanocortins in the treatment of melanoma, the recent discovery of the 
function of the melanocortin MC4-R opens a new field of potential applications 
for melanocortin peptides.
In this chapter, the results presented in chapters 3, 4 and 5 are summarised and put 
into context with the current state of melanocortin research.
6.1. Origin of a - MSH
a-MSH and ACTH are a group of related peptides containing the typical core 
sequence, His-Phe-Arg-Trp, and are derived from a common precursor, 
proopiomelanocortin (POMC). They occur in the pituitary, some brain regions, and 
also in several peripheral tissues. Adult humans do not have a pituitary 
intermediate lobe, and thus have very little a-MSH in the serum. In addition, most 
of p-LPH is not processed into P-MSH, so that p-LPH and ACTH are the two 
predominant melanocortin in man, while a-MSH is the predominant melanocortin 
in most other species198. Although POMC appears to be processed differently in 
various brain regions. The highest concentration of a-MSH in the brain is in the 
hypothalamus. Also of interest is the presence in some species of desacetyl-a-
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MSH, which has a slightly different pharmacological profile to a-MSH, and will 
not exhibit all its functions201.
6.2. Identification of a Family of MSH Receptors
A family of five melanocortin receptor subtypes has been identified to date. Each 
member of the melanocortin receptor family has a distinct tissue distribution. All 
are G-protein-coupled receptors that activate adenylyl cyclase and bind 
melanocortins. To date the MC1-R has been reported to be expressed in 
melanocytes, melanoma tissue15’16, and macrophages126’127, while the MC2-R is 
expressed in all the adrenal cortex15. The MC3-R and MC4-R are predominantly 
expressed in brain. The MC3-R has a restricted distribution, with the greatest 
density in hypothalamic cells62. In contrast, MC4-R is more widely expressed than 
MC3-R and is found in multiple sites in almost every brain region197. In addition to 
its expression in brain, the MC3-R was found in placenta and stomach, pancreas17. 
The MC5-R was found in a broad spectrum of tissues including skin, brain, 
skeletal, muscle, lung, spleen thymus, bone marrow, testis, ovary, uterus, and 
adrenal gland171' 177.
The melanocortin receptors have different pharmacological properties, as predicted 
by binding and c-AMP assay. The MC1-R binds and is stimulated well by a-MSH, 
while MC2-R preferentially binds ACTH. The MC3-R appeared to respond 
relatively well to y-MSH; while MC4-R had a higher affinity for p-MSH. MC5-R 
has been expressed in four species and each has a slightly different 
pharmacological profile among species.
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6.3. Selective Ligands for Melanocortin Receptors
6.3.1. C-Terminal Substitution
At murine MC1-R, the C-terminal amino acids play an important role in 
differentiating between MC1-R and MC3-R. At the murine MC1-R, proline 12 
(numbering with reference to a-MSH) appears to be important residue for 
recognition. Replacement of this position with any residue was expected to 
influence the properties of a-MSH and y-MSH analogues as long as L- 
phenylalanine was present in position 7.
The experimental work carried out here suggested at MC1-R, all analogues of 
[Nle4,D-Phe7]a-MSH bound with equal affinity and exhibited the same biological 
activities irrespective of their substitution at position 12, but the a-MSH analogue, 
[Phel2]a-MSH, showed a significant reduction of both affinity and activity. All y- 
MSH peptides showed very low affinity and activity at the MC1-R. This was 
expected from the literature53,186. Of the y-MSH peptides tested, only 
[Nle3,Pron ]yi-MSH was more potent than yi-MSH. Substitutions with multiple 
alanine within the C-terminal had lower activity than a-MSH. Therefore, it was 
concluded that position 12 is important in the interaction of a-MSH with murine 
MC1-R.
At the MC3-R, C-terminal substitutions to a-MSH did not result in significant 
changes on the potency. All analogues of [Nle4,D-Phe7]a-MSH showed higher 
affinity and increased biological activity, suggesting that D-Phe7 analogues bound 
more stably to the receptor. The a-MSH analogue, [Phe12]a-MSH, had its activity
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similar to a-MSH. y-MSH peptides bound to the rat MC3-R with reduced affinity 
compared to a-MSH, but their biological activity was in the same range as that of 
a-MSH. All y-MSH analogues except [Nle3,Prou ]yi-MSH showed increased 
selectivity for the MC3-R. [Nle3,Pron ]yi-MSH was not more selective for the 
MC3-R than a-MSH. The observation of increased efficacy and selectivity of y-
ffyMSH peptides at the MC3-R supported the suggestion originally made , that the 
MC3-R may respond to y-MSH.
It was concluded that substitutions at the C-terminal of a-MSH have greater 
impact at MC1-R than MC3-R as long as position 7 remains in the L- 
configuration. Thus, the C-terminal might be the way to distinguish between the 
activity of linear peptide at the MC1-R and MC3-R.
6.3.2. Antagonist
It has been known for sometime that replacement of phenylalanine in position 7 of 
a-MSH with its D-isomer increases both stability and activity of the peptide, and 
this has led to synthesis of the highly potent analogue [Nle4,D-Phe7]a-MSH152. 
Thus, a series of substitutions at 7 were investigated. In general, substitution with 
L-amino acids led to peptides with lower affinity than those substituted with their 
D-isomers at both MC1-R and MC3-R. These peptides had lower affinity than a- 
MSH except for [D-Tyr7]a-MSH, which had a similar affinity and activity to a-
n
MSH. Tyrosine is structurally closer to phenylalanine than tryptophan. [D-Trp ]a- 
MSH had full agonist activity at the MC1-R and MC4-R but antagonised the 
action of a-MSH with an IC50 of 1.95 ± 0.628 x 10'7M. Therefore, [D-Trp7]a-
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MSH may be a lead compound for development of selective ligands.
Hruby et a l 159 reported that substitution in the position 7 of Ac-[Nle4,Asp5,D-
— T1Phe ,Lys ]a-MSH4-io can produce potent and selective antagonists for 
melanocortin receptors. [D-Trp7]a-MSH appears to be a selective antagonist for 
MC3-R.
6.3.3. Cyclic Peptides
In this study, addition of the C-terminal in cyclic peptides did not appear to be as 
important at MC1-R compared to studies of linear peptides. [Nle4, Asp5,D-
y I i Q
Phe ,Lys ]a-MSH4.,3 showed similar affinity and activity at murine B16 
melanoma cells compared to [Nle4,Asp5,D-Phe7,Lys10]a-MSH4-io at human MC1- 
R. In contrast, addition of the N-terminal to produce 1-13 analogue led to higher 
affinity and activity compared to others in this study, suggesting that the N- 
terminal was important to enhance the activity of cyclic peptides based on 
[Nle4,Asp5,D-Phe7,Lys10]a-MSH4.io . Such as [Nle4,Asp5,D-Phe7,Lys10]a-MSHi.n 
had 17-fold higher affinity and 25-fold higher activity than a-MSH. These peptides 
with further study at need to be compared with the Hruby et al. compared MT-II.
6.4. Agouti and Obesity
Mammalian melanocytes can produce two types of melanin, eumelanin (black or 
brown) and phaeomelanin (red or yellow). The pathways are controlled by the 
products of two classical coat-colour controlling gene loci, extension and agouti.
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The mouse agouti gene encoded an 131 amino acid agouti protein that instructs 
hair follicle melanocytes to switch from black to yellow pigment. When agouti is 
overexpressed in yellow mutant mice, it induces obesity and diabetes. Lu et al.*5 
have shown that the agouti protein is an antagonist at the MC1-R. This explains 
the effects of agouti on pigmentation, however, it remains possible that agouti 
peptide has other physiological actions, either via melanocortin receptor or 
independent of melanocortin receptor. Hunt et al.93 have demonstrated that the 
agouti protein can act independently of MSH to inhibit melanogenesis. 
Intracellular free Ca2+ concentration is elevated in skeletal muscle of yellow mice 
compared with nonagouti mice and agouti peptide induces an increase in 
intracellular Ca2+ in isolated skeletal muscle from wild type mice92.
Recently, activity has focused on the potential role of melanocortin peptides in the 
yellow obese mouse since the discovery that agouti peptide not only antagonises a- 
MSH at the MC1-R but also antagonises a-MSH at the MC4-R85. Lu et al.*5 
expressed MSH receptors in 293 cells and assayed the ability of agouti to inhibit 
generation of adenylyl cyclase activity by a-MSH. The results demonstrated that 
agouti was a high affinity antagonist of both the MC1 -R and MC4-R in vitro, but 
not of the MC3-R and MC5-R. This suggests that antagonism of the MC4-R might 
be crucial in regulating weight. Injecting synthetic peptides mimicking
OQ
melanocortin into the brain of both normal and obesity mutant mice, Fan et al. 
found that the molecules bind to MC4-R and suppress feeding, even when the 
mice are given neuropeptide Y, potent appetite-stimulating neurotransmiter, to 
increase the animal’s appetites during the night or after a prior fast. Huszar et al. 199 
show that depletion of the MC4-R produces an obesity syndrome, thus defining a
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novel function for the MC4-R in the regulation of energy balance. The synthetic a- 
MSH antagonist used by these authors was SHU9119, which is a potent antagonist 
at MC4-R, but full agonist at MC1-R thus confirming the involvement of the 
MC4-R in the control of feeding behaviour.
6.5. Future Work
The effect of melanocortin peptides, notably a-MSH, on melanogenesis in 
melanocytes appears well established, but their role in melanocyte and melanoma 
cell proliferation is less clear and remains to be investigated in more detail. The 
presence of MCI-R on melanocytes and more importance melanoma cells might in 
the future be exploited for diagnostic and/ or therapeutic purposes. To this end, 
selective, high-affmity ligands of MCI-R are needed.
The role of the MC3-R, as that of the MC5-R, remain unclear. While the MC3-R 
shows a comparative preference for y-MSH peptides, it seems unlikely that it 
participates in mediating the cardiovascular actions of these peptides. The 
discovery of a selective MC3-R antagonist (described in chapter 4) might help in 
elucidating the biological roles of this receptor. The antagonist, [D-Trp7]a-MSH, 
is of low affinity, but acts as an agonist at MC1-R and MC4-R. It is predicted that 
will be chemical stable under in vitro and in vivo conditions due to the D-amino 
acid in position 7. It could therefore be used directly, or might serve as a lead 
compound in the search for selective antagonists with higher affinity.
The discovery that MC4-R participates in the control of body weight has led to 
renewed interest in melanocortin receptors and MSH peptides. The development of
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MC4-R antagonist that can be used in weight-reducing therapies is potentially of 
great therapeutic and commercial interest. This also opens the field for the design 
of non-peptide antagonists, which would have an advantage over peptide 
antagonist, as they are generally less expensive to produce and have better 
pharmacokinetic properties.
There are several physiological properties of melanocortin peptides that cannot be 
explained by their actions at the receptors already known, the existence of future 
melanocortin receptors seems likely.
The mode of interaction of melanocortin receptors with their ligands remains to be 
studied. For the MC1-R, attempts have been made by point-mutation studies, to 
identify the binding site of the receptor. These studies need to be continued and 
also carried out with other melanocortin receptors. They would greatly helped by 
the existence of antibodies, but to date, the only one described in the literature is a 
polyclonal MC1-R antibody.
Finally, the existence of high-affinity cyclic agonists and antagonists will enable 
conformational and molecular modelling studies to elucidate the interaction of 
MSH peptides with their receptor.
6 .6 . Final Conclusions
As with many pieces of scientific work, and particularly with those strictly limited 
by time or resources, the experiments and results reported in this thesis suffer 
shortcomings that might be rectified if further time were made available or if the 
project were to be started again with the benefit of hindsight. Two principal issues 
are as follows:
• If the work were being repeated it might increase the value of the results if
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experiments were performed using human cell lines and receptors instead of, or 
in addition to mouse cell lines and receptors. Although cell lines containing a 
range of human MSH receptors were not available at the time this work was 
started, recently the human MSH-R has become available transfected into Cos7 
cells or into the murine L cell line.
• In addition to the in vitro experiments performed on cultured cells, it would 
have been useful, and it would be valuable in the future, if some experiments 
were performed in vivo in animal models. In particular it would be interesting to 
test the compound [D-Trp7]a-MSH, shown in this thesis to be a selective 
antagonist of rat MC3-R, in behavioural studies and possibly also using in situ 
hybridisation studies in the rat.
Looking back at the thesis as a whole there are some sections of results which 
rather than provide answers to questions, instead pose further questions.
A fundamental issue that is the basis of any study looking at a range of analogues 
of a pharmacologically active compound, in this case analogues of the peptide a- 
MSH, is the relationship between binding affinity and biological activity. It is 
expected that modification of the lead compound will either decrease or increase 
the binding affinity. If the binding affinity is increased and there is also an 
increase in biological activity, the new analogue is likely to be a potent agonist. 
Sometimes what is observed is no change or perhaps an increase in binding affinity 
but with reduced or perhaps no associated biological activity. In this case the 
analogue is likely to be an antagonist. If an agonist or an antagonist is selective in 
its action it is likely to be useful in elucidating the role of the associated receptor.
• In the present work a wide range of modifications to melanocortins have 
produced changes in binding affinity and biological activity. One set of 
experiments have produced results that are at present not easily explained, but 
should be noted as of interest for the future. The measure of biological response 
used in this thesis has been elevation of c-AMP levels. In a number of 
experiments, modification of the peptide has resulted in a change in the binding
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affinity, in most instances as expected the associated biological activity, as 
measured by c-AMP levels changes proportionally. In a few cases there is a 
relative reduction in c-AMP levels, interpreted as the action of an antagonist. 
However in some cases the change in c-AMP levels is such that it suggests 
increased biological activity for a given level of binding affinity. Examples of 
this observation can be seen with compound tested in lanes 6,7 and 8  in Fig 
3.7B (page 87) and in lane 1 in Fig. 4,6C (page 132). One interpretation of these 
results is that they are artifacts associated with the relative sensitivity of the 
binding assay and the c-AMP assay. While the c-AMP assay is known to be a 
difficult assay the evidence in this thesis does not indicate any lack of 
reliability. However it would be interesting in future work, in particular with 
those compounds giving these anomolous responses, to look at other alternative 
measures of biological response, perhaps tyrosinase enzyme levels or melanin 
production where appropriate.
Taking into account the areas above which leave room for improvement and 
further work, it is worth emphasising the principal results which have arisen out of 
this thesis and which may act as leads for further work and hopefully may 
contribute, albeit in a small way, to a greater understanding to the action of 
melanocortins.
• The main finding in this thesis is the discovery of a selective antagonist for the 
rat MC3 receptor. The MSH analogue [D-Trp7]a-MSH is selective for rat MC3- 
R with an IC50 of 1.95 x 10'7M. This is seen most clearly in Figs. 4.3C and 4.4. 
In relation to this observation, it has been proposed that the [D-Phe7]a-MSH 
substitution leads to a minimum energy conformation within the central a-MSH 
‘core sequence’, His-Phe-Arg-Trp, causing high affinity binding. The 
hypothesis has previously been put forward that the D-isomer in [D-Phe7]a- 
MSH might lead to ‘irreversible’ binding at the MC1-R and this might have 
relevance to the observations reported here with [D-Trp7]a-MSH and MC3-R. 
The discovery that [D-Trp7] a-MSH is a selective antagonist of rat MC3-R may 
be of direct use in the elucidation of the biological importance of this receptor
/
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or it may lead to the development of higher affinity antagonists in the future.
Lastly it should be asked if the results reported in this thesis may have any use in 
clinical treatment of human disease. There are two clinical areas where the 
development of high affinity agonists or antagonists may be of clinical value.
• Firstly there is increasing evidence of the importance of melanocortins in a 
number of physiological functions and in associated pathological conditions. 
These include, in addition to pigmentation disorders, nerve regeneration, 
behavioural functions e.g mood control, and most recently and importantly 
functions associated with obesity. The development of a selective agonists and 
antagonists for example [D-Trp7]a-MSH may be of benefit to research and 
eventually treatments in these areas.
• Secondly it has been suggested that one approach to treatment of those cancers 
not effectively treated by surgery, radiotherapy or current chemotherapy 
protocols might be treated more effectively by cytotoxic agents if they could be 
delivered selectively to the target cells. In the case of melanoma, which is a 
cancer that is often fatal and is increasing in incidence in the UK, there exists 
the possibility that cytotoxic agents could be targeted to melanoma cells by 
attaching the cytotoxic agent to a ligand for melanocortin receptors. In this way 
the cytotoxic agent might be selectively delivered to melanoma cells. A number 
of difficulties exist in this approach, receptors are likely to found on cells other 
than the melanoma cells and these cells might also be killed. Also there may be 
difficulties in delivering enough cytotoxic molecules to each cell, the number of 
MC receptors per cell is likely to be in the order of 10’s of thousands whereas 
the number of cytotoxic molecules required per cell to effect killing may be 
orders of magnitude higher. For example it has been estimated that the 
commonly used cytotoxic agent methotrexate requires approximately 1 0 6 
molecules per cell to kill the cell. In the future the use of more potent cytotoxic 
agents or perhaps the use of gene therapy agents may mean that smaller 
numbers of molecules are needed per cell. In this case the development of high 
affinity MC-R ligands may be useful as targeting agents.
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Appendix 1.1: Data of  Binding Assay in a-MSH analogues at B-16 Melanoma Cel l s .
ROW Cl C2 C3
1 1 1.04 0.03922
2 1 1.89 0.63658
3 1 1.62 0.48243
4 1 1.86 0.62058
5 1 2.01 0.69813
6 2 0.55 -0.59784
7 2 0.14 -1.95193
8 2 0.48 -0.73397
9 2 0.25 -1.39837
10 2 0.21 -1.54178
11 3 0.11 -2.21641
12 3 0.09 -2.41800
13 3 0.10 -2.34237
14 4 0.13 -2.06357
15 4 0.28 -1.26231
16 4 0.16 -1.86433
17 5 0.28 -1.25878
18 5 0.33 -1.10262
19 5 0.31 -1.17441
20 5 0.28 -1.26585
21 5 0.14 -1.95193
22 6 76.10 4.33205
23 6 143.00 4.96284
24 6 199.00 5.29330
25 7 24.80 3.21084
26 7 37.00 3.61092
27 7 95.60 4.56017
28 8 399.00 5.98896
29 8 6380.00 8.76092
30 8 1420.00 7.25841
31 9 635.00 6.45363
32 9 343.00 5.83773
33 9 179.00 5.18739
34 10 2222.00 7.70616
35 10 999.00 6.90675
36 10 819.00 6.70808
37 11 1100.00 7.00307
38 11 1980.00 7.59085
39 11 2790.00 7.93380
40 12 110.00 4.70048
41 12 43.20 3.76584
42 12 21.50 3.06805
43 13 1020.00 6.92756
44 13 764.00 6.63857
45 13 401.00 5.99396
46 14 1920.00 7.56008
47 14 1160.00 7.05618
48 14 1520.00 7.32647
MTB > onew c3 c l ;  
SUBC> f i she r  0.05;  
SUBC> tukey.
ANALYSIS OF VARIANCE ON C3
SOURCE DF SS MS F p








INDIVIDUAL 95 PCT Cl'S FOR MEAN 
BASED ON POOLED STDEV
LEVEL N MEAN STDEV -------------- +-------------- +---------------+-----
1 5 0.4954 0.2669 (*-)
2 5 -1.2448 0.5682 <*-)
3 3 -2.3256 0.1018 (-*-)
4 3 -1.7301 0.4172 (-*-)
5 5 -1.3507 0.3427 (*-)
6 3 4.8627 0.4884 (-*-)
7 3 3.7940 0.6930 (-*-)
8 3 7.3361 1.3876 ( -*-)
9 3 5.8262 0.6332 (-*-)
10 3 7.1070 0.5283 ( -*-)
11 3 7.5092 0.4707 (*-)
12 3 3.8448 0.8191 (-*-)
13 3 6.5200 0.4780 (-*-)
14 3 7.3142 0.2522 (-*-)
POOLED STDEV = 0.5799 0.0 3.5 7.0
176
i
Tukey's pairwise comparisons 
Family error rate = 0.0500 
Individual  error rate = 0.000987
C r i t i c a l  value = 5.10
Interv a l s  for (column l e v e l  mean) -  (row l e v e l  mean)












































































































































































14 -1.686 -3.195 -1.915 -1.512 -5 .177 -2.502
1.729 0.219 1.500 1.902 -1 .762  0.913
Fisher ' s  pairwise comparisons
Family error rate = 0.738  
Individual  error rate = 0.0500
C r i t i c a l  value = 2.032
Interva ls  for (column l e v e l  mean) -  (row l e v e l  mean)
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Appendix 1.2: Data o f  c-AMP in  a-MSH analogues at  B-16 Melanoma C e l l s .
ROW Cl C2 C3
1 1 28 3.3322
2 1 32 3.4657
3 1 33 3.4965
4 1 20 2.9806
5 1 13 2.5572
6 1 39 3.6636
7 2 4 1.3913
8 2 1 -0.3147
9 2 1 -0.5604
10 2 1 0.3920
11 2 2 0.8020
12 2 1 -0.0010
13 3 2 0.5710
178
14 3 6 1.8148
15 3 7 1.9473
16 3 9 2.1702
17 3 6 1.7901
18 4 3 1.1756
19 4 4 1.4398
20 4 2 0.5766
21 5 4 1.4303
22 5 3 0.9478
23 5 1 0.2852
24 5 1 0.3577
25 6 1310 7.1778
26 6 841 6.7346
27 6 4620 8.4382
28 7 4000 8.2940
29 7 6300 8.7483
30 7 3210 8.0740
31 8 194000 12.1756
32 8 576000 13.2639
33 8 148000 11.9050
34 9 . 59400 10.9920
35 9 45700 10.7299
36 9 28900 10.2716
37 10 10000 9.2103
38 11 40000 10.5966
39 11 80000 11.2898
40 12 2440 7.7998
41 12 2200 7.6962
42 12 390 5.9661
43 12 415 6.0283
44 13 17900 9.7926
45 13 41000 10.6213
46 13 30300 10.3189
47 14 68800 11.1390






c3 c l ;
9.4880
SUBC> f i sher  0.05;  
SUBC> tukey.
ANALYSIS OF VARIANCE ON C3
SOURCE DF SS MS
Cl 13 894.776 68.829
ERROR 35 14.456 0.413
TOTAL 48 909.232
LEVEL N MEAN STDEV
1 6 3.249 0.409
2 6 0.285 0.729
3 5 1.659 0.626
4 3 1.064 0.442
5 4 0.755 0.539
6 3 7.450 0.884
7 3 8.372 0.344
8 3 12.448 0.719
9 3 10.665 0.365
10 1 9.210 0.000
11 2 10.943 0.490
12 4 6.873 1.012
13 3 10.244 0.419
14 3 10.312 0.825
POOLED STDEV = 0.643
F p
166.65 0.000
INDIVIDUAL 95 PCT Cl'S FOR MEAN 
BASED ON POOLED STDEV
( * )
( - * )
(*-)
( - * - )
(-*-)
< - * - )
<-*->
( - * - )
( - * - )
( _ * _ _ )
<*->
( - * )
( - * - )
0.0 4.0 8.0 12.0
1
Tukey's pairwise comparisons
Family error rate = 0.0500 
Individual error rate = 0.000980
C ri t i c a l  value = 5.09
Intervals  for (column le v e l  mean) -  (row le v e l  mean)
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Fish er ' s  pairwise comparisons
Family error rate = 0.739  
Individual  error rate = 0.0500
C r i t i c a l  value = 2.030
Interva l s  for (column l e v e l  mean) -  (row l e v e l  mean)
1 2 3 4 5 6 7






















































































































































































Appendix 1.3: Data o f  Binding Assay in  a-MSH analogues at  MC3-R.
ROW Cl C2 C3
1 1 48.0 3.87120
2 1 47.5 3.86073
3 1 102.0 4.62497
4 2 4.1 1.41342
5 2 2.1 0.75142
6 2 2.1 0.72271
7 2 1.0 0.01980
8 2 1.5 0.41211
9 3 2.1 0.72755
10 3 1.0 0.00000
11 3 1.0 0.03922
12 3 0.9 -0.13582
13 3 1.1 0.10436
14 4 1.1 0.13103
15 4 0.9 -0.12897
16 4 0.6 -0.52594
17 4 0.5 -0.60331
18 4 0.9 -0.05235
19 5 3.0 1.09527
181
20 5 1.5 0.38526
21 5 1.6 0.45108
22 5 1.3 0.22314
23 5 1.1 0.12222
24 5 1.3 0.27003
25 6 4810.0 8.47845
26 6 14400.0 9.57498
27 6 6440.0 8.77028
28 7 702.0 6.55393
29 7 475.0 6.16331
30 7 681.0 6.52356
31 8 4530.0 8.41848
32 8 14000.0 9.54681
33 8 4270.0 8.35937
34 9 1910.0 7.55486
35 9 2000.0 7.60090
36 9 2720.0 7.90839
37 9 4110.0 8.32118
38 10 1860.0 7.52833
39 10 1470.0 7.29302
40 10 1730.0 7.45588
41 11 2490.0 7.82004
42 11 3880.0 8.26359
43 11 3520.0 8.16622
44 12 1320.0 7.18539
45 12 1140.0 7.03878
46 12 3380.0 8.12563
47 13 7030.0 8.85794
48 13 4980.0 8.51319
49 13 2110.0 7.65444
50 14 4650.0 8.44462
51 14 3170.0 8.06149
52 14 2400.0 7.78322
MTB > onew c3 c l ;  
SUBC> f i sher  0.05;  
SUBC> tukey.
ANALYSIS OF VARIANCE ON C3
SOURCE DF SS MS
Cl 13 723.086 55.622
ERROR 38 6.726 0.177
TOTAL 51 729.812
LEVEL N MEAN STDEV
1 3 4.1190 0.4382
2 5 0.6639 0.5126
3 5 0.1471 0.3362
4 5 -0.2359 0.3158
5 6 0.4245 0.3487
6 3 8.9412 0.5679
7 3 6.4136 0.2173
8 3 8.7749 0.6692
9 4 7.8463 0.3533
10 3 7.4257 0.1205
11 3 8.0833 0.2331
12 3 7.4499 0.5897
13 3 8.3419 0.6198
14 3 8.0964 0.3321
POOLED STDEV = 0.4207
F p
314.26 0.000
INDIVIDUAL 95 PCT C l ’S FOR MEAN 
BASED ON POOLED STDEV
( - * )
( * )
( * - )
( * )
( * - )
< - * ) '
( * - )
( * - )
( * - )
(-*)
( - * - )
(-*)
( - * )
(-*-)
0.0 3.0 6.0 9.0
Tukey's pairwise comparisons
Family error rate = 0.0500 
Individual error rate = 0.000964 
C ri t i c a l  value = 5.06
Intervals  for (column le v e l  mean) -  (row le v e l  mean)


















































































































































































Fisher ' s  pairwise comparisons
Family error rate = 0.744 
Individual  error rate = 0.0500
C r i t i c a l  value = 2.024
Interva l s  for (column le v e l  mean) -  (row l e v e l  mean)












































































































































































Appendix 1.4: Data o f  c-AMP in  a-MSH analogues at  MC3-R.
ROW Cl C2 C3
1 1 1.990 0.68813
2 1 0.633 -0.45728
3 1 6.080 1.80500
4 1 0.748 -0.29035
5 2 0.043 -3.14888
6 2 0.126 -2.07147
7 2 0.207 -1.57504
8 3 0.506 -0.68122
9 3 0.433 -0.83702
10 3 0.136 -1.99510
11 4 0.283 -1.26231
12 4 0.426 -0.85332
13 4 0.110 -2.20727
14 5 0.473 -0.74866
15 5 0.183 -1.69827
16 5 0.212 -1.55117
17 6 5.130 1.63511
18 6 21.500 3.06805
19 6 3.330 1.20297
20 7 0.773 -0.25748
21 7 1.360 0.30748
22 7 0.670 -0.40048
23 8 2.410 0.87963
24 8 3.860 1.35067
25 8 56.500 4.03424
26 9 6.180 1.82132
27 9 4.530 1.51072
28 9 2.350 0.85442
29 10 9.560 2.25759
184
30 10 42.200 3.74242
31 10 68.200 4.22244
32 10 56.900 4.04130
33 11 136.000 4.91265
34 11 64.800 4.17131
35 11 136.000 4.91265
36 12 8.740 2.16791
37 12 1.560 0.44469
38 12 3.000 1.09861
39 13 20.700 3.03013
40 13 20.700 3.03013
41 13 5.150 1.63900
42 14 82.200 4.40916
43 14 92.300 4.52504
44 14 14.000 2.63906
MTB > onew ic3 c l ;
SUBC> f i sh er  0.05;
SUBC> tukey




















INDIVIDUAL 95 PCT Cl'S FOR MEAN 
BASED ON POOLED STDEV
LEVEL N MEAN STDEV
1 4 0.4364 1.0430
2 3 -2.2651 0.8046 ( - —*— )
3 3 -1.1711 0.7178 (---- *-----)
4 3 -1.4410 0.6944 (---- *---- )
5 3 -1.3327 0.5111 (---- *-----)
6 3 1.9687 0.9763 (---- *-----j
7 3 -0.1168 0.3744 (------*-----)
8 3 2.0882 1.7017 (---- *------ )
9 3 1.3955 0.4936 (------*— )
10 4 3.5659 0.8944
11 3 4.6655 0.4280 (---- *-----
12 3 1.2371 0.8699 (----*-----)
13 3 2.5664 0.8032 (— * - — )
14 3 3.8578 1.0570 (— *------)
POOLED STDEV = 0.8821 -2 .5  0.0 2 .5 5.0
Tukey's pairwise comparisons
Family error rate = 0. 0500
Individual error rate = 0. 00102
Cri t i ca l  value = 5.15
Intervals for (column le ve l mean) - (!row le v e l mean)





















































































11 -6.6827 -9.5536 -8.4596 -8.7294 -8.6212 -5.3198 -7.4053






















































































F ish er ' s  pairwise comparisons
Family error rate = 0.731 
Individual  error rate = 0.0500
C r i t i c a l  value = 2.042
In ter va l s  for (column l e v e l  mean) -  (row l e v e l  mean)

























































































































































































Appendix 1.5: Data of  binding Assay for Multiple Alanine Subst i tut ion Analogues in
a-MSH at B-16 Melanoma Cel l s .
ROW Cl C2 C3
1 1 1.040 0.03922
2 1 1.890 0.63658
3 1 1.620 0.48243
4 1 1.860 0.62058
5 1 2.010 0.69813
6 2 0.550 -0.59784
7 2 0.142 -1.95193
8 2 0.480 -0.73397
9 2 0.247 -1.39837
10 2 0.214 -1.54178
11 3 35.000 3.55535
12 3 43.500 3.77276
13 3 27.500 3.31419
14 4 3.820 1.34025
15 4 4.830 1.57485
16 4 1.670 0.51282
17 5 6.640 1.89311
18 5 4.130 1.41828
19 5 2.210 0.79299
20 6 1.560 0.44469




MTB > onew c3 c l ;
SUBC> f i sher  0.05;
SUBC> tukey.
ANALYSIS OF VARIANCE ON C3
SOURCE DF SS MS F p
Cl 5 45.401 9.080 28.25 0.000
ERROR 16 5.143 0.321
TOTAL 21 50.544
INDIVIDUAL 95 PCT Cl'S FOR MEAN 
BASED ON POOLED STDEV
LEVEL M MEAN o 1 DCiV
1 5 0.4954 0.2669 ( -* - - )
2 5 -1.2448 0.5682 (*-*-)
3 3 3.5474 0.2294 ( - * - - )
4 3 1.1426 0.5579
5 3 1.3681 0.5518
6 3 0.9528 1.0560
POOLED STDEV = 0.5670 0.0 2.0 4.0
1
Tukey's pairwise comparisons
Family error rate = 0.0500 
Individual error rate = 0.00530
187
C r i t i c a l  value = 4.5































Fish er ' s pairwise comparisons
Family error  
Individual  error
rate = 0.32 6 
rate = 0.0500
C r i t i c a l value = 2.120
Inte rva l s  for (column l e v e l  mean) -  I[row le v e l mean)
































Appendix 1.6: Data of  c-AMP for Multiple Alanine Sub st i tu t io n  Analogues in  a-MSH
at B-16 Melanoma C el l s .
ROW Cl C2 C3
1 1 28.00 3.33220
2 1 32.00 3.46574
3 1 33.00 3.49651
4 1 19.70 2.98062
5 1 12.90 2.55723
6 1 39.00 3.66356
7 2 4.02 1.39128
8 2 0.73 -0.31471
9 2 0.57 -0.56037
10 2 1.48 0.39204
11 2 2.23 0.80200
12 2 1.00 -0.00100
13 3 2230.00 7.70976
14 3 6880.00 8.83637
15 3 2250.00 7.71869
16 4 423.00 6.04737
17 4 342.00 5.83481
18 4 131.00 4.87520
19 5 593.00 6.38519
20 5 749.00 6.61874
21 5 837.00 6.72982
22 6 1560.00 7.35244
23 6 4500.00 8.41183
24 6 5150.00 8.54675
188
MTB > onew c3 c l ;  
SUBC> f i sher  0.05;  
SUBC> tud 
SUBC> tukey.















INDIVIDUAL 95 PCT Cl'S FOR MEAN 


































( -* - - )
POOLED STDEV = 0.5790
— + 




rate = 0.0500 
rate = 0.00524
C ri t i c a l value = 4.49
Interval s  for (column le v e l  mean) -  (row le ve l mean)
































Fisher ' s pairwise comparisons
Family error 
Individual  error




C ri t i c a l value = 2.101
Interval s  for (column le v e l  mean) - (row le ve l mean)
































Appendix 1.7: Data of Binding Assay for Alanine Substitution Analogues in a-MSH at
MC3-R.
ROW Cl C2 C3
1 1 83.90 4.42963
2 1 68.30 4.22391
3 1 74.50 4.31080
4 2 4.11 1.41342
5 2 2.12 0.75142
6 2 2.06 0.72271
7 2 1.02 0.01980
8 2 1.51 0.41211
9 3 1770.00 7.47873
10 3 1930.00 7.56528
11 3 2070.00 7.63530
12 3 2420.00 7.79152
13 3 1550.00 7.34601
14 4 944.00 6.85013
15 4 728.00 6.59030
16 4 285.00 5.65249
17 4 836.00 6.72863
18 4 843.00 6.73697
19 5 107.00 4.67283
20 5 125.00 4.82831
21 5 84.90 4.44147
22 6 1280.00 7.15462
23 6 1950.00 7.57558
24 6 1020.00 6.92756
MTB > onew c3 c l ;  
SUBC> f i sh er  0.05;  
SUBC> tukey.
ANALYSIS OF VARIANCE ON C3
SOURCE DF SS MS
Cl 5 154.606 30.921
ERROR 18 2.433 0.135
TOTAL 23 157.039
LEVEL N MEAN STDEV
1 3 4.3214 0.1033
2 5 0.6639 0.5126
3 5 7;5634 0.1671
4 5 6.5117 0.4891
5 3 4.6475 0.1947
6 3 7.2193 0.3288
POOLED STDEV = 0.3676
1
Tukey's pairwise comparisons
Family error rate = 0.0500 
Individual  error rate = 0.00524
C r i t i c a l  value = 4.49
F p
228.77 0.000
INDIVIDUAL 95 PCT Cl'S FOR MEAN 
BASED ON POOLED STDEV
(*-)
( - * )
( * - )
<*)
( - * )
( _ * _ )
2.5 5.0 7.5
Interva ls for (column l e v e l mean) - (row l e v e l mean)































Fisher ' s  pairwise comparisons
190
Family error rate = 0.330 
Individual  error rate = 0.0500
C r i t i c a l  value = 2.101































Appendix 1.8: Data of  c-AMP for Alanine Subst i tut ion Analogues in a-MSH at MC3-R.
ROW Cl C2 C3
1 1 0.2590 -1.35093
2 1 0.5220 -0.65009
3 1 6.6600 1.89612
4 2 0.0429 -3.14888
5 2 0.1260 -2.07147
6 2 0.2070 -1.57504
7 3 2.5400 0.93216
8 3 2.7500 1.01160
9 3 3.3200 1.19996
10 3 4.2500 1.44692
11 4 4.6500 1.53687
12 4 2.8700 1.05431
13 4 2.6700 0.98208
14 4 1.9900 0.68813
15 4 1.9400 0.66269
16 5 0.3830 -0.95972
17 5 0.3360 -1.09064
18 5 0.9670 -0.03356
19 6 1.1200 0.11333
20 6 1.7200 0.54232
21 6 1.8800 0.63127
MTB > onew c3 c l ;
SUBC> f i s h er  0.05;
SUBC> tukey.
















LEVEL N MEAN STDEV
1 3 -0.0350 1.7087
2 3 -2.2651 0.8046
3 4 1.1477 0.2289
4 5 0.9848 0.3540
5 3 -0.6946 0.5762





INDIVIDUAL 95 PCT Cl'S FOR MEAN 
BASED ON POOLED STDEV
(-
( ---------- * — )
POOLED STDEV = 0.7576 -3 .0  -1 .5  0.0 1.5
Tukey's pairwise comparisons
Family error rate = 0.0500 
Individual  error rate = 0.00543
C r i t i c a l  value = 4.59
Interva ls  for (column le ve l  mean) -  (row le ve l  mean)
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-1.2400 -3.1314  
2.3516 0.8841
F ish er ' s pairwises comparisons
Family error 
Individual  error
rate = 0.323  
rate = 0.0500
C r i t i c a l value = 2.131
Interva l s  for (column l e v e l  mean) -  (row l e v e l  mean)





























-0.6232 -2.4419  
1.7349 0.1946
Appendix 1.9: Data o f  Binding Assay for [L/D-Tyr7]a-MSH
Melanoma C el l s .
ROW Cl C2 C3
1 1 10.40 2.34181
2 1 18.90 2.93916
3 1 16.20 2.78501
4 1 18.60 2.92316
5 1 20.10 3.00072
6 2 5.50 1.70475
7 2 1.42 0.35066
8 2 4.80 1.56862
9 2 2.47 0.90422
10 2 2.14 0.76081
11 3 117.00 4.76217
12 3 209.00 5.34233
13 3 245.00 5.50126
14 4 7850.00 8.96827
15 4 6040.00 8.70616
16 4 3150.00 8.05516
17 5 3.78 1.32972
18 5 5.92 1.77834
19 5 5.53 1.71019
20 5 3.16 1.15057
21 5 5.21 1.65058
22 6 8.83 2.17815
23 6 21.60 3.07269
24 6 20.70 3.03013
25 6 10.20 2.32239
MTB > onew c3 c l ;
SUBC> f i s h er  0.05;
SUBC> tukey .
192
ANALYSIS OF VARIANCE ON C3
SOURCE DF SS MS
Cl 5 137.696 27.539
ERROR 19 3.267 0.172
TOTAL 24 140.963
LEVEL N MEAN STDEV
1 5 2.7980 0.2669
2 5 1.0578 0.5682
3 3 5.2019 0.3890
4 3 8.5765 0.4702
5 5 1.5239 0.2704
6 4 2.6508 0.4666
POOLED STDEV = 0.4147
F p
160.17 0.000
INDIVIDUAL 95 PCT Cl'S FOR MEAN 
BASED ON POOLED STDEV
( * - )
( * - )
( - * - )





Family error rate = 0.0500 
Individual  error rate -  0.00515
C r i t i c a l  value = 4.47
In terva l s  for (column l e v e l  mean) -  (row le v e l  mean)































F is h e r ' s pairwise comparisons
Family error  
Individual  error
rate = 0.332  
rate = 0.0500
C r i t i c a l value = 2.093
Inte rva l s  for (column l e v e l  mean) -  I[row le v e l mean)































Appendix 1.10: Data of  c-AMP for [L/D-Tyr7]a-MSH, [L/D-Trp7] a-MSH at  B-16 Melanoma
C el l s .
ROW Cl C2 C
1 1 2.80 1.02962
2 1 3.20 1.16315
3 1 3.30 1.19392
4 1 1.97 0.67803
5 1 1.29 0.25464
6 1 3.90 1.36098
7 2 0.40 -0.91130
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8 2 0.07 -2.61730
9 2 0.06 -2.86295
10 2 0.15 -1.91054
11 2 0.22 -1.50058
12 2 0.10 -2.30359
13 3 4870.00 8.49085
14 3 1960.00 7.58070
15 3 4310.00 8.36869
16 3 9390.00 9.14740
17 4 2150.00 7.67322
18 4 2230.00 7.70976
19 4 2310.00 7.74500
20 4 1350.00 7.20786
21 5 9.22 2.22137
22 5 1.98 0.68310
23 5 3.52 1.25846
24 6 14.80 2.69463
25 6 22.80 3.12676
26 6 11.90 2.47654
MT3 > onew c3 c l ;
SUBC> f i s h e r  0.05
* NOTE * Subcommand does not end in  
SUBC> f i s h e r  0.05;
SUBC> tukey.
ANALYSIS OF VARIANCE ON C3
SOURCE DF SS MS
Cl 5 382.394 76.479
ERROR 20 6.354 0.318
TOTAL 25 388.747
LEVEL N MEAN STDEV
1 6 0.9467 0.4093
2 6 -2.0177 0.7292
3 4 8.3969 0.6427
4 4 7.5840 0.2524
5 3 1.3876 0.7772
6 3 2.7660 0.3309
POOLED STDEV = 0.5636
. or ; (; assumed).
F p
240.74 0.000
INDIVIDUAL 95 PCT Cl'S FOR MEAN 
BASED ON POOLED STDEV
( - * )
(*-)
( - * - )
( - * )
(_*_)
( _ * _ )
0.0 3 .5 7.0
Tukey's pairwise comparisons
Family error rate = 0.0500 
Individual  error rate = 0.00508
C r i t i c a l  value = 4.45  
In terva l s  for (column l e v e l mean) - (row le v e l mean)































F isher ' s  pairwise comparisons
Family error rate = 0.333 
Individual  error rate = 0.0500
C r i t i c a l  value = 2.086
































Appendix 1.11: Data of Binding Assay for [L/D-Tyr7]a-MSH, [L/D-Trp7]a-MSH at MC3-R.
ROW Cl C2 C3
1 1 4.8000 1.56862
2 1 4.7500 1.55814
3 1 10.2000 2.32239
4 2 0.4110 -0.88916
5 2 0.2120 -1.55117
6 2 0.2060 -1.57988
7 2 0.1020 -2.28278
8 2 0.1510 -1.89048
9 3 0.0452 -3.09666
10 3 0.0428 -3.15122
11 3 0.0537 -2.92434
12 3 0.0515 -2.96617
13 4 0.0133 -4.31999
14 4 0.0285 -3.55785
15 4 0.0172 -4.06110
16 4 0.0245 -3.70908
17 5 2.9700 1.08856
18 5 3.8400 1.34547
20 5 5.8500 1.76644
21 6 2.7800 1.02245
22 6 2.8500 1.04732
23 6 4.2800 1.45395
MTB > onew c3 c l ;
SUBC> f i sh er  0.05;
SUBC> tukey.
ANALYSIS OF VARIANCE ON C3
SOURCE DF SS MS F p
Cl 5 115.424 23.085 170.00 0.000
ERROR 17 2.308 0.136
TOTAL 22 117.733
INDIVIDUAL 95 PCT Cl'S FOR MEAN
BASED ON POOLED STDEV
LEVEL N MEAN STDEV
1 3 1.8164 0.4382 ( -*-)
2 5 -1.6387 0.5126 ( -*-)
3 4 -3.0346 0.1069 ( -*-)
4 4 -3.9120 0.3441 (-*-)
5 4 1.5050 0.3494 (-*)
6 3 1.1746 0.2423 1( -*-)
POOLED STDEV = 0.3685 - 4 .0  - 2 .0  0.0 2.0
Tukey's pairwise comparisons
Family error rate = 0.0500 
Individual  error rate = 0.00529
C r i t i c a l  value = 4.52
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F is h er ' s  pairwise comparisons
Family error rate = 0.328 
Individua l  error rate = 0.0500
C r i t i c a l  value = 2.110
I n te rv a l s  for (column le v e l  mean) -  (row l e v e l  mean)





















6 0.0069 -3.3811 -4.8030 -5.6804
1.2767 -2.2454 -3.6153 -4.4927 0.9243
Appendix 1.12: Data of c-AMP for [L/D-Tyr7]a-MSH at MC-3R.
ROW Cl C2 C3
1 1 1.990 0.68813
2 1 0.633 -0.45728
3 1 6.080 1.80500
4 1 0.748 -0.29035
5 2 0.043 -3.14888
6 2 0.126 -2.07147
7 2 0.207 -1.57504
8 3 254.000 5.53733
9 3 75.900 4.32942
10 3 142.000 4.95583
11 3 41.800 3.73290
12 4 2.700 0.99325
13 4 1.750 0.55962
14 4 3.530 1.26130
MTB > onew c3 c l ;
SUBC> f i s h e r  0.05;
SUBC> tukey.
ANALYSIS OF VARIANCE ON C3
SOURCE DF SS MS F p
Cl 3 85.847 28.616 43.14 0.000
ERROR 10 6.633 0.663
TOTAL 13 92.480
INDIVIDUAL 95 PCT Cl'S FOR MEAN 
BASED ON POOLED STDEV
LEVEL N MEAN STDEV -----+-------- --- +---------------+- -----------+—
1 4 0.4364 1.0430
2 3 -2.2651 0.8046
3 4 4.6389 0.7798
4 3 0.9381 0.3541
POOLED STDEV = 0.8144 -2 .5 0.0 2 .5 5.0
Tukey's pairwise comparisons
Family error rate = 0.0500  
Individual  error rate = 0.0120
C r i t i c a l  value = 4.33
Interva l s  for (column l e v e l  mean) -  (row l e v e l  mean) 





4 -2.4062 -5.2392 1.7963
1.4028 -1.1672 5.6053
Fish er ' s  pairwise comparisons
Family error rate = 0.181  
Individual  error rate = 0.0500
C r i t i c a l  value = 2.228













Appendix 1.13: Data o f  c-AMP Antagonist for [L/D-Trp7] a-MSH at  MC3-R.
ROW Cl C2 C3
1 1 6.12 1.81156
2 1 3.67 1.30019
3 1 7.21 1.97547
4 2 124.00 4.82028
5 2 244.00 5.49717
6 2 218.00 5.38450
MTB > onew c3 c l ;  
SUBC> f i sh er  0.05;  
SUBC> tukey.






















INDIVIDUAL 95 PCT Cl'S FOR MEAN 
BASED ON POOLED STDEV
STDEV ---- +----------------+------------- +----------------+-
0.3522 (— *— )
0.3627 (— *- — )
 + ---------------------------+ ---------------------- + ---------------------------+ -
POOLED STDEV = 0.3575 1.5 3.0 4.5 6. 0
Tukey's pairwise comparisons
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Family error rate = 0.0500 
Individual  error rate = 0.0500
C r i t i c a l  value = 3.93





Fisher ' s  pairwise comparisons
Family error rate = 0.0500 
Individual  error rate = 0.0500
C r i t i c a l  value = 2.776




Appendix 1.14: Data of  Binding Assay for [L/D-Trp7]a-MSH at MC4-R.
ROW Cl C2 C3
1 1 108.00 4.68213
2 1 114.00 4.73620
3 1 192.00 5.25750
4 2 6.50 1.87180
5 2 4.51 1.50630
6 2 4.22 1.43984
7 3 457.00 6.12468
8 3 359.00 5.88332
9 4 49.90 3.91002
10 4 42.20 3.74242
11 4 43.80 3.779
MTB > onew c3 c l ;
SUBC> f i sh er  0.05;
SUBC> tukey.
ANALYSIS OF VARIANCE ON C3
SOURCE DF SS MS F p








INDIVIDUAL 95 PCT Cl'S FOR MEAN 
BASED ON POOLED STDEV
LEVEL N MEAN STDEV
1 3 4.8919 0.3177 (_*_)
2 3 1.6060 0.2326 ( -*-)
3 2 6.0040 0.1707 (-*•
4 3 3.8107 0.0880 (-*- )
POOLED STDEV = 0.2251 1.5 3.0 4.5 6.0
Tukey's pairwise comparisons
Family error rate = 0.0500 
Individual  error rate = 0.0130
C r i t i c a l  value = 4.68
Interva ls  for (column l e v e l  mean) -  (row l e v e l  mean) 









Fisher ' s  pairwise comparisons
Family error rate = 0.172 
Individual  error rate = 0.0500
C r i t i c a l  value = 2.366











Appendix 1.15: Data o f  c-AMP for [L/D-Trp7]a-MSH at  MC4-R.
ROW Cl C2 C3
1 1 0.752 -0.28502
2 1 0.511 -0.67139
3 1 1.150 0.13976
4 2 17.300 2.85071
5 2 12.500 2.52573
6 2 15.700 2.75366
7 3 5.260 1.66013
8 3 2.880 1.05779
9 3 7.550 2.02155
MTB > onew c3 c l ;  
SUBC> f i s h e r  0.05;  
SUBC> tukey.



























POOLED STDEV = 0.3784
INDIVIDUAL 95 PCT Cl'S FOR MEAN 
BASED ON POOLED STDEV
STDEV ----------- +---------------+-------------- +------------
0.4057 (-------* — )




Family error rate = 0.0500 
Individual  error rate = 0.0220
C r i t i c a l  value = 4.34 





Fish er ' s  pairwise comparisons
Family error rate = 0.109  
Individual  error rate = 0.0500
C r i t i c a l  value = 2.448








Appendix 1.16: Data of  Binding Assay for Ac-[Nle4, As^5, D-Phe7, L j s 10] a-MSH4-i3 at  B-16
C e l l s .
ROW Cl C2 C3
1 1 10.400 2.34181
2 1 18.900 2.93916
3 1 16.200 2.78501
4 1 18.600 2.92316
5 1 20.100 3.00072
6 2 5.500 1.70475
7 2 1.420 0.35066
8 2 4.800 1.56862
9 2 2.470 0.90422
10 2 2.140 0.76081
11 3 2.130 0.75612
12 3 1.420 0.35066
13 3 1.840 0.60977
14 4 14.100 2.64617
15 4 20.400 3.01553
16 4 9.460 2.24707
17 4 24.800 3.21084
18 5 1.130 0.12222
20 5 1.080 0.07696
21 5 1.110 0.10421
MTB >
MTB > anew c3 c l ;
SUBC> f i sh er  0.05;
SUBC> tukey •
ANALYSIS OF VARIANCE ON C3
SOURCE DF SS
Cl 4 28 .690
ERROR 16 2 .659
TOTAL 20 31 .349
LEVEL N MEAN
1 5 2. 7980 0
2 5 1. 0578 0
3 3 0. 5722 0
4 4 2. 7799 0








INDIVIDUAL 95 PCT Cl'S FOR MEAN 
BASED ON POOLED STDEV
(  *  )
0 . 0 1 . 2POOLED STDEV = 0.4077
Tukey's pairwise comparisons
Family error rate = 0.0500  
Individual  error rate = 0.00745 
C ri t i c a l  value = 4.33
Interva ls  for (column l e v e l  mean) -  (row l e v e l  mean)
2.4













-2.5594 -3.1611  
-0.8848 -1.2544
5 2.0541 0.3139 -0.2877 1.9907
3.7287 1.9886 1.6189 3.7560
F isher ' s pairwise comparisons
Family error rate = 0.259
Individual  error rate = 0.0500
200
C r i t i c a l  value = 2.120









2.3116 0.5715 0.0055 2.2622
3.4712 1.7310 1.3257 3.4845
Appendix 1.17: Data o f  c-AMP for Ac- [Nle4, Asp5, D-Phe7, L^s10] a-MSH4-i3 at  B-16
Melanoma C el l s .
ROW Cl C2 C3
1 1 199.000 5.29330
2 1 63.000 4.14313
3 1 608.000 6.41017
4 1 74.800 4.31482
5 2 4.290 1.45629
6 2 12.600 2.53370
7 2 20.700 3.03013
8 3 3.500 1.25276
9 3 6.720 1.90509
10 3 1.290 0.25464
11 3 0.507 -0.67924
12 4 8.990 2.19611
13 4 9.620 2.26384
14 4 1.860 0.62058
15 4 4.480 1.49962
16 5 0.720 -0.32850
17 5 1.110 0.10436
18 5 0.606 -0.50088
19 5 1.850 0.61519
MTB > onew c3 c l ;
SUBC> f i s h e r  0.05;
SUBC> tukey.
ANALYSIS OF VARIANCE ON C3
SOURCE DF SS MS F p
Cl 4 61.066 15.266 19.56 0.000
ERROR 14 10.926 0.780
TOTAL 18 71.992
INDIVIDUAL 95 PCT Cl'S FOR MEAN
BASED ON POOLED STDEV
LEVEL N MEAN STDEV
1 4 5.0404 1.0443 (------*- — )
2 3 2.3400 0.8046 (--------*------ )
3 4 0.6833 1.1339 (— *------ )
4 4 1.6450 0.7653 (------*------ )
5 4 -0.0275 0.4984 (------*------ )
POOLED STDEV = 0.8834 0.0 2.0 4.0 6.0
Tukey's pairwise  comparisons
Family error rate = 0.0500 
Individual  error rate = 0.00755
C r i t i c a l  value = 4.41
In te rv a l s  for (column l e v e l  mean) -  (row l e v e l  mean)



















Fish er ' s  pairwise comparisons
Family error rate = 0.256  
Individual  error rate = 0.0500
C r i t i c a l  value = 2.145
In terva l s  for (column l e v e l  mean) -  (row le v e l  mean)
1 2
1.2530
4.1476
3.0171 0.2094
5.6970 3.1040
2.0554 -0.7523
4.7353 2.1423
3.7279 0.9202
6.4078 3.8148
-2.3017
0.3782
-0.6292
2.0507
0.3326
3.0124
